


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:00:33Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12410004" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12410004</identifier>
    <datestamp>2025-09-05</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochem Soc Trans</journal-id><journal-id journal-id-type="iso-abbrev">Biochem Soc Trans</journal-id><journal-id journal-id-type="pmc-domain-id">671</journal-id><journal-id journal-id-type="pmc-domain">portlandopen</journal-id><journal-id journal-id-type="publisher-id">bst</journal-id><journal-title-group><journal-title>Biochemical Society Transactions</journal-title></journal-title-group><issn pub-type="ppub">0300-5127</issn><issn pub-type="epub">1470-8752</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Portland Press Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12410004</article-id><article-id pub-id-type="pmcid-ver">PMC12410004.1</article-id><article-id pub-id-type="pmcaid">12410004</article-id><article-id pub-id-type="pmcaiid">12410004</article-id><article-id pub-id-type="doi">10.1042/BST20241045</article-id><article-id pub-id-type="publisher-id">BST-2024-1045</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group><subj-group><subject>Cancer</subject><subject>Therapeutics &amp; Molecular Medicine</subject><subject>RNA</subject><subject>Gene Expression &amp; Regulation</subject></subj-group></article-categories><title-group><article-title>Advances in understanding and targeting eIF4E activity</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4858-8873</contrib-id><name name-style="western"><surname>D'Agostino</surname><given-names initials="S">Sabrina</given-names></name><role vocab="CRediT" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; Original Draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff1" ref-type="aff"/><xref rid="an1" ref-type="author-notes">*</xref><email>dagostino@icr.ac.uk</email></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-5421-8094</contrib-id><name name-style="western"><surname>Davies</surname><given-names initials="C">Caitlin</given-names></name><role vocab="CRediT" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; Original Draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff1" ref-type="aff"/><xref rid="an1" ref-type="author-notes">*</xref><email>caitlin.davies@icr.ac.uk</email></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0775-4908</contrib-id><name name-style="western"><surname>Powers</surname><given-names initials="MV">Marissa V</given-names></name><role vocab="CRediT" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; Original Draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="CRediT" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; Review &amp; Editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff1" ref-type="aff"/><xref rid="an1" ref-type="author-notes">*</xref><email>marissa.powers@icr.ac.uk</email></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9342-1290</contrib-id><name name-style="western"><surname>Clarke</surname><given-names initials="PA">Paul A</given-names></name><role vocab="CRediT" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; Review &amp; Editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/><email>paul.clarke@icr.ac.uk</email></contrib></contrib-group><aff id="aff1">Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, U.K</aff><author-notes><fn fn-type="equal" id="an1"><label>*</label><p>These authors are contributed equally to this work.</p></fn><corresp id="cor1"><bold>Correspondence:</bold> Paul A Clarke (<email>paul.clarke@icr.ac.uk</email>)</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>7</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">496254</issue-id><elocation-id>BST20241045</elocation-id><history><date date-type="received"><day>2</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>06</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-05 10:25:38.007"><day>05</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s).</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CC BY)</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="bst-BST20241045.pdf"/><self-uri xlink:href="bst-BST20241045.pdf"/><abstract><p>Eukaryotic translation initiation factor 4E (eIF4E) has long been recognised as a pivotal regulator of cap-dependent protein synthesis initiation. More recently, eIF4E has emerged as a multifunctional factor proposed to influence various aspects of RNA metabolism, including nuclear export of mRNA to the cytoplasm. Its versatile roles are largely attributed to its ability to bind the methyl-7-guanosine cap (m<sup>7</sup>G-cap) of mRNAs and participate in critical protein&#8211;protein interactions. Deregulated eIF4E expression or activity has been implicated in several diseases, but it is most prominently studied as an oncogene where its activity can drive cancer onset, progression and drug resistance. Consequently, eIF4E is a highly attractive target for the development of novel anti-tumour therapeutics. Recent advancements have provided new insights into the mechanism of action of eIF4E, leveraging fragment-based compound screening and genetically modified cell models to identify and characterise binding sites on this challenging-to-drug protein target. In this review, we summarise the multiple roles of eIF4E and features that underpin its activity in both the cytoplasm and nucleus, and the key findings related to the modulation of its activity and therapeutic potential.</p></abstract><kwd-group><kwd>translation factors</kwd><kwd>cancer</kwd><kwd>therapeutics</kwd><kwd>translation</kwd><kwd>translation factors</kwd><kwd>cancer</kwd><kwd>drug discovery and design</kwd><kwd>molecular basis of health and disease</kwd></kwd-group><funding-group specific-use="FundRef"><award-group award-type="grant" id="award-1"><funding-source><institution-wrap><institution>Astex Pharmaceuticals</institution></institution-wrap></funding-source></award-group><award-group award-type="institutional" id="award-2"><funding-source><institution-wrap><institution>The Institute of Cancer Research</institution></institution-wrap></funding-source></award-group><funding-statement>core funding</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Regulation of protein synthesis is critical, as it accounts for approximately a quarter of energy consumption in normal cells [<xref rid="BST-2024-1045C1" ref-type="bibr">1</xref>]. This process must be highly responsive, enabling cells to adapt swiftly to various physiological conditions and maintain cellular homeostasis through efficient protein production. Importantly, deregulation of protein synthesis is often associated with the onset and progression of various disorders, including cancer, neurodegenerative conditions and cardiovascular diseases [<xref rid="BST-2024-1045C2" ref-type="bibr">2&#8211;4</xref>]. Protein synthesis is a complex process involving multiple steps, requiring the co-ordinated activity of ribosomes, tRNAs, amino acids and regulatory proteins [<xref rid="BST-2024-1045C5" ref-type="bibr">5</xref>]. Among these steps, mRNA cap binding by eukaryotic translation initiation factor (eIF4E) and recruitment of initiation factors is a major regulatory checkpoint controlling translation efficiency.</p><p>Beyond its canonical role in translation initiation, eIF4E has also been implicated in post-transcriptional processes, including RNA capping, splicing and polyadenylation [<xref rid="BST-2024-1045C6" ref-type="bibr">6</xref>,<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>]. Additionally, eIF4E participates in the selective nuclear export of specific RNAs, leading Mars and colleagues to propose that eIF4E &#8216;terraforms&#8217; the RNA landscape to support cellular needs [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>]. Understanding the multifunctional role of eIF4E requires in-depth knowledge of its structure and its binding to different ligands. Structurally, eIF4E contains three highly conserved binding surfaces: 1. a ventral surface with the methyl-7-guanosine cap-binding pocket; 2. a dorsal surface involved in canonical protein&#8211;protein interactions (PPIs) with protein synthesis initiation factors such as eIF4G and 4E-BPs; and, 3. a lateral surface that mediates non-canonical PPIs. Recent findings suggest that effectively inhibiting eIF4E requires disruption of RNA cap binding or, alternatively, interfering with both canonical and non-canonical interactions with eIF4G [<xref rid="BST-2024-1045C8" ref-type="bibr">8</xref>].</p><p>The role of eIF4E in human disease is significant, particularly in cancer, where it acts as an oncogene. Overexpression of eIF4E has been demonstrated in tumours, and it has oncogenic activity in <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> models of cell transformation, which has made eIF4E a prominent therapeutic target [<xref rid="BST-2024-1045C8" ref-type="bibr">8</xref>,<xref rid="BST-2024-1045C9" ref-type="bibr">9</xref>]. While significant progress has been made in understanding eIF4E&#8217;s cellular role, questions remain regarding the balance between its roles in mRNA export and translation and its function within the translation initiation complex. The development of potent, highly selective tool compounds that directly modulate eIF4E&#8217;s different cellular functions would complement biophysical, biochemical and genetic approaches to study its role in both normal and disease cell models. For example, screening efforts have identified small molecules that block the eIF4E&#8211;eIF4G interaction [<xref rid="BST-2024-1045C9" ref-type="bibr">9</xref>]. However, these compounds currently exhibit poor drug-like properties, and so far, none have proven to be effective chemical tools or advanced to clinical trials (reviewed in [<xref rid="BST-2024-1045C10" ref-type="bibr">10</xref>,<xref rid="BST-2024-1045C11" ref-type="bibr">11</xref>]).</p><p>This review explores the multifunctional nature of eIF4E, with a focus on its structural interactions and regulatory roles. We summarise current research efforts aimed at refining our understanding of the molecular mechanisms of eIF4E activities, which could inform the development of novel and more effective therapeutic strategies for cancer and other human diseases.</p><sec id="s1-1"><title>eIF4E and RNA processing</title><sec id="s1-1-1"><title>eIF4E and m<sup>7</sup>G capping</title><p>The m<sup>7</sup>G cap is a crucial 5'-epi-transcriptomic modification in eukaryotic mRNA that provides stability and protection against degradation [<xref rid="BST-2024-1045C12" ref-type="bibr">12</xref>,<xref rid="BST-2024-1045C13" ref-type="bibr">13</xref>] and serves as a binding site for proteins, such as eIF4E, facilitating mRNA nuclear export and translation (<xref rid="BST-2024-1045F1" ref-type="fig">Figure&#160;1</xref>). Capping is an active process dependent on RNGTT (RNA guanylyltransferase and 5' phosphatase) and RNMT (RNA guanine-7-methyltransferase), both of which are essential for eukaryotic cell survival (reviewed elsewhere [<xref rid="BST-2024-1045C14" ref-type="bibr">14</xref>,<xref rid="BST-2024-1045C15" ref-type="bibr">15</xref>]). Recent methodological advances have revealed that capping levels for certain RNAs are often below the expected 100%, challenging the notion of capping as a static housekeeping modification [<xref rid="BST-2024-1045C14" ref-type="bibr">14</xref>,<xref rid="BST-2024-1045C16" ref-type="bibr">16</xref>]. Instead, RNAs can undergo dynamic cycles of capping and de-capping, regulated by cell differentiation stage, development or oncogene expression [<xref rid="BST-2024-1045C14" ref-type="bibr">14</xref>,<xref rid="BST-2024-1045C17" ref-type="bibr">17&#8211;19</xref>].</p><fig position="float" id="BST-2024-1045F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><title>Potential role of eIF4E in different stages of RNA maturation.</title><p>In eukaryotic cells, mRNA synthesised in the nucleus undergoes extensive modifications to produce a mature transcript capable of nuclear transport and subsequent translation in the cytoplasm. These RNA processing steps include the addition of the 5' m<sup>7</sup>G cap &#8211; a dynamic modification dependent on RNGTT (RNA guanylyltransferase and 5&#8217; phosphatase), RNMT (RNA guanine-7-methyltransferase) and its cofactor RAM (RNMT activating mini-protein) using S-adenosyl methionine (SAM) as the methyl donor that can also occur in the cytoplasm to regulate translation &#8211; splicing, RNA cleavage within the 3' untranslated region, 3' polyadenylation, nuclear transport (see <xref rid="BST-2024-1045F2" ref-type="fig">Figure&#160;2</xref> for details) and translation into protein (see <xref rid="BST-2024-1045F3" ref-type="fig">Figure&#160;3</xref> for details). eIF4E plays a key role in regulating gene expression by co-ordinating RNA processing and translation to adapt to cellular demands (see text for more details), for example, eIF4E increases capping and translation of c-MYC transcripts which includes S-adenosylhomocysteine hydrolase (SAHH) which catalyses the hydrolysis of S-adenosylhomocysteine (SAH), an inhibitory by-product of RNMT methyltransferase activity, to L-homocysteine (HCY). Created in BioRender. <ext-link xlink:href="https://BioRender.com/p75q573" ext-link-type="uri">https://BioRender.com/p75q573</ext-link>.</p></caption><graphic position="float" orientation="portrait" xlink:href="bst-BST20241045-g001.jpg"/></fig><p>Overexpression of eIF4E has been shown to enhance the capping efficiency of select transcripts from less than 40% to nearly 90% suggesting that eIF4E has roles beyond merely protecting the m<sup>7</sup>G cap [<xref rid="BST-2024-1045C16" ref-type="bibr">16</xref>]. Specifically, eIF4E overexpression increases the levels of RNGTT, RNMT and its co-factor RAM (RNMT activating mini-protein) by promoting nuclear export and the translational efficiency of their mRNAs [<xref rid="BST-2024-1045C16" ref-type="bibr">16</xref>]. RNMT directly interacts with the dorsal surface of eIF4E, a region also known to bind factors critical for translation and nuclear export, including eIF4G and 4E-BP1 [<xref rid="BST-2024-1045C20" ref-type="bibr">20</xref>]. Interestingly, the binding sites of eIF4E and RAM on RNMT overlap, suggesting potential competition between these protein interactions. However, the broader implications of the dynamics of eIF4E/RNMT binding remain to be fully elucidated.</p><p>In cancer cells, eIF4E boosts both the capping and translation of oncogenic transcripts including c-MYC, MDM2, CTNNB1 and CCND1 [<xref rid="BST-2024-1045C16" ref-type="bibr">16</xref>,<xref rid="BST-2024-1045C21" ref-type="bibr">21</xref>]. Downstream of eIF4E, elevated c-MYC stimulates RNMT activity by increasing expression of S-adenosylhomocysteine hydrolase (SAHH), that counters the inhibitory effects of S-adenosylhomocysteine (SAH), a by-product of RNMT methyltransferase activity (<xref rid="BST-2024-1045F1" ref-type="fig">Figure&#160;1</xref>) [<xref rid="BST-2024-1045C22" ref-type="bibr">22</xref>,<xref rid="BST-2024-1045C23" ref-type="bibr">23</xref>]. These data suggest that eIF4E-dependent capping may be an important node linking transcription and translation that could be exploited to inhibit cancer through pharmacological inhibition of eIF4E</p></sec><sec id="s1-1-2"><title>eIF4E and splicing</title><p>Following 5' capping, many pre-mRNAs are processed by the spliceosome, which removes introns and ligates adjacent exons to produce mature mRNA [<xref rid="BST-2024-1045C24" ref-type="bibr">24</xref>,<xref rid="BST-2024-1045C25" ref-type="bibr">25</xref>] (<xref rid="BST-2024-1045F1" ref-type="fig">Figure&#160;1</xref>). Further diversification of the transcriptome and proteome can occur through alternative splicing. This is a tightly regulated process that varies the inclusion of exons in the final mRNA transcript and enables organisms to adapt to developmental and environmental cues by generating multiple protein isoforms from a single gene [<xref rid="BST-2024-1045C24" ref-type="bibr">24&#8211;27</xref>].</p><p>A recent study showed that eIF4E overexpression significantly alters splice site selection in 100&#8211;1000s of pre-mRNAs, particularly in cancer cells [<xref rid="BST-2024-1045C28" ref-type="bibr">28</xref>]. These data suggest a model where eIF4E exerts indirect effects on splice site selection by enhancing the nuclear export and translation of mRNAs encoding splicing factors while also influencing splicing directly through its interactions with specific pre-mRNAs or components of the spliceosome [<xref rid="BST-2024-1045C28" ref-type="bibr">28</xref>]. Further investigation will be needed to elucidate the precise mechanistic role of eIF4E in splicing regulation and to explore whether these effects extend beyond cancer contexts.</p></sec><sec id="s1-1-3"><title>eIF4E mRNA cleavage and polyadenylation</title><p>Cleavage and polyadenylation (CPA) are essential steps in the maturation of RNA transcripts. CPA involves cleavage of the pre-mRNA within the 3' untranslated region (UTR) downstream of a polyadenylation signal (PAS) by the endonuclease CPSF3. Subsequent polyadenylation by poly(A) polymerase enhances transcript stability, facilitates nuclear export and promotes translation (<xref rid="BST-2024-1045F1" ref-type="fig">Figure&#160;1</xref>) [<xref rid="BST-2024-1045C29" ref-type="bibr">29</xref>,<xref rid="BST-2024-1045C30" ref-type="bibr">30</xref>]. Alternative polyadenylation (APA) adds another layer of diversity in the transcriptome and proteome by utilising different PAS sites within the 3' UTR, introns or exons. APA generates transcript isoforms with varying coding sequences or 3' UTR lengths, affecting transcript stability, localisation and translation efficiency and potentially leading to proteins with altered functions [<xref rid="BST-2024-1045C29" ref-type="bibr">29</xref>,<xref rid="BST-2024-1045C30" ref-type="bibr">30</xref>].</p><p>Emerging evidence suggests that eIF4E may play a regulatory role in CPA and APA, particularly in cancer [<xref rid="BST-2024-1045C29" ref-type="bibr">29&#8211;32</xref>]. Expression of eIF4E can promote the generation of mature transcripts that are more efficiently exported and translated [<xref rid="BST-2024-1045C29" ref-type="bibr">29&#8211;33</xref>]. Similar to its impact on splicing, eIF4E&#8217;s role in CPA and APA could be indirectly mediated by altered nuclear export or translation of mRNAs encoding CPA components or via interactions with the CPA machinery to enhance 3'-end CPA of specific RNAs [<xref rid="BST-2024-1045C32" ref-type="bibr">32</xref>]. Further research will be necessary to clarify the involvement of eIF4E and to determine broader implications in cancer or normal cell contexts.</p></sec></sec><sec id="s1-2"><title>eIF4E-dependent nuclear export of mRNAs and nuclear trafficking of eIF4E</title><p>RNA export is a highly regulated process [<xref rid="BST-2024-1045C34" ref-type="bibr">34&#8211;38</xref>], requiring m<sup>7</sup>G cap addition, mRNA splicing and 3' polyadenylation [<xref rid="BST-2024-1045C39" ref-type="bibr">39&#8211;41</xref>]. This process controls the cytoplasmic availability of transcripts for protein translation and serves as a critical mechanism for mRNA surveillance [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>,<xref rid="BST-2024-1045C42" ref-type="bibr">42</xref>]. The selective export of specific mRNA subsets, determined by conserved cis-acting elements called Untranslated Sequence Elements for Regulation (USER) codes, enables dynamic changes in the cellular proteome in response to cellular stimuli [<xref rid="BST-2024-1045C43" ref-type="bibr">43&#8211;45</xref>]. Perhaps not surprisingly, deregulation of mRNA export has been implicated in human disease [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>,<xref rid="BST-2024-1045C36" ref-type="bibr">36</xref>,<xref rid="BST-2024-1045C46" ref-type="bibr">46&#8211;48</xref>].</p><p>During export, co-transcriptional recruitment of export factors results in the formation of large RNA-associated messenger ribonucleoprotein (mRNP) complexes that accumulate in the interchromatin compartment [<xref rid="BST-2024-1045C49" ref-type="bibr">49&#8211;52</xref>]. Most RNAs are substrates of the NXF1:NXT1 mediated bulk export pathway [<xref rid="BST-2024-1045C53" ref-type="bibr">53</xref>,<xref rid="BST-2024-1045C54" ref-type="bibr">54</xref>], while a subset of RNAs utilise an alternative export pathway involving the CRM1/XPO1 complex (<xref rid="BST-2024-1045F2" ref-type="fig">Figure&#160;2</xref>) [<xref rid="BST-2024-1045C54" ref-type="bibr">54&#8211;56</xref>].</p><fig position="float" id="BST-2024-1045F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><title>Nuclear export of RNA.</title><p>
<bold>A</bold>) The transcription export (TREX) complex (comprising UAP56, CIP29 and Aly/Ref proteins) is recruited to and assembled around the 5' cap-binding complex (CBC) of mRNAs containing exon-junction complexes (EJCs). Together with the THO multi-subunit complex, TREX bridges interactions between the target mRNA and the NXF1:NXT1 receptor complex facilitating transport through the nuclear pore complex (NPC). Upon reaching the cytoplasmic face of the NPC, cargo mRNA release is mediated by the ATP-dependent DEAD-box helicase DDX19 and its co-factor Gle1, allowing mRNA transcripts to diffuse into the cytoplasm for translation by ribosomes. Subsequently, the major cytoplasmic fibril component RanBP2 plays a key role in recycling export-factors back into the nucleus. <bold>B</bold>) RNAs containing 4ESE USER codes follow an alternative export pathway driven by eIF4E and the Chromosomal Maintenance 1/Exportin 1 (CRM1/XPO1) export receptor in a Ran-dependent manner. CRM1 does not bind mRNA directly but instead recognizes leucine-rich nuclear export signals within shuttling and adaptor proteins, which in turn associate with RNA or RNA-binding proteins. In eIF4E-specific export, the RNA-binding protein human antigen leucine-rich pentatricopeptide repeat containing protein (LRPPRC) binds both the 4ESE and cap-bound eIF4E. To facilitate CRM1-mRNP complex export, CRM1 directly interacts with nucleoporins (Nups) at the nuclear basket of the NPC. In the cytoplasm, Ran GTPase-activating protein (RanGAP) promotes GTP hydrolysis, leading to the dissociation of CRM1 from its cargo and subsequent mRNA release. Finally, cap-free eIF4E is targeted by Importin 8 for re-import into the nucleus [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>,<xref rid="BST-2024-1045C36" ref-type="bibr">36</xref>]. Created in BioRender. <ext-link xlink:href="https://BioRender.com/j26w708" ext-link-type="uri">https://BioRender.com/j26w708</ext-link>.</p></caption><graphic position="float" orientation="portrait" xlink:href="bst-BST20241045-g002.jpg"/></fig><p>eIF4E contributes to gene expression regulation by directly mediating mRNA export [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>,<xref rid="BST-2024-1045C57" ref-type="bibr">57&#8211;60</xref>]. Mutagenesis studies have highlighted the distinct role of eIF4E in nuclear export. For instance, the S53A mutation retains translation initiation activity but disrupts mRNA export and the oncogenic transformation activity of eIF4E [<xref rid="BST-2024-1045C61" ref-type="bibr">61&#8211;63</xref>]. However, not all residues and interactions are essential for mRNA export. For example, the W73A mutant that disrupts eIF4G binding retains export activity, suggesting that export and translation initiation mechanisms can be separated [<xref rid="BST-2024-1045C57" ref-type="bibr">57</xref>,<xref rid="BST-2024-1045C60" ref-type="bibr">60</xref>].</p><p>Approximately 3,500 mRNAs have been identified as potential eIF4E nuclear export targets. These mRNAs contain a ~ 50-nucleotide eIF4E sensitivity element (4ESE) USER code in their 3' UTRs [<xref rid="BST-2024-1045C64" ref-type="bibr">64</xref>]. This 4ESE, together with the 5' m<sup>7</sup>G cap, is sufficient to drive eIF4E-dependent mRNA export [<xref rid="BST-2024-1045C58" ref-type="bibr">58</xref>,<xref rid="BST-2024-1045C64" ref-type="bibr">64</xref>]. The eIF4E-dependent export pathway relies on the leucine-rich pentatricopeptide repeat containing protein (LRPPRC) within the CRM1/XPO1 complex. LRPPRC binds directly to the 4ESE (<xref rid="BST-2024-1045F2" ref-type="fig">Figure&#160;2</xref>) [<xref rid="BST-2024-1045C60" ref-type="bibr">60</xref>,<xref rid="BST-2024-1045C64" ref-type="bibr">64</xref>,<xref rid="BST-2024-1045C65" ref-type="bibr">65</xref>] and recruits eIF4E, which interacts with the m<sup>7</sup>G cap of target mRNAs [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>,<xref rid="BST-2024-1045C58" ref-type="bibr">58</xref>,<xref rid="BST-2024-1045C64" ref-type="bibr">64</xref>]. LRPPRC associates with the dorsal surface of eIF4E through its N-terminus, while simultaneously engaging the CRM1 receptor, allowing the export of the LRPPRC-4ESE-eIF4E complex [<xref rid="BST-2024-1045C64" ref-type="bibr">64</xref>]. Knockdown of LRPPRC reduces eIF4E&#8217;s ability to bind 4ESE-containing mRNAs and inhibits eIF4E-dependent export, highlighting its key role in this pathway [<xref rid="BST-2024-1045C60" ref-type="bibr">60</xref>]. Certain co-factors are shared between the NXF1 and eIF4E/CRM1/XPO1 pathways, suggesting cross-talk between these pathways [<xref rid="BST-2024-1045C60" ref-type="bibr">60</xref>]. Meanwhile, endogenous 4ESE-containing mRNAs with long 3' UTRs containing competing USER codes can use both the bulk and eIF4E-dependent pathways [<xref rid="BST-2024-1045C57" ref-type="bibr">57&#8211;59</xref>].</p><p>Once in the cytoplasm, eIF4E is recycled back to the nucleus by Importin 8, which binds the positively charged region of the cap-binding site [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>,<xref rid="BST-2024-1045C66" ref-type="bibr">66</xref>]. Mutation of the positively charged R157, K159 and K162 residues in the cap-binding site significantly reduces the affinity of eIF4E for Importin 8. This contrasts with the mutation of W56, which disrupts mRNA cap-binding and RNA export [<xref rid="BST-2024-1045C58" ref-type="bibr">58</xref>], but has no impact on importin 8 binding, indicating that the positive charge, rather than the entire cap-binding site, is critical for Importin 8-mediated nuclear import [<xref rid="BST-2024-1045C66" ref-type="bibr">66</xref>]. The mutually exclusive binding of Importin 8 and the m<sup>7</sup>G cap ensures that eIF4E export complexes release their mRNA cargo before eIF4E is recycled to the nucleus. Importantly, eIF4E actively involved in translation cannot be imported back into the nucleus [<xref rid="BST-2024-1045C66" ref-type="bibr">66</xref>]. Loss of Importin 8 leads to cytoplasmic accumulation of eIF4E, nuclear retention of 4ESE-containing mRNAs, reduced protein levels encoded by these mRNAs and impaired eIF4E-mediated oncogenic transformation [<xref rid="BST-2024-1045C66" ref-type="bibr">66</xref>]. Interestingly, RNA-free LRPPRC is also recycled via Importin 8, and eIF4E promotes the mRNA export of Importin 8 itself, regulating its cytoplasmic levels and mRNA targets [<xref rid="BST-2024-1045C64" ref-type="bibr">64</xref>].</p></sec><sec id="s1-3"><title>Cap-dependent translation</title><p>The cytoplasmic function of eIF4E primarily revolves around regulating cap-dependent translation initiation (<xref rid="BST-2024-1045F3" ref-type="fig">Figure&#160;3A</xref>). Upon binding to the 5' cap of mRNAs, eIF4E initiates the formation of the eIF4F complex by recruiting eIF4G [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>]. eIF4G, a scaffold protein, facilitates the recruitment of the helicase eIF4A, which unwinds secondary mRNA structures, enabling ribosome binding to the 5' UTRs [<xref rid="BST-2024-1045C67" ref-type="bibr">67</xref>]. The interaction between eIF4E and eIF4G can be inhibited by the repressor protein 4E-BP1 (4E binding protein), which competes with eIF4G for the same binding site on eIF4E [<xref rid="BST-2024-1045C68" ref-type="bibr">68&#8211;70</xref>]. When eIF4E binds to unphosphorylated 4E-BP1, the assembly of the eIF4F complex is inhibited [<xref rid="BST-2024-1045C71" ref-type="bibr">71</xref>].</p><fig position="float" id="BST-2024-1045F3" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><title>Cap-dependent protein translation.</title><p>Protein synthesis is a complex process involving the co-ordinated activity of ribosomes, tRNAs, amino acids and regulatory proteins [<xref rid="BST-2024-1045C5" ref-type="bibr">5</xref>]. It can be divided into several steps: 1) mRNA cap binding and recruitment of initiation factors, 2) assembly of the ribosome at the mRNA initiator codon, 3) polypeptide chain elongation by the ribosome, 4) termination of elongation and ribosome release from the mRNA and 5) ribosome recycling for subsequent rounds of translation. Among these steps, initiation is the primary regulatory checkpoint controlling translation efficiency. <bold>A</bold>) Translation initiation begins with the binding of eIF4E to the m<sup>7</sup>G cap structure of the mRNA to induce eIF4F complex formation (eIF4E-eIF4G-EIF4A). Once bound to the 5' mRNA, eIF4E recruits eIF4G to its dorsal surface. eIF4G acts as scaffold protein for recruitment of eIF4A RNA helicase which unwinds RNA secondary structure and promotes the binding of the 43 S pre-initiation complex (PIC) through eIF3. The poly(A)-binding protein (PABP) also binds to the eIF4F complex via eIF4G forming a circular mRNA and enhancing translation. 4E-BP1 competes with eIF4G for binding to the dorsal surface. When hypo-phosphorylated, 4E-BP1 shows a higher affinity for eIF4E impairing the interaction with eIF4G, hence disrupting the formation of eIF4F complex. mTOR protein kinase indirectly regulates eIF4E function by phosphorylating 4E-BP1. When phosphorylated, 4E-BP1 is released from eIF4E which can, in this way, interact with eIF4G for the eIF4F complex formation. MNK protein kinase can directly phosphorylate eIF4E on S209 increasing eIF4E activity. <bold>B</bold>) The cap-binding complex (CBC) can mediate eIF4E-independent, cap-dependent translation of specific mRNAs. The CBC comprises two key components: nuclear cap-binding protein 2 (NCBP2), which directly binds to the 5'-cap structure, and nuclear cap-binding protein 1 (NCBP1) which associates with NCBP2. CBC binding to RNA occurs in the nucleus, this complex is exported to the cytoplasm following splicing and poly-adenylation of the CBC-associated mRNAs. CBC-bound mRNAs interact with CTIF (CBC-dependent translation initiation factor), which facilitates recruitment of the 40S ribosomal subunit via association with the eIF3 complex. In contrast with eIF4G, CTIF cannot bind PABP. To date, there is no known poly(A)-binding protein specific for the CBC cap-dependent translation. <bold>C</bold>) DAP5-eIF3d complex is a previously unknown cap-dependent translation mechanism needing further investigation to better understand which proteins are involved in the formation of this complex. To date it is known that subunit eIF3d, from complex eIF3, can directly bind the 5'-cap of several mRNAs recruiting DAP5 protein, also known as eIF4G2, which is an eIF4GI homologous that can bind eIF4A but not eIF4E and PABP because it is lacking the N-terminal domain.</p></caption><graphic position="float" orientation="portrait" xlink:href="bst-BST20241045-g003.jpg"/></fig><p>4E-BP1 phosphorylation is regulated by the mechanistic target of rapamycin (mTOR), a protein kinase that exists in two functionally distinct complexes (mTORC1 or 2). mTORC1 is directly responsible for regulating 4E-BP1 activity and is activated in response to growth factors, nutrients or favourable energy conditions. Depending on the activating stimulus, mTORC1 phosphorylates 4E-BP1 at multiple different serine and threonine residues (Thr37, Thr46, Ser65 and Thr70). This phosphorylation reduces the affinity of 4EBP1 for eIF4E, causing it to dissociate from eIF4E, freeing eIF4E to interact with eIF4G and form the eIF4F complex. Inhibition of mTORC1 following stress, nutrient deprivation or treatment with pharmacological inhibitors prevents 4EBP1 phosphorylation, enabling 4E-BP1 to tightly bind and sequester eIF4E, preventing binding to eIF4G and effectively repressing eIF4E-dependent initiation. Through this mechanism, mTOR acts as a molecular switch to integrate upstream signals and finely tune protein synthesis [<xref rid="BST-2024-1045C72" ref-type="bibr">72</xref>].</p><p>The interaction of eIF4E with the m<sup>7</sup>G cap relies on cation-&#960; interactions involving two conserved tryptophan residues (W56 and W102) and a glutamate residue (E103) [<xref rid="BST-2024-1045C10" ref-type="bibr">10</xref>,<xref rid="BST-2024-1045C68" ref-type="bibr">68</xref>]. Key charged residues (R157, K159 and K162) in the cap-binding pocket also help stabilise interactions with the m<sup>7</sup>G cap through hydrogen bonding and electrostatic interactions (reviewed in [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>]). Substituting W56, W102 or E103 with leucine (L) or alanine (A) abolishes the cap-binding activity of eIF4E, while the W56A mutant disrupts both nuclear-cytoplasmic mRNA export and translation initiation (<xref rid="BST-2024-1045F4" ref-type="fig">Figure&#160;4</xref>, <xref rid="BST-2024-1045T1" ref-type="table">Table&#160;1</xref>) [<xref rid="BST-2024-1045C58" ref-type="bibr">58</xref>,<xref rid="BST-2024-1045C73" ref-type="bibr">73</xref>].</p><fig position="float" id="BST-2024-1045F4" fig-type="figure" orientation="portrait"><label>Figure 4</label><caption><title>eIF4E X-ray structure and associated mutations.</title><p>
<bold>A</bold> ) The secondary structure of eIF4E is shown in ribbon representation (PDP: 8QM4). The majority of the protein (grey), canonical peptide derived from 4E-BP1 attached to the N-terminus of eIF4E (blue), loop region between the C-terminus of the &#945;1-helix and N-terminus of the &#946;3-sheet (yellow). The fragment hit bound in site 2 is depicted as green lines. Key features are highlighted, including the location of site 2 in comparison with the cap-binding site (the Cap-site ligand (m7-GTP) is shown for illustration purposes only. The surface representations of the fragment and m7-GTP are shown in cyan and magenta, respectively <bold>B</bold> ) X-ray crystal structure of eIF4E protein (PDB: 8QM9) overlaid with eIF4G peptide as shown. The location of residues selected for mutational analysis are highlighted. <bold>C</bold> ) Overlay of the eIF4G peptide (green ribbon) with the protein conformation of compound <bold>4</bold> bound eIF4E (grey ribbon) showing the two flexible loop conformations for compound <bold>4</bold> bound and unbound eIF4E (PDB: 8QM9). The reorganisation of &#945;1-helix and the flexible loop region following compound <bold>4</bold> binding is displayed as a yellow ribbon, the Connolly surface of compound <bold>4</bold> is displayed in cyan. the original flexible loop conformation from the PDB: 5T46 structure of eIF4E bound to an eIF4G peptide is displayed as a red ribbon. <bold>D</bold> ) Overlay of eIF4G peptide (green ribbon and green Connolly surface) with the protein conformation of compound <bold>4</bold> bound eIF4E. The orientation has been rotated by~90&#176; in the horizontal plane compared with that shown in the bottom left panel. figure adapted from [<xref rid="BST-2024-1045C8" ref-type="bibr">8</xref>].<ext-link xlink:href="https://BioRender.com/m21j443" ext-link-type="uri"/>
</p></caption><graphic position="float" orientation="portrait" xlink:href="bst-BST20241045-g004.jpg"/></fig><table-wrap position="float" id="BST-2024-1045T1" orientation="portrait"><label>Table 1</label><caption><title>Table reporting eIF4E mutants often used to study eIF4E function.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">eIF4E mutant</th><th align="center" colspan="2" rowspan="1">eIF4E activity</th><th align="left" rowspan="1" colspan="1">Effect</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Cap- dependent Translation</th><th align="left" rowspan="1" colspan="1">Nuclear export</th><th align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Binding to the CAP</td><td align="left" rowspan="1" colspan="1">W56A</td><td align="left" rowspan="1" colspan="1">Inhibited</td><td align="left" rowspan="1" colspan="1">Inhibited</td><td align="left" rowspan="1" colspan="1">Prevents m7G Cap-binding [<xref rid="BST-2024-1045C58" ref-type="bibr">58</xref>,<xref rid="BST-2024-1045C64" ref-type="bibr">64</xref>,<xref rid="BST-2024-1045C73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Binding to EFBPs</td><td align="left" rowspan="1" colspan="1">W73F</td><td align="left" rowspan="1" colspan="1">Inhibited</td><td align="left" rowspan="1" colspan="1">Not altered</td><td align="left" rowspan="1" colspan="1">Prevents binding to eIF4G [<xref rid="BST-2024-1045C68" ref-type="bibr">68</xref>,<xref rid="BST-2024-1045C73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Y76A</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Reduce binding to Z-protein [<xref rid="BST-2024-1045C74" ref-type="bibr">74</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">W130F</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Altering Cap-site conformation [<xref rid="BST-2024-1045C74" ref-type="bibr">74</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">S53A</td><td align="left" rowspan="1" colspan="1">Not altered</td><td align="left" rowspan="1" colspan="1">Impaired</td><td align="left" rowspan="1" colspan="1">Not well characterised [<xref rid="BST-2024-1045C61" ref-type="bibr">61&#8211;63</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">L134R</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Affects protein conformation [<xref rid="BST-2024-1045C8" ref-type="bibr">8</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">W73A</td><td align="left" rowspan="1" colspan="1">Inhibited</td><td align="left" rowspan="1" colspan="1">Not altered</td><td align="left" rowspan="1" colspan="1">Prevents binding to eIF4G [<xref rid="BST-2024-1045C60" ref-type="bibr">60</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">V69/W73A</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">Impaired</td><td align="left" rowspan="1" colspan="1">Reduced association with LRPPRC [<xref rid="BST-2024-1045C60" ref-type="bibr">60</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Post- Translational Modifications</td><td align="left" rowspan="1" colspan="1">S209 / T210A<xref rid="BST-2024-1045T1FN2" ref-type="table-fn">
<sup>1</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">Not altered</td><td align="left" rowspan="1" colspan="1">Reduced up 50% (<italic toggle="yes">in vivo</italic>)</td><td align="left" rowspan="1" colspan="1">Impairs eIF4E phosphorylation by MNK1/2 [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>,<xref rid="BST-2024-1045C77" ref-type="bibr">77</xref>,<xref rid="BST-2024-1045C78" ref-type="bibr">78</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="BST-2024-1045T1FN1"><p>Mutations are grouped considering their impact to eIF4E function. For each mutation, effects on eIF4E conformation, cap binding, PPIs and post-translational modifications, are reported. L134R affects site 2 and protein conformation, L85R affects conformation of the flexible loop inactivated by compound 4 binding.</p></fn><fn id="BST-2024-1045T1FN2"><label>1</label><p> S209 is the site of MNK phosphorylation but mutation to S209A results in phosphorylation of neighbouring T210 [<xref rid="BST-2024-1045C75" ref-type="bibr">75</xref>,<xref rid="BST-2024-1045C76" ref-type="bibr">76</xref>]. Therefore, to accurately evaluate the role of S209 phosphorylation, a double S209A/T210A mutation was engineered [<xref rid="BST-2024-1045C77" ref-type="bibr">77</xref>]. Created in BioRender. <ext-link xlink:href="https://BioRender.com/m21j443" ext-link-type="uri">https://BioRender.com/m21j443</ext-link>.</p></fn></table-wrap-foot></table-wrap><p>eIF4G interaction with the dorsal surface of eIF4E can further increase eIF4E cap-affinity by approx. two fold, which is counteracted through competitive binding of 4E-BP to an overlapping binding site (reviewed in [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>]). Residues V69, W73, L131 and G139 on the dorsal surface of eIF4E are critical for interactions with eIF4G or 4E-BPs [<xref rid="BST-2024-1045C68" ref-type="bibr">68</xref>,<xref rid="BST-2024-1045C79" ref-type="bibr">79</xref>,<xref rid="BST-2024-1045C80" ref-type="bibr">80</xref>]. Substituting tryptophan at position 73 with phenylalanine (W73F) yields an eIF4E mutant unable to integrate into the eIF4F complex, thereby inhibiting cap-dependent translation without affecting mRNA transport [<xref rid="BST-2024-1045C73" ref-type="bibr">73</xref>] (<xref rid="BST-2024-1045F4" ref-type="fig">Figure&#160;4</xref>
<xref rid="BST-2024-1045T1" ref-type="table">, Table 1</xref>). In mouse lymphoma models, wildtype (WT) eIF4E accelerated tumour development, while tumours expressing W56A or W73F mutants grew more slowly, highlighting that the oncogenic role of eIF4E requires cap-binding and translation initiation through binding to eIF4G [<xref rid="BST-2024-1045C73" ref-type="bibr">73</xref>].</p><p>The precise molecular mechanism by which eIF4F promotes recruitment of the ribosomal pre-initiation complex to mRNA prior to 5' UTR scanning remains unclear. Two models are proposed: 1) a slotting model, where the mRNA directly inserts into the ribosome&#8217;s mRNA-binding cleft with minimal structural remodelling, or 2) a threading model, where mRNA is actively fed through a narrow channel in the 40S ribosome, potentially utilising the eIF4A1 RNA helicase and requiring conformational changes (reviewed in [<xref rid="BST-2024-1045C81" ref-type="bibr">81</xref>]). A related question is whether the 5' mRNA cap and eIF4E remain tethered to the small ribosomal complex during 5&#8217; UTR scanning. The threading model requires the release of eIF4E from the cap and allows multiple ribosomal complexes to scan the same 5&#8217; UTR. In contrast, a tethered eIF4E would restrict scanning to a single ribosomal complex per mRNA 5' UTR. Recent cryo-EM studies of the 48S ribosomal complex did not detect eIF4E in post-cap recognition complexes, suggesting eIF4E releases the mRNA cap before or upon start-codon selection [<xref rid="BST-2024-1045C81" ref-type="bibr">81&#8211;83</xref>]. However, further research is needed to pinpoint the precise timing and the mechanistic relevance of eIF4E release to mRNA binding and scanning.</p><p>eIF4E activity can be regulated through secondary interactions on its dorsal surface. Proteins with the Really Interesting New Gene (RING) domain, such as PML and the arenaviral Z-protein, induce conformational changes in eIF4E that reduce cap-binding affinity by ~100 fold [<xref rid="BST-2024-1045C74" ref-type="bibr">74</xref>]. In contrast, interactions with eIF4G or 4E-BP1 enhance the cap-binding affinity of eIF4E [<xref rid="BST-2024-1045C79" ref-type="bibr">79</xref>]. While the Z-protein and eIF4G have binding sites that partially overlap, there are also additional distinct regions of interaction [<xref rid="BST-2024-1045C74" ref-type="bibr">74</xref>]. Mutations that reduce Z-protein binding (Y76A or W130F) do not affect eIF4G interactions, demonstrating that different proteins can have distinct eIF4E-binding modes with different regions on the dorsal surface [<xref rid="BST-2024-1045C74" ref-type="bibr">74</xref>](<xref rid="BST-2024-1045F4" ref-type="fig">Figure&#160;4</xref>, <xref rid="BST-2024-1045T1" ref-type="table">Table&#160;1</xref>). Further studies on the Z-eIF4E interaction could provide valuable insights into viral infection mechanisms [<xref rid="BST-2024-1045C84" ref-type="bibr">84</xref>]. Moreover, the Z-protein binding region of eIF4E may represent an additional druggable site on the eIF4E structure [<xref rid="BST-2024-1045C63" ref-type="bibr">63</xref>].</p><p>Post-translational modifications (PTMs) also tightly regulate eIF4E activity. Phosphorylation of eIF4E at S209, mediated by MNK kinases, has been shown to enhance eIF4E activity in response to stimuli such as stress and mitogens [<xref rid="BST-2024-1045C77" ref-type="bibr">77</xref>,<xref rid="BST-2024-1045C85" ref-type="bibr">85</xref>,<xref rid="BST-2024-1045C86" ref-type="bibr">86</xref>]. The transformation and tumourigenesis abilities of elevated phospho-eIF4E are completely abrogated upon S209 mutations [<xref rid="BST-2024-1045C77" ref-type="bibr">77</xref>]. Furthermore, S209 mutations reduce eIF4E-mediated mRNA export by up to 50%, possibly due to loss of association with 4ESE-binding proteins resulting in impaired transport of oncogenic mRNA transcripts and activation of stress responses [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>,<xref rid="BST-2024-1045C77" ref-type="bibr">77</xref>]. However, although S209 phosphorylation is increased in various tumours, its functional significance remains unclear, as some studies suggest it is not essential under normal physiological conditions [<xref rid="BST-2024-1045C78" ref-type="bibr">78</xref>,<xref rid="BST-2024-1045C87" ref-type="bibr">87</xref>,<xref rid="BST-2024-1045C88" ref-type="bibr">88</xref>]. These observations are further complicated by potentially compensatory phosphorylation of a neighbouring T210 in S209A mutants of eIF4E [<xref rid="BST-2024-1045C75" ref-type="bibr">75</xref>,<xref rid="BST-2024-1045C77" ref-type="bibr">77</xref>].</p><p>In addition to phosphorylation, sumoylation of eIF4E enhances translational activity by promoting dissociation from 4E-BP1, thus facilitating eIF4F complex formation [<xref rid="BST-2024-1045C67" ref-type="bibr">67</xref>,<xref rid="BST-2024-1045C89" ref-type="bibr">89</xref>]. Sumoylation which follows S209 phosphorylation induces a secondary conformational change in eIF4E, increasing affinity for eIF4G [<xref rid="BST-2024-1045C90" ref-type="bibr">90</xref>,<xref rid="BST-2024-1045C91" ref-type="bibr">91</xref>]. These findings underscore the complexity of eIF4E regulation by PTMs and suggest that selectively targeting these pathways may offer novel therapeutic strategies [<xref rid="BST-2024-1045C89" ref-type="bibr">89&#8211;91</xref>].</p><p>Cap-dependent translation initiation can also proceed through eIF4E-independent mechanisms. One such pathway involves the cap-binding complex (CBC), which binds the mRNA cap and recruits CTIF as a scaffold protein, analogous to eIF4G recruitment in eIF4E-dependent translation (<xref rid="BST-2024-1045F3" ref-type="fig">Figure&#160;3B</xref>) [<xref rid="BST-2024-1045C92" ref-type="bibr">92</xref>]. Both eIF4G and CTIF share a conserved MIF4G domain (middle domain of eIF4G), which serves as a bridging module for eIF3 complex recruitment [<xref rid="BST-2024-1045C92" ref-type="bibr">92&#8211;94</xref>]. Several studies suggest that CBC plays a critical role in initiating the first &#8216;pioneer&#8217; round of protein synthesis [<xref rid="BST-2024-1045C92" ref-type="bibr">92</xref>].</p><p>Additionally, a subset of mRNAs bypasses eIF4E and employs an alternative eIF3D-dependent mechanism to initiate translation, particularly under stress conditions or mTOR inhibition, when global translation is suppressed [<xref rid="BST-2024-1045C93" ref-type="bibr">93</xref>]. Under normal circumstances, eIF3D functions within the eIF3 complex to facilitate 40S ribosome recruitment. However, in its non-canonical role, eIF3D can directly bind 5' UTRs or the mRNA cap using a unique cap-binding domain structurally distinct from that of eIF4E [<xref rid="BST-2024-1045C93" ref-type="bibr">93</xref>]. Although it remains unclear whether this non-canonical activity still requires the eIF3 complex, it does involve DAP5 (eIF4G2), a homolog of eIF4G1 that lacks the eIF4E-binding domain and thus cannot mediate canonical cap-dependent translation (Figure 3C) [<xref rid="BST-2024-1045C94" ref-type="bibr">94</xref>]. This alternative pathway allows for selective translation of specific mRNAs during translational repression, contributing to processes such as oncogenesis, immune responses and viral replication [<xref rid="BST-2024-1045C93" ref-type="bibr">93</xref>,<xref rid="BST-2024-1045C94" ref-type="bibr">94</xref>].</p></sec><sec id="s1-4"><title>Targeting eIF4E in cancer</title><p>Components of the eIF4F complex, particularly eIF4E, are strongly implicated in cancer through gene amplification, oncogene regulation and direct involvement in cancer progression [<xref rid="BST-2024-1045C95" ref-type="bibr">95&#8211;103</xref>]. Deregulated or elevated expression of eIF4E is associated with a broad spectrum of human cancers including skin [<xref rid="BST-2024-1045C104" ref-type="bibr">104</xref>], breast [<xref rid="BST-2024-1045C105" ref-type="bibr">105</xref>], lung [<xref rid="BST-2024-1045C106" ref-type="bibr">106</xref>], gastric [<xref rid="BST-2024-1045C107" ref-type="bibr">107</xref>], colon [<xref rid="BST-2024-1045C108" ref-type="bibr">108</xref>], prostate [<xref rid="BST-2024-1045C109" ref-type="bibr">109</xref>] and the haematopoietic system [<xref rid="BST-2024-1045C67" ref-type="bibr">67</xref>,<xref rid="BST-2024-1045C99" ref-type="bibr">99</xref>]. High eIF4E levels alongside 4E-BP1 hyperphosphorylation, which enhances eIF4E availability for eIF4F complex formation, are associated with decreased overall survival in both breast and prostate cancers [<xref rid="BST-2024-1045C105" ref-type="bibr">105</xref>,<xref rid="BST-2024-1045C109" ref-type="bibr">109</xref>].</p><p>As described in the previous section, there are other examples of initiation factors, including eIF3D or NCBP2 &#8211; which forms a cap binding complex (CBC) with its adaptor NCBP1 &#8211; that can initiate cap-dependent translation independently of eIF4E (Figure 3C) [<xref rid="BST-2024-1045C93" ref-type="bibr">93</xref>,<xref rid="BST-2024-1045C110" ref-type="bibr">110</xref>]. However, targeting eIF4E still holds significant therapeutic promise, since beyond its established role in initiating protein synthesis, the oncogenic activity of eIF4E may also extend to the nuclear export of specific mRNAs possessing oncogenic properties as well as serving as a key convergence point for three major oncogenic pathways: c-MYC, PI3K/mTOR and RAS/RAF/MEK signalling via MNK kinases [<xref rid="BST-2024-1045C99" ref-type="bibr">99</xref>,<xref rid="BST-2024-1045C111" ref-type="bibr">111</xref>,<xref rid="BST-2024-1045C112" ref-type="bibr">112</xref>]. A major node of these oncogenic pathways is c-MYC which controls transcription of many genes, including eIF4E, required to induce malignant transformation [<xref rid="BST-2024-1045C113" ref-type="bibr">113</xref>]. In turn, eIF4E regulates translation of c-MYC, ultimately creating a feedforward loop that, when dysregulated, promotes tumourigenesis [<xref rid="BST-2024-1045C103" ref-type="bibr">103</xref>,<xref rid="BST-2024-1045C114" ref-type="bibr">114</xref>]. eIF4E overexpression and hyperactivation is sufficient to induce tumourigenic transformation of fibroblasts [<xref rid="BST-2024-1045C115" ref-type="bibr">115</xref>] and primary epithelial cells [<xref rid="BST-2024-1045C116" ref-type="bibr">116</xref>] both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>. Furthermore, transgenic mice overexpressing eIF4E develop cancers of distinct histological origin including lymphomas, hepatomas, lung adenocarcinomas and hepatocellular adenomas, many of which are among the human cancers associated with eIF4E overexpression [<xref rid="BST-2024-1045C99" ref-type="bibr">99</xref>,<xref rid="BST-2024-1045C117" ref-type="bibr">117</xref>].</p><p>A critical question is whether therapeutic strategies targeting eIF4E can produce consistent effects in cancer cells while maintaining a therapeutic window that spares normal tissues. Exploring diverse approaches targeting eIF4E is therefore essential. The dependency of cancer cells on eIF4E, coupled with the presence of other cap-binding proteins which could compensate for loss or inhibition of eIF4E activity, suggests the possibility of a therapeutic window. A haplo-insufficient mouse model has demonstrated that partial loss of eIF4E can indeed be tolerated [<xref rid="BST-2024-1045C118" ref-type="bibr">118</xref>]. In these mice, loss of one eIF4E allele and the resulting reduction in eIF4E protein expression did not impair embryonic development or maintenance of global protein synthesis levels. Despite the tolerance to reduced eIF4E expression, these mice exhibited strong resistance to cellular transformation and tumourigenicity induced by oncogenes such as H-RAS, further supporting the existence of a therapeutic window [<xref rid="BST-2024-1045C118" ref-type="bibr">118</xref>]. <xref rid="BST-2024-1045T2" ref-type="table">Table&#160;2</xref> summarises current efforts to inhibit eIF4E using direct and indirect methods, including small-molecule or peptide mimetics, disruption of PPIs and improved antisense delivery [<xref rid="BST-2024-1045C11" ref-type="bibr">11</xref>].</p><table-wrap position="float" id="BST-2024-1045T2" orientation="portrait"><label>Table 2</label><caption><title>Overview of different approaches to inhibit eIF4E and their current development stage (D &amp; D, discovery and development). Clinical trial status at time of reporting March 2025, (<ext-link xlink:href="https://clinicaltrials.gov" ext-link-type="uri">https://clinicaltrials.gov</ext-link>).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Primary mechanism of action</th><th align="left" rowspan="1" colspan="1">Name</th><th align="left" rowspan="1" colspan="1">Type of agent</th><th align="left" rowspan="1" colspan="1">Development stage</th><th align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">
<bold>4E-BP1 phosphorylation</bold>
</td></tr><tr><td align="left" rowspan="4" colspan="1">
<bold>mTORC1-specific</bold>
</td><td align="left" rowspan="1" colspan="1">Rapamycin</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Phase II</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C119" ref-type="bibr">119</xref>,<xref rid="BST-2024-1045C120" ref-type="bibr">120</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Everolimus</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Approved</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C121" ref-type="bibr">121</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Temsirolimus</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Approved</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C122" ref-type="bibr">122</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Ridaforolimus</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Phase III</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C123" ref-type="bibr">123</xref>]</td></tr><tr><td align="left" rowspan="8" colspan="1">
<bold>mTORC-kinases</bold>
</td><td align="left" rowspan="1" colspan="1">Torin 1</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C124" ref-type="bibr">124</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Torin 2</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C125" ref-type="bibr">125</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PP242</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C126" ref-type="bibr">126</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PP30</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C126" ref-type="bibr">126</xref>,<xref rid="BST-2024-1045C127" ref-type="bibr">127</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">MLN0128</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Phase II</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C128" ref-type="bibr">128</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">AZD8055</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C129" ref-type="bibr">129</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">OSI-027</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C130" ref-type="bibr">130</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Rapalink-1</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C131" ref-type="bibr">131</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>PI3K signalling pathway</bold>
</td><td align="left" rowspan="1" colspan="1">PI-103</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C132" ref-type="bibr">132</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Alpelisib</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Phase IV</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C133" ref-type="bibr">133</xref>]</td></tr><tr><td align="left" rowspan="3" colspan="1">
<bold>AKT</bold>
</td><td align="left" rowspan="1" colspan="1">MK-2206</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Phase II</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C134" ref-type="bibr">134</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Ipatasertib</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Phase III</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C135" ref-type="bibr">135</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Capivasertib</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Approved</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C136" ref-type="bibr">136</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CDK4</bold>
</td><td align="left" rowspan="1" colspan="1">Palbociclib</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Approved</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C137" ref-type="bibr">137</xref>,<xref rid="BST-2024-1045C138" ref-type="bibr">138</xref>]</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>eIF4E-dependent</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>RNA export - XPO1</bold>
</td><td align="left" rowspan="1" colspan="1">Selinexor</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Approved</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C139" ref-type="bibr">139</xref>,<xref rid="BST-2024-1045C140" ref-type="bibr">140</xref>]</td></tr><tr><td align="left" rowspan="5" colspan="1">
<bold>eIF4E phosphorylation - MNK1</bold>
</td><td align="left" rowspan="1" colspan="1">Tomivorsetib</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Phase II</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C141" ref-type="bibr">141</xref>,<xref rid="BST-2024-1045C142" ref-type="bibr">142</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Cercosporamide</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C143" ref-type="bibr">143</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="pmc:entrez-protein" xlink:href="CGP57380">CGP57380</ext-link></td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C144" ref-type="bibr">144</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Bay1143269</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">Terminated</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C145" ref-type="bibr">145</xref>,<xref rid="BST-2024-1045C146" ref-type="bibr">146</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">VNLG-152R</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C147" ref-type="bibr">147</xref>]</td></tr><tr><td align="left" rowspan="9" colspan="1">
<bold>eIF4E:eIF4G interaction</bold>
</td><td align="left" rowspan="1" colspan="1">4EGI-1</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C148" ref-type="bibr">148</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">4E1RCat</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C149" ref-type="bibr">149</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Compound <bold>4</bold>
</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C8" ref-type="bibr">8</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">i4EG-BiP</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C150" ref-type="bibr">150</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">d4E-6</td><td align="left" rowspan="1" colspan="1">PROTAC</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C150" ref-type="bibr">150</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">d4E-2</td><td align="left" rowspan="1" colspan="1">PROTAC</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C150" ref-type="bibr">150</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HCS-4E-BP1</td><td align="left" rowspan="1" colspan="1">Peptidomimetic</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C151" ref-type="bibr">151</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">mHCS-4E-BP1</td><td align="left" rowspan="1" colspan="1">Peptidomimetic</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C152" ref-type="bibr">152</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">LacB-4E-BP1</td><td align="left" rowspan="1" colspan="1">Peptidomimetic</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C153" ref-type="bibr">153</xref>]</td></tr><tr><td align="left" rowspan="6" colspan="1">
<bold>mRNA cap-binding</bold>
</td><td align="left" rowspan="1" colspan="1">Compound <bold>33</bold>
</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C154" ref-type="bibr">154</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">4EI-1</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C155" ref-type="bibr">155</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Ribavirin</td><td align="left" rowspan="1" colspan="1">Nucleoside analogue</td><td align="left" rowspan="1" colspan="1">Phase II</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C156" ref-type="bibr">156</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Bn7gdp-based PROTAC</td><td align="left" rowspan="1" colspan="1">PROTAC</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C157" ref-type="bibr">157</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Cap analogue 5</td><td align="left" rowspan="1" colspan="1">Prodrug</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C158" ref-type="bibr">158</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Cap-binding covalent inhibitor 12</td><td align="left" rowspan="1" colspan="1">Small molecule</td><td align="left" rowspan="1" colspan="1">D &amp; D</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C159" ref-type="bibr">159</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>eIF4 expression</bold>
</td><td align="left" rowspan="1" colspan="1">LY2275796</td><td align="left" rowspan="1" colspan="1">Oligonucleotide</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C160" ref-type="bibr">160</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">ISIS 183750</td><td align="left" rowspan="1" colspan="1">Oligonucleotide</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">[<xref rid="BST-2024-1045C161" ref-type="bibr">161</xref>]</td></tr></tbody></table></table-wrap><p>Antisense oligonucleotides targeting eIF4E have demonstrated the ability to inhibit human breast cancer xenograft growth [<xref rid="BST-2024-1045C162" ref-type="bibr">162</xref>]. In clinical studies, ISIS 183750, an eIF4E antisense, successfully reduced eIF4E expression. However, Phase II clinical trials did not show objective tumour responses, and further development was halted [<xref rid="BST-2024-1045C160" ref-type="bibr">160</xref>,<xref rid="BST-2024-1045C161" ref-type="bibr">161</xref>]. The clinical application of antisense technology has been limited by inefficient delivery. However, advancements in aptamer conjugates, nanoparticles, or lipid-based delivery may overcome these challenges, potentially reviving interest in antisense strategies.</p><p>Alternatively, targeting eIF4E indirectly, either through inhibition of the eIF4F-associated RNA helicase eIF4A or upstream kinases has demonstrated altered translation of oncogenic mRNAs, suggesting a tailored therapeutic strategy [<xref rid="BST-2024-1045C99" ref-type="bibr">99</xref>]. One approach is to target the mRNA export activity of eIF4E through its dependence on the nuclear export protein XPO1. Selinexor is a selective small molecular inhibitor of CRM1/XPO1 transport that has been demonstrated in pre-clinical and clinical studies to impair eIF4E protein export and eIF4E-dependent mRNA export and is FDA approved for use in relapsed or refractory diffuse large B-cell lymphoma or in combination with dexamethasone or bortezomib for the treatment of relapsed or refractory multiple myeloma [<xref rid="BST-2024-1045C57" ref-type="bibr">57</xref>,<xref rid="BST-2024-1045C139" ref-type="bibr">139</xref>,<xref rid="BST-2024-1045C140" ref-type="bibr">140</xref>,<xref rid="BST-2024-1045C163" ref-type="bibr">163</xref>,<xref rid="BST-2024-1045C164" ref-type="bibr">164</xref>].</p><p>One class of eIF4E modulators that have advanced to the clinic are MNK inhibitors, which block the phosphorylation of multiple downstream factors, including hnRNPA1, PSF, cPLA<sub>2</sub> and Spry2 and eIF4E [<xref rid="BST-2024-1045C165" ref-type="bibr">165</xref>]. Tomivosertib (eFT-508) is a potent, highly selective and orally bioavailable inhibitor of MNK1 and MNK2. In Phase I/II clinical trials, Tomivosertib only showed modest efficacy as a single agent, and further clinical development as a single agent was halted. Preclinical studies suggested synergistic effects with immune checkpoint inhibitors; however, clinical trials with combinations found limited improvement in overall response rates compared with checkpoint inhibitor monotherapy [<xref rid="BST-2024-1045C166" ref-type="bibr">166</xref>]. Nonetheless, several genetically engineered mouse model studies have suggested alternative combination strategies with Tomivosertib. For example, Knight and colleagues demonstrated that while inhibiting S209 phosphorylation alone did not affect K-RAS-driven tumour growth, it significantly sensitised tumours to the mTORC1 inhibitor, rapamycin [<xref rid="BST-2024-1045C167" ref-type="bibr">167</xref>]. Furthermore, Tomivosertib showed strong anti-tumour effects in pancreatic cancer mouse models by impairing ketogenesis during dietary fasting, highlighting its potential in specific metabolic contexts and revealing a new therapeutic strategy to treat pancreatic cancer [<xref rid="BST-2024-1045C168" ref-type="bibr">168</xref>].</p><p>An alternative strategy involves targeting either the mRNA cap-binding process or PPIs with critical partners like eIF4G. However, both approaches present unique challenges, such as the polar nature of the cap-binding sites or the extensive binding interface between eIF4E and eIF4G. Ribavirin, a guanosine analogue originally developed as an antiviral agent, has also shown activity in early clinical trials as a monotherapy and in combination regimens [<xref rid="BST-2024-1045C7" ref-type="bibr">7</xref>,<xref rid="BST-2024-1045C169" ref-type="bibr">169&#8211;172</xref>]. Preclinical and clinical data have indicated that Ribavirin competes with eIF4E cap-binding, stimulating re-localisation from a predominantly nuclear location to the cytoplasm, with relapse linked to continued nuclear localisation or re-localisation from the cytoplasm [<xref rid="BST-2024-1045C170" ref-type="bibr">170</xref>]. While this evidence supports eIF4E modulation as a key factor in the mechanism of action of Ribavirin, it is important to note that this drug interacts with multiple molecular pathways, all of which could contribute to its cancer-specific mechanism of action [<xref rid="BST-2024-1045C11" ref-type="bibr">11</xref>,<xref rid="BST-2024-1045C169" ref-type="bibr">169</xref>,<xref rid="BST-2024-1045C173" ref-type="bibr">173</xref>].</p><p>Preclinical and clinical studies with drugs such as Ribavirin, Selinexor and MNK1/2 or mTORC inhibitors have demonstrated that inhibiting eIF4E activity is tractable. However, their use as chemical tools to complement genetic knockout strategies is limited, as these agents either exhibit poly-pharmacology targeting multiple proteins including eIF4E - or act on distal regulators of eIF4E but have additional downstream targets. Thus, it remains challenging to unequivocally attribute any of their anticancer effects to eIF4E inhibition alone. A more effective approach for probing eIF4E function and developing therapeutics is to directly and selectively target eIF4E itself. Over the past two decades, biochemical screening of compound libraries has identified proof-of-concept pharmacophores [<xref rid="BST-2024-1045C174" ref-type="bibr">174&#8211;177</xref>]. Lead compounds with low-nanomolar biochemical potency can block mRNA cap binding, while others inhibit the eIF4E:eIF4G interaction. However, these tool compounds lack key features of high-quality chemical probes, such as confirmed selectivity, cellular potency and structurally related inactive controls, in addition to favourable physiochemical properties like solubility [<xref rid="BST-2024-1045C174" ref-type="bibr">174</xref>,<xref rid="BST-2024-1045C178" ref-type="bibr">178</xref>]. To date, no reports indicate that these early tool compounds have progressed into drug-like chemical series with improved pharmaceutical properties [<xref rid="BST-2024-1045C178" ref-type="bibr">178</xref>].</p><p>We recently addressed these challenges by screening a small fragment library using a combination of ligand-observed NMR and X-ray crystallography to identify potentially druggable sites [<xref rid="BST-2024-1045C8" ref-type="bibr">8</xref>]. This unbiased approach differed from previous screening methods that specifically targeted the cap-binding or the interaction between eIF4E and eIF4G peptide sequences [<xref rid="BST-2024-1045C154" ref-type="bibr">154</xref>,<xref rid="BST-2024-1045C175" ref-type="bibr">175&#8211;177</xref>]. Fragment hits were identified that bound to the mRNA cap-binding site and a second site (site <bold>2;</bold>
<xref rid="BST-2024-1045F4" ref-type="fig">Figure&#160;4</xref>) on the lateral surface of eIF4E proximal to both the canonical and non-canonical eIF4G/4E-BP1 interaction sites described by both Sekiyama and Gruner [<xref rid="BST-2024-1045C8" ref-type="bibr">8</xref>,<xref rid="BST-2024-1045C70" ref-type="bibr">70</xref>,<xref rid="BST-2024-1045C179" ref-type="bibr">179</xref>]. Through iterative rounds of structure-based design, the site <bold>2</bold> binding fragment hits were optimised to compound <bold>4</bold>, that binds eIF4E with a 90 nM <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">d</italic>
</sub>. Binding of compound <bold>4</bold> induces a conformational change to the &#945;1-helix and flexible loop proximal to the non-canonical eIF4G/4E-BP1 binding site that could potentially affect these eIF4E interactors (<xref rid="BST-2024-1045F4" ref-type="fig">Figure&#160;4</xref>). Consistent with this idea, compound <bold>4</bold> disrupted the eIF4E:eIF4G interaction and inhibited translation in cell lysates.</p><p>At the time of screening, site <bold>2</bold> had unknown functional relevance, although more recently Fischer and colleagues reported a biphenyl-derivative of 4EGI-1 (i4EG-BiP), which binds in the same region but makes different interactions to those identified for compound <bold>4</bold> [<xref rid="BST-2024-1045C70" ref-type="bibr">70</xref>,<xref rid="BST-2024-1045C148" ref-type="bibr">148</xref>,<xref rid="BST-2024-1045C150" ref-type="bibr">150</xref>]. Compound <bold>4</bold> could displace binding of full-length eIF4G in cell lysates (EC<sub>50</sub> &#8776; 1.5 &#956;M) similar to 4EGI-1 and i4EG-BiP (56 and 67 &#956;M IC<sub>50</sub> respectively in an eIF4E:eIF4G peptide fluorescence polarisation assay). Interestingly, displacement of eIF4G from eIF4E by compound <bold>4</bold> did not result in the recruitment of 4E-BP1 to eIF4G that was reported following 4EGI-1 or i4EG-BiP treatment [<xref rid="BST-2024-1045C148" ref-type="bibr">148</xref>]. This suggested compound <bold>4</bold> has a different binding mode to 4EGI-1 and i4EG-BiP and warrant further in-depth studies to understand the complexities of 4E-BP1 or eIF4G binding to eIF4E and the impact of small molecules.</p><p>Compound <bold>4</bold> could bind to eIF4E in intact cells at 1&#8211;2 &#956;M; however, the activity of compound <bold>4</bold> dropped significantly in live-cell assays of protein synthesis. Cell-based mutational analysis showed that simultaneous disruption of both the canonical and non-canonical eIF4G binding sites was necessary to elicit a strong cellular response from mutation or compound [<xref rid="BST-2024-1045C8" ref-type="bibr">8</xref>]. These findings underscore the importance of structural insights and ligand-binding site mutations to guide the understanding of eIF4E function and the development of potent small-molecule inhibitors or degraders targeting eIF4E.</p></sec><sec id="s1-5"><title>eIF4E in human disease: roles beyond cancer</title><p>While eIF4E is primarily studied for its role in cancer, its deregulation and functional involvement also extends to several non-cancerous human diseases such as autism, Alzheimer&#8217;s disease and type 2 diabetes [<xref rid="BST-2024-1045C76" ref-type="bibr">76</xref>,<xref rid="BST-2024-1045C180" ref-type="bibr">180&#8211;193</xref>]. These conditions highlight the broader implications of eIF4E in regulating translation and RNA metabolism, underscoring its relevance in various pathological contexts and its broad physiological importance beyond oncogenesis. By regulating cap-dependent translation, eIF4E affects processes critical for neuronal health, metabolism, cardiovascular function, immune responses and development. These insights also position eIF4E as a potential therapeutic target in diverse pathological contexts, including neurodegenerative, metabolic and inflammatory diseases (<xref rid="BST-2024-1045T3" ref-type="table">Table&#160;3</xref>).</p><table-wrap position="float" id="BST-2024-1045T3" orientation="portrait"><label>Table 3</label><caption><title>Summary of the potential influence of eIF4E in non-cancerous human disease.figure</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Disease type</th><th align="left" rowspan="1" colspan="1">Role of eIF4E</th><th align="left" rowspan="1" colspan="1">Pre-Clinical targeting</th><th align="left" rowspan="1" colspan="1">Clinical trials</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">
<bold>Neurodegenerative diseases</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Fragile X syndrome</td><td align="left" rowspan="1" colspan="1">Abnormal signalling of the mTOR pathway regulates eIF4E activity, enhanced translation is linked to synaptic dysfunction and cognitive impairment [<xref rid="BST-2024-1045C180" ref-type="bibr">180</xref>]</td><td align="left" rowspan="1" colspan="1">Rapamycin, Tomivosertib, Cercosporamide, Metformin [<xref rid="BST-2024-1045C194" ref-type="bibr">194&#8211;197</xref>]</td><td align="left" rowspan="1" colspan="1">Metformin [<xref rid="BST-2024-1045C198" ref-type="bibr">198</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Autism spectrum disorders</td><td align="left" rowspan="1" colspan="1">Enhanced signalling regulating eIF4E/eIF4G interaction affects synaptic protein synthesis [<xref rid="BST-2024-1045C182" ref-type="bibr">182</xref>]</td><td align="left" rowspan="1" colspan="1">4EG-1<break/>[<xref rid="BST-2024-1045C181" ref-type="bibr">181</xref>,<xref rid="BST-2024-1045C182" ref-type="bibr">182</xref>]</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Alzheimer&#8217;s Disease</td><td align="left" rowspan="1" colspan="1">Deregulated synthesis of synaptic proteins and accumulation of misfolded proteins, exacerbating neurodegeneration [<xref rid="BST-2024-1045C183" ref-type="bibr">183</xref>]</td><td align="left" rowspan="1" colspan="1">CGP 57380<break/>[<xref rid="BST-2024-1045C183" ref-type="bibr">183</xref>]</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>Metabolic disorders</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Type 2 diabetes mellitus</td><td align="left" rowspan="1" colspan="1">Enhanced translation of transcripts involved in inflammation and lipid metabolism, contributing to insulin resistance [<xref rid="BST-2024-1045C184" ref-type="bibr">184</xref>,<xref rid="BST-2024-1045C185" ref-type="bibr">185</xref>]</td><td align="left" rowspan="1" colspan="1">Metformin, Rapamycin [<xref rid="BST-2024-1045C199" ref-type="bibr">199&#8211;201</xref>]</td><td align="left" rowspan="1" colspan="1">Metformin<break/>[<xref rid="BST-2024-1045C202" ref-type="bibr">202&#8211;204</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity</td><td align="left" rowspan="1" colspan="1">Increased adipogenesis and inflammatory cytokine production, linked to obesity-related metabolic dysfunction [<xref rid="BST-2024-1045C186" ref-type="bibr">186</xref>]</td><td align="left" rowspan="1" colspan="1">Tomivosertib, COH-SR4, Metformin<break/>[<xref rid="BST-2024-1045C186" ref-type="bibr">186</xref>,<xref rid="BST-2024-1045C205" ref-type="bibr">205</xref>,<xref rid="BST-2024-1045C206" ref-type="bibr">206</xref>]</td><td align="left" rowspan="1" colspan="1">Metformin [<xref rid="BST-2024-1045C207" ref-type="bibr">207</xref>]</td></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>Cardiovascular diseases</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiac hypertrophy</td><td align="left" rowspan="1" colspan="1">Abnormal protein synthesis in cardiomyocytes, driving pathological hypertrophy and heart failure [<xref rid="BST-2024-1045C187" ref-type="bibr">187</xref>]</td><td align="left" rowspan="1" colspan="1">Lithium, Rapamycin<break/>[<xref rid="BST-2024-1045C208" ref-type="bibr">208&#8211;211</xref>]</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Atherosclerosis</td><td align="left" rowspan="1" colspan="1">Regulates the translation of pro-inflammatory mRNAs encoding cytokines and adhesion molecules that contribute to vascular inflammation and plaque formation [<xref rid="BST-2024-1045C188" ref-type="bibr">188</xref>]</td><td align="left" rowspan="1" colspan="1">Rapamycin<break/>[<xref rid="BST-2024-1045C212" ref-type="bibr">212</xref>]</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>Infectious diseases</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Viral replication</td><td align="left" rowspan="1" colspan="1">Some viruses e.g. HIV, influenza and hepatitis C virus hijack the host translation machinery and exploit eIF4E to enhance their replication [<xref rid="BST-2024-1045C189" ref-type="bibr">189</xref>]</td><td align="left" rowspan="1" colspan="1">Ribavirin<break/>[<xref rid="BST-2024-1045C213" ref-type="bibr">213</xref>,<xref rid="BST-2024-1045C214" ref-type="bibr">214</xref>]</td><td align="left" rowspan="1" colspan="1">Ribavirin<break/>[<xref rid="BST-2024-1045C215" ref-type="bibr">215</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Immune response</td><td align="left" rowspan="1" colspan="1">eIF4E regulates the translation of immune-associated transcripts, affecting the production of cytokines and interferons during infection and impacting on immune defences [<xref rid="BST-2024-1045C190" ref-type="bibr">190</xref>]</td><td align="left" rowspan="1" colspan="1">Ribavirin, Rapamycin<break/>[<xref rid="BST-2024-1045C216" ref-type="bibr">216&#8211;219</xref>]</td><td align="left" rowspan="1" colspan="1">Rapamycin<break/>[<xref rid="BST-2024-1045C220" ref-type="bibr">220</xref>,<xref rid="BST-2024-1045C221" ref-type="bibr">221</xref>]</td></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>Inflammatory diseases</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic inflammatory disorders</td><td align="left" rowspan="1" colspan="1">eIF4E regulates the translation of pro-inflammatory cytokines and chemokines with roles in conditions such as rheumatoid arthritis and inflammatory bowel disease [<xref rid="BST-2024-1045C192" ref-type="bibr">192</xref>]</td><td align="left" rowspan="1" colspan="1">Rapamycin [<xref rid="BST-2024-1045C222" ref-type="bibr">222&#8211;224</xref>]</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>Developmental and genetic disorders</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Vanishing white matter disease</td><td align="left" rowspan="1" colspan="1">Leukodystrophy that involves mutations in translation initiation factors, includes eIF4E interactors, disrupting protein synthesis critical for myelin production [<xref rid="BST-2024-1045C76" ref-type="bibr">76</xref>,<xref rid="BST-2024-1045C191" ref-type="bibr">191</xref>]</td><td align="left" rowspan="1" colspan="1">Transcranial magnetic stimulation<break/>[<xref rid="BST-2024-1045C225" ref-type="bibr">225</xref>]</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Intellectual disability and microcephaly</td><td align="left" rowspan="1" colspan="1">Rare mutations in eIF4E and associated factors disrupt cap-dependent translation, impairing brain development and function [<xref rid="BST-2024-1045C193" ref-type="bibr">193</xref>]</td><td align="left" rowspan="1" colspan="1">&#8195;</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec></sec><sec id="s2"><title>Summary</title><p>Most research has focused on eIF4E&#8217;s canonical role in translation initiation. However, given more recent insights into its broader functions, it is essential to revisit these studies with an expanded perspective. For example, a critical factor may be the balance between the cytoplasmic and nuclear roles of eIF4E in cancer cells and other disease models. Cellular transformation often leads to elevated transcription rates, which, in turn, may increase the demand for mRNA nuclear export. This heightened burden on mRNA export could reduce the availability of eIF4E for protein synthesis initiation, as it becomes sequestered for export functions. This phenomenon may also align with observations over the past decade that cancer cells frequently utilise eIF4E-independent mechanisms to sustain protein synthesis, employing both cap-dependent and cap-independent pathways [<xref rid="BST-2024-1045C226" ref-type="bibr">226</xref>]. Increased use of eIF4E-independent pathways in cancer cells may also reflect the low levels of altered protein expression detected in global proteome profiles of cancer cells following loss of eIF4E by siRNA or eIF4E-degron approaches [<xref rid="BST-2024-1045C8" ref-type="bibr">8</xref>,<xref rid="BST-2024-1045C227" ref-type="bibr">227</xref>]. Further investigations are needed to better distinguish the contributions of eIF4E&#8217;s multiple roles in disease pathology. The availability of potent, selective tool compounds to complement existing genetic approaches will greatly facilitate these studies. Moreover, a comprehensive understanding of the pathways involving eIF4E is fundamental to identifying the best therapeutic approaches for effectively targeting this critical protein.</p><boxed-text id="BST-2024-1045B1" position="float" orientation="portrait"><caption><title>Perspectives</title></caption><list list-type="bullet"><list-item><p>Eukaryotic translation initiation factor 4E (eIF4E) is a key component of the eIF4F translation initiation complex and a regulator of nuclear export and mRNA processing. This multifunctional role is crucial for protein expression, cell survival and proliferation and is linked to human disease, particularly cancer, making eIF4E a promising therapeutic target.</p></list-item><list-item><p>A deeper understanding of eIF4E&#8217;s structure, function and binding partners will help to identify new strategies for its direct modulation. This will include exploiting synthetic lethal interactions with eIF4E inhibition or designing drug combinations to enhance treatment efficacy.</p></list-item><list-item><p>Identifying potent and selective chemical probes targeting eIF4E will provide valuable tools to complement existing biophysical, biochemical and genetic approaches to study eIF4E in normal and disease models. The availability of high-quality chemical tools will also provide starting points for the development of novel eIF4E-targeted therapeutics.</p></list-item></list></boxed-text></sec></body><back><ack><title>Acknowledgments</title><p>We thank our colleagues and collaborators at The Institute of Cancer Research and Astex Pharmaceuticals for many helpful discussions. The authors&#8217; work is supported by The Institute of Cancer Research Core funding. All figures were created using BioRender.</p></ack><sec sec-type="COI-statement" id="s3"><title>Competing Interests</title><p>S.D.A., C.D., M.V.P. and P.A.C. are employees of The Institute of Cancer Research, which has a commercial interest in a range of drug targets, including eIF4E, and operates a Rewards to Discoverers scheme, through which employees may receive financial benefits following the commercial licensing of a project.</p></sec><sec sec-type="funding" id="s4"><title>Funding</title><p>The Team's work on EIF4E was supported by both Astex Pharmaceuticals and The Institute of Cancer Research core funding.</p></sec><sec sec-type="open-access" id="s5"><title>Open Access</title><p>This article has been published open access under our Subscribe to Open programme, made possible through the support of our subscribing institutions, learn more here: <ext-link xlink:href="https://portlandpress.com/pages/open_access_options_and_prices#conditional" ext-link-type="uri">https://portlandpress.com/pages/open_access_options_and_prices#conditional</ext-link>
</p></sec><sec sec-type="author-contribution" id="s6"><title>CRediT Author Contribution</title><p>Writing &#8211; original draft: SDA, CD, MVP; Writing &#8211; review &amp; editing - MVP, PAC</p></sec><glossary><title>Abbreviations</title><def-list list-content="abbreviations"><def-item><term id="uid1">APA</term><def><p>alternative polyadenylation</p></def></def-item><def-item><term id="uid2">CPA</term><def><p>cleavage and polyadenylation</p></def></def-item><def-item><term id="uid3">PAS</term><def><p>polyadenylation signal</p></def></def-item><def-item><term id="uid4">PPI</term><def><p>protein-&#8211;protein interaction</p></def></def-item><def-item><term id="uid5">eIf4E</term><def><p>eukaryotic translation initiation factor 4E</p></def></def-item><def-item><term id="uid6">m<sup>7</sup>G-cap</term><def><p>methyl-7-guanosine cap</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="BST-2024-1045C1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Buttgereit</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Brand</surname><given-names>M.D</given-names></string-name></person-group><year>1995</year><article-title>A hierarchy of ATP-consuming processes in mammalian cells</article-title><source>Biochem. J.</source><volume>312 (Pt 1)</volume><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1042/bj3120163</pub-id><pub-id pub-id-type="pmid">7492307</pub-id><pub-id pub-id-type="pmcid">PMC1136240</pub-id></mixed-citation></ref><ref id="BST-2024-1045C2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jia</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>He</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Huang</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Li</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></string-name><string-name name-style="western"><surname>Liu</surname><given-names>K</given-names></string-name></person-group><year>2024</year><article-title>Protein translation: biological processes and therapeutic strategies for human diseases</article-title><source>Signal Transduct. Target. Ther.</source><volume>9</volume><elocation-id>44</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-024-01749-9</pub-id><pub-id pub-id-type="pmid">38388452</pub-id><pub-id pub-id-type="pmcid">PMC10884018</pub-id></mixed-citation></ref><ref id="BST-2024-1045C3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Deng</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Jankovic</surname><given-names>J</given-names></string-name></person-group><year>2015</year><article-title>The EIF4G1 gene and Parkinson&#8217;s disease</article-title><source>Acta Neurol. Scand.</source><volume>132</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1111/ane.12397</pub-id><pub-id pub-id-type="pmid">25765080</pub-id></mixed-citation></ref><ref id="BST-2024-1045C4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hofmann</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Serafin</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Schwerdt</surname><given-names>O.M.</given-names></string-name><string-name name-style="western"><surname>Fischer</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Sicklinger</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Younesi</surname><given-names>F.S.</given-names></string-name><etal>et al</etal></person-group><year>2024</year><article-title>Transient Inhibition of Translation Improves Cardiac Function After Ischemia/Reperfusion by Attenuating the Inflammatory Response</article-title><source>Circulation</source><volume>150</volume><fpage>1248</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.123.067479</pub-id><pub-id pub-id-type="pmid">39206545</pub-id><pub-id pub-id-type="pmcid">PMC11472906</pub-id></mixed-citation></ref><ref id="BST-2024-1045C5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pelletier</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Sonenberg</surname><given-names>N</given-names></string-name></person-group><year>2019</year><article-title>The organizing principles of eukaryotic ribosome recruitment</article-title><source>Annu. Rev. Biochem.</source><volume>88</volume><fpage>307</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-013118-111042</pub-id><pub-id pub-id-type="pmid">31220979</pub-id></mixed-citation></ref><ref id="BST-2024-1045C6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lejbkowicz</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Goyer</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Darveau</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Neron</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Lemieux</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Sonenberg</surname><given-names>N</given-names></string-name></person-group><year>1992</year><article-title>A fraction of the mRNA 5&#8217; cap-binding protein, eukaryotic initiation factor 4E, localizes to the nucleus</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>89</volume><fpage>9612</fpage><lpage>9616</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.20.9612</pub-id><pub-id pub-id-type="pmid">1384058</pub-id><pub-id pub-id-type="pmcid">PMC50182</pub-id></mixed-citation></ref><ref id="BST-2024-1045C7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mars</surname><given-names>J.C.</given-names></string-name><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2024</year><article-title>eIF4E orchestrates mRNA processing, RNA export and translation to modify specific protein production</article-title><source>Nucleus</source><volume>15</volume><elocation-id>2360196</elocation-id><pub-id pub-id-type="doi">10.1080/19491034.2024.2360196</pub-id><pub-id pub-id-type="pmid">38880976</pub-id><pub-id pub-id-type="pmcid">PMC11185188</pub-id></mixed-citation></ref><ref id="BST-2024-1045C8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sharp</surname><given-names>S.Y.</given-names></string-name><string-name name-style="western"><surname>Martella</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>D&#8217;Agostino</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Milton</surname><given-names>C.I.</given-names></string-name><string-name name-style="western"><surname>Ward</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>Woodhead</surname><given-names>A.J.</given-names></string-name><etal>et al</etal></person-group><year>2024</year><article-title>Integrating fragment-based screening with targeted protein degradation and genetic rescue to explore eIF4E function</article-title><source>Nat. Commun.</source><volume>15</volume><elocation-id>10037</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-54356-1</pub-id><pub-id pub-id-type="pmid">40016190</pub-id><pub-id pub-id-type="pmcid">PMC11868579</pub-id></mixed-citation></ref><ref id="BST-2024-1045C9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Fernando</surname><given-names>T.M.</given-names></string-name><string-name name-style="western"><surname>Marullo</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Calvo-Vidal</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Verma</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Yang</surname><given-names>S.</given-names></string-name><etal>et al</etal></person-group><year>2016</year><article-title>Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas</article-title><source>Blood</source><volume>127</volume><fpage>858</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-05-645069</pub-id><pub-id pub-id-type="pmid">26603836</pub-id><pub-id pub-id-type="pmcid">PMC4760090</pub-id></mixed-citation></ref><ref id="BST-2024-1045C10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></string-name><string-name name-style="western"><surname>Wu</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Wang</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Guo</surname><given-names>C</given-names></string-name></person-group><year>2023</year><article-title>Regulation of eukaryotic translation Initiation factor 4E as a potential anticancer strategy</article-title><source>J. Med. Chem.</source><volume>66</volume><fpage>12678</fpage><lpage>12696</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c00636</pub-id><pub-id pub-id-type="pmid">37725577</pub-id></mixed-citation></ref><ref id="BST-2024-1045C11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O&#8217;Rourke</surname><given-names>R.L.</given-names></string-name><string-name name-style="western"><surname>Garner</surname><given-names>A.L</given-names></string-name></person-group><year>2025</year><article-title>Chemical Probes for Studying the Eukaryotic Translation Initiation Factor 4E (eIF4E)-regulated translatome in cancer</article-title><source>ACS Pharmacol. Transl. Sci.</source><volume>8</volume><fpage>621</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1021/acsptsci.4c00674</pub-id><pub-id pub-id-type="pmid">40109752</pub-id><pub-id pub-id-type="pmcid">PMC11915038</pub-id></mixed-citation></ref><ref id="BST-2024-1045C12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Furuichi</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>LaFiandra</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Shatkin</surname><given-names>A.J</given-names></string-name></person-group><year>1977</year><article-title>5&#8217;-Terminal structure and mRNA stability</article-title><source>Nature</source><volume>266</volume><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1038/266235a0</pub-id><pub-id pub-id-type="pmid">557727</pub-id></mixed-citation></ref><ref id="BST-2024-1045C13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Murthy</surname><given-names>K.G.</given-names></string-name><string-name name-style="western"><surname>Park</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Manley</surname><given-names>J.L</given-names></string-name></person-group><year>1991</year><article-title>A nuclear micrococcal-sensitive, ATP-dependent exoribonuclease degrades uncapped but not capped RNA substrates</article-title><source>Nucleic Acids Res.</source><volume>19</volume><fpage>2685</fpage><lpage>2692</lpage><pub-id pub-id-type="doi">10.1093/nar/19.10.2685</pub-id><pub-id pub-id-type="pmid">1710342</pub-id><pub-id pub-id-type="pmcid">PMC328187</pub-id></mixed-citation></ref><ref id="BST-2024-1045C14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Borden</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Cowling</surname><given-names>V.H</given-names></string-name></person-group><year>2021</year><article-title>To cap it all off, again: dynamic capping and recapping of coding and non-coding RNAs to control transcript fate and biological activity</article-title><source>Cell Cycle</source><volume>20</volume><fpage>1347</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1080/15384101.2021.1930929</pub-id><pub-id pub-id-type="pmid">34241559</pub-id><pub-id pub-id-type="pmcid">PMC8344758</pub-id></mixed-citation></ref><ref id="BST-2024-1045C15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Galloway</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Cowling</surname><given-names>V.H</given-names></string-name></person-group><year>2019</year><article-title>mRNA cap regulation in mammalian cell function and fate</article-title><source>Biochim. Biophys. Acta Gene Regul. Mech</source><volume>1862</volume><fpage>270</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2018.09.011</pub-id><pub-id pub-id-type="pmid">30312682</pub-id><pub-id pub-id-type="pmcid">PMC6414751</pub-id></mixed-citation></ref><ref id="BST-2024-1045C16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Skrabanek</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Revuelta</surname><given-names>M.V.</given-names></string-name><string-name name-style="western"><surname>Gasiorek</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Cowling</surname><given-names>V.H.</given-names></string-name><string-name name-style="western"><surname>Cerchietti</surname><given-names>L.</given-names></string-name><etal>et al</etal></person-group><year>2020</year><article-title>The eukaryotic translation initiation factor eIF4E elevates steady-state m<sup>7</sup>G capping of coding and noncoding transcripts</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>117</volume><fpage>26773</fpage><lpage>26783</lpage><pub-id pub-id-type="doi">10.1073/pnas.2002360117</pub-id><pub-id pub-id-type="pmid">33055213</pub-id><pub-id pub-id-type="pmcid">PMC7604501</pub-id></mixed-citation></ref><ref id="BST-2024-1045C17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schoenberg</surname><given-names>D.R.</given-names></string-name><string-name name-style="western"><surname>Maquat</surname><given-names>L.E</given-names></string-name></person-group><year>2009</year><article-title>Re-capping the message</article-title><source>Trends Biochem. Sci.</source><volume>34</volume><fpage>435</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2009.05.003</pub-id><pub-id pub-id-type="pmid">19729311</pub-id><pub-id pub-id-type="pmcid">PMC2743798</pub-id></mixed-citation></ref><ref id="BST-2024-1045C18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Otsuka</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Kedersha</surname><given-names>N.L.</given-names></string-name><string-name name-style="western"><surname>Schoenberg</surname><given-names>D.R</given-names></string-name></person-group><year>2009</year><article-title>Identification of a cytoplasmic complex that adds a cap onto 5&#8217;-monophosphate RNA</article-title><source>Mol. Cell. Biol.</source><volume>29</volume><fpage>2155</fpage><lpage>2167</lpage><pub-id pub-id-type="doi">10.1128/MCB.01325-08</pub-id><pub-id pub-id-type="pmid">19223470</pub-id><pub-id pub-id-type="pmcid">PMC2663312</pub-id></mixed-citation></ref><ref id="BST-2024-1045C19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mukherjee</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Patil</surname><given-names>D.P.</given-names></string-name><string-name name-style="western"><surname>Kennedy</surname><given-names>B.A.</given-names></string-name><string-name name-style="western"><surname>Bakthavachalu</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Bundschuh</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Schoenberg</surname><given-names>D.R</given-names></string-name></person-group><year>2012</year><article-title>Identification of cytoplasmic capping targets reveals a role for cap homeostasis in translation and mRNA stability</article-title><source>Cell Rep.</source><volume>2</volume><fpage>674</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2012.07.011</pub-id><pub-id pub-id-type="pmid">22921400</pub-id><pub-id pub-id-type="pmcid">PMC3462258</pub-id></mixed-citation></ref><ref id="BST-2024-1045C20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Osborne</surname><given-names>M.J.</given-names></string-name><string-name name-style="western"><surname>Volpon</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Memarpoor-Yazdi</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Pillay</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Thambipillai</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Czarnota</surname><given-names>S</given-names></string-name>. <etal>et al</etal></person-group><year>2022</year><article-title>Identification and characterization of the Interaction between the Methyl-7-Guanosine cap maturation enzyme RNMT and the cap-binding protein eIF4E</article-title><source>J. Mol. Biol.</source><volume>434</volume><fpage>167451</fpage><pub-id pub-id-type="doi">10.1016/j.jmb.2022.167451</pub-id><pub-id pub-id-type="pmid">35026230</pub-id><pub-id pub-id-type="pmcid">PMC9288840</pub-id></mixed-citation></ref><ref id="BST-2024-1045C21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2022</year><article-title>Cancer cells hijack RNA processing to rewrite the message</article-title><source>Biochem. Soc. Trans.</source><volume>50</volume><fpage>1447</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.1042/BST20220621</pub-id><pub-id pub-id-type="pmid">36282006</pub-id><pub-id pub-id-type="pmcid">PMC9704515</pub-id></mixed-citation></ref><ref id="BST-2024-1045C22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dunn</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Cowling</surname><given-names>V.H</given-names></string-name></person-group><year>2015</year><article-title>Myc and mRNA capping</article-title><source>Biochim. Biophys. Acta</source><volume>1849</volume><fpage>501</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.03.007</pub-id><pub-id pub-id-type="pmid">24681440</pub-id><pub-id pub-id-type="pmcid">PMC6414814</pub-id></mixed-citation></ref><ref id="BST-2024-1045C23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fernandez-Sanchez</surname><given-names>M.E.</given-names></string-name><string-name name-style="western"><surname>Gonatopoulos-Pournatzis</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Preston</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>Lawlor</surname><given-names>M.A.</given-names></string-name><string-name name-style="western"><surname>Cowling</surname><given-names>V.H</given-names></string-name></person-group><year>2009</year><article-title>S-adenosyl homocysteine hydrolase is required for Myc-induced mRNA cap methylation, protein synthesis, and cell proliferation</article-title><source>Mol. Cell. Biol.</source><volume>29</volume><fpage>6182</fpage><lpage>6191</lpage><pub-id pub-id-type="doi">10.1128/MCB.00973-09</pub-id><pub-id pub-id-type="pmid">19805518</pub-id><pub-id pub-id-type="pmcid">PMC2786700</pub-id></mixed-citation></ref><ref id="BST-2024-1045C24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marasco</surname><given-names>L.E.</given-names></string-name><string-name name-style="western"><surname>Kornblihtt</surname><given-names>A.R</given-names></string-name></person-group><year>2023</year><article-title>The physiology of alternative splicing</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>24</volume><fpage>242</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/s41580-022-00545-z</pub-id><pub-id pub-id-type="pmid">36229538</pub-id></mixed-citation></ref><ref id="BST-2024-1045C25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wright</surname><given-names>C.J.</given-names></string-name><string-name name-style="western"><surname>Smith</surname><given-names>C.W.J.</given-names></string-name><string-name name-style="western"><surname>Jiggins</surname><given-names>C.D</given-names></string-name></person-group><year>2022</year><article-title>Alternative splicing as a source of phenotypic diversity</article-title><source>Nat. Rev. Genet.</source><volume>23</volume><fpage>697</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1038/s41576-022-00514-4</pub-id><pub-id pub-id-type="pmid">35821097</pub-id></mixed-citation></ref><ref id="BST-2024-1045C26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rogalska</surname><given-names>M.E.</given-names></string-name><string-name name-style="western"><surname>Vivori</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Valc&#225;rcel</surname><given-names>J</given-names></string-name></person-group><year>2023</year><article-title>Regulation of pre-mRNA splicing: roles in physiology and disease, and therapeutic prospects</article-title><source>Nat. Rev. Genet.</source><volume>24</volume><fpage>251</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/s41576-022-00556-8</pub-id><pub-id pub-id-type="pmid">36526860</pub-id></mixed-citation></ref><ref id="BST-2024-1045C27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gehring</surname><given-names>N.H.</given-names></string-name><string-name name-style="western"><surname>Roignant</surname><given-names>J.Y</given-names></string-name></person-group><year>2021</year><article-title>Anything but ordinary - emerging splicing mechanisms in eukaryotic gene regulation</article-title><source>Trends Genet</source><volume>37</volume><fpage>355</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2020.10.008</pub-id><pub-id pub-id-type="pmid">33203572</pub-id></mixed-citation></ref><ref id="BST-2024-1045C28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ghram</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Morris</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Mars</surname><given-names>J.-C.</given-names></string-name><string-name name-style="western"><surname>Gendron</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Skrabanek</surname><given-names>L.</given-names></string-name><etal>et al</etal></person-group><year>2023</year><article-title>The eukaryotic translation initiation factor eIF4E reprograms alternative splicing</article-title><source>EMBO J.</source><volume>42</volume><elocation-id>e110496</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2021110496</pub-id><pub-id pub-id-type="pmid">36843541</pub-id><pub-id pub-id-type="pmcid">PMC10068332</pub-id></mixed-citation></ref><ref id="BST-2024-1045C29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Liu</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Qiu</surname><given-names>Q.</given-names></string-name><string-name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></string-name><string-name name-style="western"><surname>Ding</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></string-name><etal>et al</etal></person-group><year>2021</year><article-title>Alternative polyadenylation: methods, mechanism, function, and role in cancer</article-title><source>J. Exp. Clin. Cancer Res.</source><volume>40</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.1186/s13046-021-01852-7</pub-id><pub-id pub-id-type="pmid">33526057</pub-id><pub-id pub-id-type="pmcid">PMC7852185</pub-id></mixed-citation></ref><ref id="BST-2024-1045C30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mitschka</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Mayr</surname><given-names>C</given-names></string-name></person-group><year>2022</year><article-title>Context-specific regulation and function of mRNA alternative polyadenylation</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>23</volume><fpage>779</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1038/s41580-022-00507-5</pub-id><pub-id pub-id-type="pmid">35798852</pub-id><pub-id pub-id-type="pmcid">PMC9261900</pub-id></mixed-citation></ref><ref id="BST-2024-1045C31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Lyu</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>Han</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Nie</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Shen</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>W.</given-names></string-name><etal>et al</etal></person-group><year>2018</year><article-title>3&#8217; UTR lengthening as a novel mechanism in regulating cellular senescence</article-title><source>Genome Res.</source><volume>28</volume><fpage>285</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1101/gr.224451.117</pub-id><pub-id pub-id-type="pmid">29440281</pub-id><pub-id pub-id-type="pmcid">PMC5848608</pub-id></mixed-citation></ref><ref id="BST-2024-1045C32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Davis</surname><given-names>M.R.</given-names></string-name><string-name name-style="western"><surname>Delaleau</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2019</year><article-title>Nuclear eIF4E Stimulates 3&#8217;-End Cleavage of Target RNAs</article-title><source>Cell Rep</source><volume>27</volume><fpage>1397</fpage><lpage>1408</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.04.008</pub-id><pub-id pub-id-type="pmid">31042468</pub-id><pub-id pub-id-type="pmcid">PMC6661904</pub-id></mixed-citation></ref><ref id="BST-2024-1045C33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mayr</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Bartel</surname><given-names>D.P</given-names></string-name></person-group><year>2009</year><article-title>Widespread shortening of 3&#8217;UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells</article-title><source>Cell</source><volume>138</volume><fpage>673</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.06.016</pub-id><pub-id pub-id-type="pmid">19703394</pub-id><pub-id pub-id-type="pmcid">PMC2819821</pub-id></mixed-citation></ref><ref id="BST-2024-1045C34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bensidoun</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Zenklusen</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Oeffinger</surname><given-names>M</given-names></string-name></person-group><year>2021</year><article-title>Choosing the right exit: How functional plasticity of the nuclear pore drives selective and efficient mRNA export</article-title><source>Wiley Interdiscip. Rev. RNA</source><volume>12</volume><elocation-id>e1660</elocation-id><pub-id pub-id-type="doi">10.1002/wrna.1660</pub-id><pub-id pub-id-type="pmid">33938148</pub-id></mixed-citation></ref><ref id="BST-2024-1045C35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bonnet</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Palancade</surname><given-names>B</given-names></string-name></person-group><year>2014</year><article-title>Regulation of mRNA trafficking by nuclear pore complexes</article-title><source>Genes (Basel)</source><volume>5</volume><fpage>767</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.3390/genes5030767</pub-id><pub-id pub-id-type="pmid">25184662</pub-id><pub-id pub-id-type="pmcid">PMC4198930</pub-id></mixed-citation></ref><ref id="BST-2024-1045C36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2013</year><article-title>Aiding and abetting cancer: mRNA export and the nuclear pore</article-title><source>Trends Cell Biol</source><volume>23</volume><fpage>328</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2013.03.004</pub-id><pub-id pub-id-type="pmid">23582887</pub-id><pub-id pub-id-type="pmcid">PMC3700650</pub-id></mixed-citation></ref><ref id="BST-2024-1045C37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khan</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Hou</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Lei</surname><given-names>H</given-names></string-name></person-group><year>2023</year><article-title>Mechanisms of RNA export and nuclear retention</article-title><source>Wiley Interdiscip. Rev. RNA</source><volume>14</volume><elocation-id>e1755</elocation-id><pub-id pub-id-type="doi">10.1002/wrna.1755</pub-id><pub-id pub-id-type="pmid">35978483</pub-id></mixed-citation></ref><ref id="BST-2024-1045C38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Natalizio</surname><given-names>B.J.</given-names></string-name><string-name name-style="western"><surname>Wente</surname><given-names>S.R</given-names></string-name></person-group><year>2013</year><article-title>Postage for the messenger: designating routes for nuclear mRNA export</article-title><source>Trends Cell Biol</source><volume>23</volume><fpage>365</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2013.03.006</pub-id><pub-id pub-id-type="pmid">23583578</pub-id><pub-id pub-id-type="pmcid">PMC3729607</pub-id></mixed-citation></ref><ref id="BST-2024-1045C39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stutz</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Izaurralde</surname><given-names>E</given-names></string-name></person-group><year>2003</year><article-title>The interplay of nuclear mRNP assembly, mRNA surveillance and export</article-title><source>Trends Cell Biol.</source><volume>13</volume><fpage>319</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/s0962-8924(03)00106-5</pub-id><pub-id pub-id-type="pmid">12791298</pub-id></mixed-citation></ref><ref id="BST-2024-1045C40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKee</surname><given-names>A.E.</given-names></string-name><string-name name-style="western"><surname>Silver</surname><given-names>P.A</given-names></string-name></person-group><year>2007</year><article-title>Systems perspectives on mRNA processing</article-title><source>Cell Res.</source><volume>17</volume><fpage>581</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1038/cr.2007.54</pub-id><pub-id pub-id-type="pmid">17621309</pub-id></mixed-citation></ref><ref id="BST-2024-1045C41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maniatis</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Reed</surname><given-names>R</given-names></string-name></person-group><year>2002</year><article-title>An extensive network of coupling among gene expression machines</article-title><source>Nature</source><volume>416</volume><fpage>499</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1038/416499a</pub-id><pub-id pub-id-type="pmid">11932736</pub-id></mixed-citation></ref><ref id="BST-2024-1045C42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hieronymus</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Yu</surname><given-names>M.C.</given-names></string-name><string-name name-style="western"><surname>Silver</surname><given-names>P.A</given-names></string-name></person-group><year>2004</year><article-title>Genome-wide mRNA surveillance is coupled to mRNA export</article-title><source>Genes Dev.</source><volume>18</volume><fpage>2652</fpage><lpage>2662</lpage><pub-id pub-id-type="doi">10.1101/gad.1241204</pub-id><pub-id pub-id-type="pmid">15489286</pub-id><pub-id pub-id-type="pmcid">PMC525545</pub-id></mixed-citation></ref><ref id="BST-2024-1045C43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2018</year><article-title>The impact of post-transcriptional control: Better living through rna regulons</article-title><source>Front. Genet.</source><volume>9</volume><elocation-id>512</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2018.00512</pub-id><pub-id pub-id-type="pmid">30455716</pub-id><pub-id pub-id-type="pmcid">PMC6230556</pub-id></mixed-citation></ref><ref id="BST-2024-1045C44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blackinton</surname><given-names>J.G.</given-names></string-name><string-name name-style="western"><surname>Keene</surname><given-names>J.D</given-names></string-name></person-group><year>2014</year><article-title>Post-transcriptional RNA regulons affecting cell cycle and proliferation</article-title><source>Semin. Cell Dev. Biol</source><volume>34</volume><fpage>44</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2014.05.014</pub-id><pub-id pub-id-type="pmid">24882724</pub-id><pub-id pub-id-type="pmcid">PMC4163074</pub-id></mixed-citation></ref><ref id="BST-2024-1045C45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Delaleau</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2015</year><article-title>Multiple Export Mechanisms for mRNAs</article-title><source>Cells</source><volume>4</volume><fpage>452</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.3390/cells4030452</pub-id><pub-id pub-id-type="pmid">26343730</pub-id><pub-id pub-id-type="pmcid">PMC4588045</pub-id></mixed-citation></ref><ref id="BST-2024-1045C46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Siddiqui</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2012</year><article-title>mRNA export and cancer</article-title><source>Wiley Interdiscip. Rev. RNA</source><volume>3</volume><fpage>13</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1002/wrna.101</pub-id><pub-id pub-id-type="pmid">21796793</pub-id></mixed-citation></ref><ref id="BST-2024-1045C47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baralle</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Buratti</surname><given-names>E</given-names></string-name></person-group><year>2017</year><article-title>RNA splicing in human disease and in the clinic</article-title><source>Clin. Sci. (Lond)</source><volume>131</volume><fpage>355</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1042/CS20160211</pub-id><pub-id pub-id-type="pmid">28202748</pub-id></mixed-citation></ref><ref id="BST-2024-1045C48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baralle</surname><given-names>F.E.</given-names></string-name><string-name name-style="western"><surname>Giudice</surname><given-names>J</given-names></string-name></person-group><year>2017</year><article-title>Alternative splicing as a regulator of development and tissue identity</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>18</volume><fpage>437</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.27</pub-id><pub-id pub-id-type="pmid">28488700</pub-id><pub-id pub-id-type="pmcid">PMC6839889</pub-id></mixed-citation></ref><ref id="BST-2024-1045C49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bentley</surname><given-names>D.L</given-names></string-name></person-group><year>2014</year><article-title>Coupling mRNA processing with transcription in time and space</article-title><source>Nat. Rev. Genet.</source><volume>15</volume><fpage>163</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1038/nrg3662</pub-id><pub-id pub-id-type="pmid">24514444</pub-id><pub-id pub-id-type="pmcid">PMC4304646</pub-id></mixed-citation></ref><ref id="BST-2024-1045C50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bentley</surname><given-names>D.L</given-names></string-name></person-group><year>2005</year><article-title>Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors</article-title><source>Curr. Opin. Cell Biol.</source><volume>17</volume><fpage>251</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2005.04.006</pub-id><pub-id pub-id-type="pmid">15901493</pub-id></mixed-citation></ref><ref id="BST-2024-1045C51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bj&#246;rk</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Wieslander</surname><given-names>L</given-names></string-name></person-group><year>2017</year><article-title>Integration of mRNP formation and export</article-title><source>Cell. Mol. Life Sci.</source><volume>74</volume><fpage>2875</fpage><lpage>2897</lpage><pub-id pub-id-type="doi">10.1007/s00018-017-2503-3</pub-id><pub-id pub-id-type="pmid">28314893</pub-id><pub-id pub-id-type="pmcid">PMC5501912</pub-id></mixed-citation></ref><ref id="BST-2024-1045C52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tuck</surname><given-names>A.C.</given-names></string-name><string-name name-style="western"><surname>Tollervey</surname><given-names>D</given-names></string-name></person-group><year>2013</year><article-title>A transcriptome-wide atlas of RNP composition reveals diverse classes of mRNAs and lncRNAs</article-title><source>Cell</source><volume>154</volume><fpage>996</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.07.047</pub-id><pub-id pub-id-type="pmid">23993093</pub-id><pub-id pub-id-type="pmcid">PMC3778888</pub-id></mixed-citation></ref><ref id="BST-2024-1045C53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Ren</surname><given-names>Y</given-names></string-name></person-group><year>2019</year><article-title>Mechanisms of nuclear mRNA export: A structural perspective</article-title><source>Traffic</source><volume>20</volume><fpage>829</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1111/tra.12691</pub-id><pub-id pub-id-type="pmid">31513326</pub-id><pub-id pub-id-type="pmcid">PMC7074880</pub-id></mixed-citation></ref><ref id="BST-2024-1045C54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tingey</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Li</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Yu</surname><given-names>W.</given-names></string-name><string-name name-style="western"><surname>Young</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Yang</surname><given-names>W</given-names></string-name></person-group><year>2022</year><article-title>Spelling out the roles of individual nucleoporins in nuclear export of mRNA</article-title><source>Nucleus</source><volume>13</volume><fpage>170</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1080/19491034.2022.2076965</pub-id><pub-id pub-id-type="pmid">35593254</pub-id><pub-id pub-id-type="pmcid">PMC9132428</pub-id></mixed-citation></ref><ref id="BST-2024-1045C55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hutten</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Kehlenbach</surname><given-names>R.H</given-names></string-name></person-group><year>2007</year><article-title>CRM1-mediated nuclear export: to the pore and beyond</article-title><source>Trends Cell Biol.</source><volume>17</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2007.02.003</pub-id><pub-id pub-id-type="pmid">17317185</pub-id></mixed-citation></ref><ref id="BST-2024-1045C56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Izaurralde</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Lewis</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Gamberi</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Jarmolowski</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>McGuigan</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Mattaj</surname><given-names>I.W</given-names></string-name></person-group><year>1995</year><article-title>A cap-binding protein complex mediating U snRNA export</article-title><source>Nature</source><volume>376</volume><fpage>709</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1038/376709a0</pub-id><pub-id pub-id-type="pmid">7651522</pub-id></mixed-citation></ref><ref id="BST-2024-1045C57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Culjkovic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Topisirovic</surname><given-names>I.</given-names></string-name><string-name name-style="western"><surname>Skrabanek</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Ruiz-Gutierrez</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2006</year><article-title>eIF4E is a central node of an RNA regulon that governs cellular proliferation</article-title><source>J. Cell Biol.</source><volume>175</volume><fpage>415</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1083/jcb.200607020</pub-id><pub-id pub-id-type="pmid">17074885</pub-id><pub-id pub-id-type="pmcid">PMC2064519</pub-id></mixed-citation></ref><ref id="BST-2024-1045C58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Culjkovic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Topisirovic</surname><given-names>I.</given-names></string-name><string-name name-style="western"><surname>Skrabanek</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Ruiz-Gutierrez</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2005</year><article-title>eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3&#8217;UTR</article-title><source>J. Cell Biol.</source><volume>169</volume><fpage>245</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1083/jcb.200501019</pub-id><pub-id pub-id-type="pmid">15837800</pub-id><pub-id pub-id-type="pmcid">PMC2171863</pub-id></mixed-citation></ref><ref id="BST-2024-1045C59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Culjkovic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L</given-names></string-name></person-group><year>2009</year><article-title>Understanding and targeting the eukaryotic translation initiation factor eIF4E in Head and neck cancer</article-title><source>J. Oncol.</source><volume>2009</volume><elocation-id>981679</elocation-id><pub-id pub-id-type="doi">10.1155/2009/981679</pub-id><pub-id pub-id-type="pmid">20049173</pub-id><pub-id pub-id-type="pmcid">PMC2798714</pub-id></mixed-citation></ref><ref id="BST-2024-1045C60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Topisirovic</surname><given-names>I.</given-names></string-name><string-name name-style="western"><surname>Siddiqui</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Lapointe</surname><given-names>V.L.</given-names></string-name><string-name name-style="western"><surname>Trost</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Thibault</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Bangeranye</surname><given-names>C.</given-names></string-name><etal>et al</etal></person-group><year>2009</year><article-title>Molecular dissection of the eukaryotic initiation factor 4E (eIF4E) export-competent RNP</article-title><source>EMBO J.</source><volume>28</volume><fpage>1087</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1038/emboj.2009.53</pub-id><pub-id pub-id-type="pmid">19262567</pub-id><pub-id pub-id-type="pmcid">PMC2683702</pub-id></mixed-citation></ref><ref id="BST-2024-1045C61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Polunovsky</surname><given-names>V.A.</given-names></string-name><string-name name-style="western"><surname>Rosenwald</surname><given-names>I.B.</given-names></string-name><string-name name-style="western"><surname>Tan</surname><given-names>A.T.</given-names></string-name><string-name name-style="western"><surname>White</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Chiang</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Sonenberg</surname><given-names>N.</given-names></string-name><etal>et al</etal></person-group><year>1996</year><article-title>Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc</article-title><source>Mol. Cell. Biol.</source><volume>16</volume><fpage>6573</fpage><lpage>6581</lpage><pub-id pub-id-type="doi">10.1128/MCB.16.11.6573</pub-id><pub-id pub-id-type="pmid">8887686</pub-id><pub-id pub-id-type="pmcid">PMC231659</pub-id></mixed-citation></ref><ref id="BST-2024-1045C62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Baguet</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Volpon</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Amri</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2012</year><article-title>The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation</article-title><source>Cell Rep.</source><volume>2</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2012.07.007</pub-id><pub-id pub-id-type="pmid">22902403</pub-id><pub-id pub-id-type="pmcid">PMC3463940</pub-id></mixed-citation></ref><ref id="BST-2024-1045C63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Osborne</surname><given-names>M.J.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2015</year><article-title>The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled</article-title><source>Immunol. Rev.</source><volume>263</volume><fpage>210</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1111/imr.12240</pub-id><pub-id pub-id-type="pmid">25510279</pub-id><pub-id pub-id-type="pmcid">PMC4269245</pub-id></mixed-citation></ref><ref id="BST-2024-1045C64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Volpon</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Sohn</surname><given-names>H.S.</given-names></string-name><string-name name-style="western"><surname>Blanchet-Cohen</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Osborne</surname><given-names>M.J.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2017</year><article-title>A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export machinery</article-title><source>RNA</source><volume>23</volume><fpage>927</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1261/rna.060137.116</pub-id><pub-id pub-id-type="pmid">28325843</pub-id><pub-id pub-id-type="pmcid">PMC5435865</pub-id></mixed-citation></ref><ref id="BST-2024-1045C65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bollmann</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Fechir</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Nowag</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Koch</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Art</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Kleinert</surname><given-names>H</given-names></string-name>. <etal>et al</etal></person-group><year>2013</year><article-title>Human inducible nitric oxide synthase (iNOS) expression depends on chromosome region maintenance 1 (CRM1)- and eukaryotic translation initiation factor 4E (elF4E)-mediated nucleocytoplasmic mRNA transport</article-title><source>Nitric Oxide</source><volume>30</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.niox.2013.02.083</pub-id><pub-id pub-id-type="pmid">23471078</pub-id></mixed-citation></ref><ref id="BST-2024-1045C66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Volpon</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Osborne</surname><given-names>M.J.</given-names></string-name><string-name name-style="western"><surname>Ramteke</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></string-name><string-name name-style="western"><surname>Niesman</surname><given-names>A</given-names></string-name>. <etal>et al</etal></person-group><year>2016</year><article-title>Importin 8 mediates m</article-title><source>Proceedings of the National Academy of Sciences</source><volume>113</volume><fpage>5263</fpage><lpage>5268</lpage><pub-id pub-id-type="doi">10.1073/pnas.1524291113</pub-id><pub-id pub-id-type="pmcid">PMC4868427</pub-id><pub-id pub-id-type="pmid">27114554</pub-id></mixed-citation></ref><ref id="BST-2024-1045C67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>An</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Tan</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Xie</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Liu</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Xu</surname><given-names>B</given-names></string-name></person-group><year>2023</year><article-title>Biological functions and research progress of eIF4E</article-title><source>Front. Oncol.</source><volume>13</volume><fpage>1076855</fpage><pub-id pub-id-type="doi">10.3389/fonc.2023.1076855</pub-id><pub-id pub-id-type="pmid">37601696</pub-id><pub-id pub-id-type="pmcid">PMC10435865</pub-id></mixed-citation></ref><ref id="BST-2024-1045C68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marcotrigiano</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Gingras</surname><given-names>A.C.</given-names></string-name><string-name name-style="western"><surname>Sonenberg</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Burley</surname><given-names>S.K</given-names></string-name></person-group><year>1997</year><article-title>Cocrystal structure of the messenger RNA 5&#8217; cap-binding protein (eIF4E) bound to 7-methyl-GDP</article-title><source>Cell</source><volume>89</volume><fpage>951</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)80280-9</pub-id><pub-id pub-id-type="pmid">9200613</pub-id></mixed-citation></ref><ref id="BST-2024-1045C69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Von der Haar,</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Gross</surname><given-names>J.D.</given-names></string-name><string-name name-style="western"><surname>Wagner</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>McCarthy</surname><given-names>J.E.G</given-names></string-name></person-group><year>2004</year><article-title>The mRNA cap-binding protein eIF4E in post-transcriptional gene expression</article-title><source>Nat. Struct. Mol. Biol.</source><volume>11</volume><fpage>503</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/nsmb779</pub-id><pub-id pub-id-type="pmid">15164008</pub-id></mixed-citation></ref><ref id="BST-2024-1045C70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gr&#252;ner</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Peter</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Weber</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Wohlbold</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Chung</surname><given-names>M.-Y.</given-names></string-name><string-name name-style="western"><surname>Weichenrieder</surname><given-names>O</given-names></string-name>. <etal>et al</etal></person-group><year>2016</year><article-title>The Structures of eIF4E-eIF4G Complexes Reveal an Extended Interface to Regulate Translation Initiation</article-title><source>Mol. Cell</source><volume>64</volume><fpage>467</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.09.020</pub-id><pub-id pub-id-type="pmid">27773676</pub-id></mixed-citation></ref><ref id="BST-2024-1045C71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gingras</surname><given-names>A.C.</given-names></string-name><string-name name-style="western"><surname>Gygi</surname><given-names>S.P.</given-names></string-name><string-name name-style="western"><surname>Raught</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Polakiewicz</surname><given-names>R.D.</given-names></string-name><string-name name-style="western"><surname>Abraham</surname><given-names>R.T.</given-names></string-name><string-name name-style="western"><surname>Hoekstra</surname><given-names>M.F.</given-names></string-name><etal>et al</etal></person-group><year>1999</year><article-title>Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism</article-title><source>Genes Dev.</source><volume>13</volume><fpage>1422</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1101/gad.13.11.1422</pub-id><pub-id pub-id-type="pmid">10364159</pub-id><pub-id pub-id-type="pmcid">PMC316780</pub-id></mixed-citation></ref><ref id="BST-2024-1045C72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maracci</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Motta</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Romagnoli</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Costantino</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Perego</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Di Marino</surname><given-names>D</given-names></string-name></person-group><year>2022</year><article-title>The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets</article-title><source>Curr. Med. Chem.</source><volume>29</volume><fpage>3501</fpage><lpage>3529</lpage><pub-id pub-id-type="doi">10.2174/0929867329666220224112042</pub-id><pub-id pub-id-type="pmid">35209811</pub-id></mixed-citation></ref><ref id="BST-2024-1045C73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wendel</surname><given-names>H.-G.</given-names></string-name><string-name name-style="western"><surname>Silva</surname><given-names>R.L.A.</given-names></string-name><string-name name-style="western"><surname>Malina</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Mills</surname><given-names>J.R.</given-names></string-name><string-name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Ueda</surname><given-names>T.</given-names></string-name><etal>et al</etal></person-group><year>2007</year><article-title>Dissecting eIF4E action in tumorigenesis</article-title><source>Genes Dev.</source><volume>21</volume><fpage>000</fpage>. <pub-id pub-id-type="doi">10.1101/gad.1604407</pub-id><pub-id pub-id-type="pmcid">PMC2113024</pub-id><pub-id pub-id-type="pmid">18055695</pub-id></mixed-citation></ref><ref id="BST-2024-1045C74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Volpon</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Osborne</surname><given-names>M.J.</given-names></string-name><string-name name-style="western"><surname>Capul</surname><given-names>A.A.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2010</year><article-title>Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>107</volume><fpage>5441</fpage><lpage>5446</lpage><pub-id pub-id-type="doi">10.1073/pnas.0909877107</pub-id><pub-id pub-id-type="pmid">20212144</pub-id><pub-id pub-id-type="pmcid">PMC2851782</pub-id></mixed-citation></ref><ref id="BST-2024-1045C75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scheper</surname><given-names>G.C.</given-names></string-name><string-name name-style="western"><surname>Proud</surname><given-names>C.G</given-names></string-name></person-group><year>2002</year><article-title>Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation?</article-title><source>Eur. J. Biochem.</source><volume>269</volume><fpage>5350</fpage><lpage>5359</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1033.2002.03291.x</pub-id><pub-id pub-id-type="pmid">12423333</pub-id><pub-id pub-id-type="pmcid">PMC7163980</pub-id></mixed-citation></ref><ref id="BST-2024-1045C76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scheper</surname><given-names>G.C.</given-names></string-name><string-name name-style="western"><surname>Proud</surname><given-names>C.G</given-names></string-name></person-group><year>2006</year><article-title>Defective translation initiation causes vanishing of cerebral white matter</article-title><source>Trends Mol. Med.</source><volume>12</volume><fpage>159</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2006.02.006</pub-id><pub-id pub-id-type="pmid">16545608</pub-id></mixed-citation></ref><ref id="BST-2024-1045C77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Topisirovic</surname><given-names>I.</given-names></string-name><string-name name-style="western"><surname>Ruiz-Gutierrez</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2004</year><article-title>Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities</article-title><source>Cancer Res.</source><volume>64</volume><fpage>8639</fpage><lpage>8642</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2677</pub-id><pub-id pub-id-type="pmid">15574771</pub-id></mixed-citation></ref><ref id="BST-2024-1045C78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ueda</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Watanabe-Fukunaga</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Fukuyama</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Nagata</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Fukunaga</surname><given-names>R</given-names></string-name></person-group><year>2004</year><article-title>Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development</article-title><source>Mol. Cell. Biol.</source><volume>24</volume><fpage>6539</fpage><lpage>6549</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.15.6539-6549.2004</pub-id><pub-id pub-id-type="pmid">15254222</pub-id><pub-id pub-id-type="pmcid">PMC444855</pub-id></mixed-citation></ref><ref id="BST-2024-1045C79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Siddiqui</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Tempel</surname><given-names>W.</given-names></string-name><string-name name-style="western"><surname>Nedyalkova</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Volpon</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Wernimont</surname><given-names>A.K.</given-names></string-name><string-name name-style="western"><surname>Osborne</surname><given-names>M.J.</given-names></string-name><etal>et al</etal></person-group><year>2012</year><article-title>Structural insights into the allosteric effects of 4EBP1 on the eukaryotic translation initiation factor eIF4E</article-title><source>J. Mol. Biol.</source><volume>415</volume><fpage>781</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2011.12.002</pub-id><pub-id pub-id-type="pmid">22178476</pub-id><pub-id pub-id-type="pmcid">PMC3269305</pub-id></mixed-citation></ref><ref id="BST-2024-1045C80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>German-Retana</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Walter</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Doublet</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Roudet-Tavert</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>Nicaise</surname><given-names>V.</given-names></string-name><string-name name-style="western"><surname>Lecampion</surname><given-names>C.</given-names></string-name><etal>et al</etal></person-group><year>2008</year><article-title>Mutational analysis of plant cap-binding protein eIF4E reveals key amino acids involved in biochemical functions and potyvirus infection</article-title><source>J. Virol.</source><volume>82</volume><fpage>7601</fpage><lpage>7612</lpage><pub-id pub-id-type="doi">10.1128/JVI.00209-08</pub-id><pub-id pub-id-type="pmid">18480444</pub-id><pub-id pub-id-type="pmcid">PMC2493313</pub-id></mixed-citation></ref><ref id="BST-2024-1045C81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brito Querido</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>D&#237;az-L&#243;pez</surname><given-names>I.</given-names></string-name><string-name name-style="western"><surname>Ramakrishnan</surname><given-names>V</given-names></string-name></person-group><year>2024</year><month>a</month>) <article-title>The molecular basis of translation initiation and its regulation in eukaryotes</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>25</volume><fpage>168</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/s41580-023-00624-9</pub-id><pub-id pub-id-type="pmid">38052923</pub-id></mixed-citation></ref><ref id="BST-2024-1045C82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brito Querido</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Sokabe</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Kraatz</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Gordiyenko</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Skehel</surname><given-names>J.M.</given-names></string-name><string-name name-style="western"><surname>Fraser</surname><given-names>C.S.</given-names></string-name><etal>et al</etal></person-group><year>2020</year><article-title>Structure of a human 48<italic toggle="yes">S</italic> translational initiation complex</article-title><source>Science</source><volume>369</volume><fpage>1220</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1126/science.aba4904</pub-id><pub-id pub-id-type="pmid">32883864</pub-id><pub-id pub-id-type="pmcid">PMC7116333</pub-id></mixed-citation></ref><ref id="BST-2024-1045C83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brito Querido</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Sokabe</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>D&#237;az-L&#243;pez</surname><given-names>I.</given-names></string-name><string-name name-style="western"><surname>Gordiyenko</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Fraser</surname><given-names>C.S.</given-names></string-name><string-name name-style="western"><surname>Ramakrishnan</surname><given-names>V</given-names></string-name></person-group><year>2024</year><article-title>The structure of a human translation initiation complex reveals two independent roles for the helicase eIF4A</article-title><source>Nat. Struct. Mol. Biol.</source><volume>31</volume><fpage>455</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1038/s41594-023-01196-0</pub-id><pub-id pub-id-type="pmid">38287194</pub-id><pub-id pub-id-type="pmcid">PMC10948362</pub-id></mixed-citation></ref><ref id="BST-2024-1045C84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Romagnoli</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>D&#8217;Agostino</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Ardiccioni</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Maracci</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Motta</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>La Teana</surname><given-names>A.</given-names></string-name><etal>et al</etal></person-group><year>2021</year><article-title>Control of the eIF4E activity: structural insights and pharmacological implications</article-title><source>Cell. Mol. Life Sci.</source><volume>78</volume><fpage>6869</fpage><lpage>6885</lpage><pub-id pub-id-type="doi">10.1007/s00018-021-03938-z</pub-id><pub-id pub-id-type="pmid">34541613</pub-id><pub-id pub-id-type="pmcid">PMC8558276</pub-id></mixed-citation></ref><ref id="BST-2024-1045C85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></string-name><string-name name-style="western"><surname>Cao</surname><given-names>R</given-names></string-name></person-group><year>2020</year><article-title>Phosphorylation of the mRNA cap-binding protein eIF4E and cancer</article-title><source>Cell. Signal.</source><volume>73</volume><fpage>109689</fpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2020.109689</pub-id><pub-id pub-id-type="pmid">32535199</pub-id><pub-id pub-id-type="pmcid">PMC8049097</pub-id></mixed-citation></ref><ref id="BST-2024-1045C86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Walker</surname><given-names>N.M.</given-names></string-name><string-name name-style="western"><surname>Ibuki</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>McLinden</surname><given-names>A.P.</given-names></string-name><string-name name-style="western"><surname>Misumi</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Mitchell</surname><given-names>D.C.</given-names></string-name><string-name name-style="western"><surname>Kleer</surname><given-names>G.G.</given-names></string-name><etal>et al</etal></person-group><year>2024</year><article-title>MNK-driven eIF4E phosphorylation regulates the fibrogenic transformation of mesenchymal cells and chronic lung allograft dysfunction</article-title><source>J. Clin. Invest.</source><volume>134</volume><elocation-id>e168393</elocation-id><pub-id pub-id-type="doi">10.1172/JCI168393</pub-id><pub-id pub-id-type="pmid">39145446</pub-id><pub-id pub-id-type="pmcid">PMC11324311</pub-id></mixed-citation></ref><ref id="BST-2024-1045C87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carroll</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2013</year><article-title>The oncogene eIF4E: using biochemical insights to target cancer</article-title><source>J. Interferon Cytokine Res.</source><volume>33</volume><fpage>227</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1089/jir.2012.0142</pub-id><pub-id pub-id-type="pmid">23472659</pub-id><pub-id pub-id-type="pmcid">PMC3653383</pub-id></mixed-citation></ref><ref id="BST-2024-1045C88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carter</surname><given-names>J.H.</given-names></string-name><string-name name-style="western"><surname>Deddens</surname><given-names>J.A.</given-names></string-name><string-name name-style="western"><surname>Spaulding</surname><given-names>N.R.</given-names><suffix>IV</suffix></string-name><string-name name-style="western"><surname>Lucas</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Colligan</surname><given-names>B.M.</given-names></string-name><string-name name-style="western"><surname>Lewis</surname><given-names>T.G.</given-names></string-name><etal>et al</etal></person-group><year>2016</year><article-title>Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma</article-title><source>Br. J. Cancer</source><volume>114</volume><fpage>444</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1038/bjc.2015.450</pub-id><pub-id pub-id-type="pmid">26882068</pub-id><pub-id pub-id-type="pmcid">PMC4815768</pub-id></mixed-citation></ref><ref id="BST-2024-1045C89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Vatsyayan</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Gao</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Bakkenist</surname><given-names>C.J.</given-names></string-name><string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name></person-group><year>2010</year><article-title>Sumoylation of eIF4E activates mRNA translation</article-title><source>EMBO Rep.</source><volume>11</volume><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1038/embor.2010.18</pub-id><pub-id pub-id-type="pmid">20224576</pub-id><pub-id pub-id-type="pmcid">PMC2854592</pub-id></mixed-citation></ref><ref id="BST-2024-1045C90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Li</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Huang</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Xing</surname><given-names>W.</given-names></string-name><string-name name-style="western"><surname>Guo</surname><given-names>W.</given-names></string-name><string-name name-style="western"><surname>He</surname><given-names>J.</given-names></string-name><etal>et al</etal></person-group><year>2014</year><article-title>SUMO-2 promotes mRNA translation by enhancing interaction between eIF4E and eIF4G</article-title><source>PLoS ONE</source><volume>9</volume><elocation-id>e100457</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0100457</pub-id><pub-id pub-id-type="pmid">24971752</pub-id><pub-id pub-id-type="pmcid">PMC4074059</pub-id></mixed-citation></ref><ref id="BST-2024-1045C91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Gan</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Gan</surname><given-names>X.</given-names></string-name><etal>et al</etal></person-group><year>2015</year><article-title>Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue</article-title><source>Oncotarget</source><volume>6</volume><fpage>15111</fpage><lpage>15121</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3615</pub-id><pub-id pub-id-type="pmid">25915158</pub-id><pub-id pub-id-type="pmcid">PMC4558139</pub-id></mixed-citation></ref><ref id="BST-2024-1045C92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maquat</surname><given-names>L.E.</given-names></string-name><string-name name-style="western"><surname>Tarn</surname><given-names>W.Y.</given-names></string-name><string-name name-style="western"><surname>Isken</surname><given-names>O</given-names></string-name></person-group><year>2010</year><article-title>The pioneer round of translation: features and functions</article-title><source>Cell</source><volume>142</volume><fpage>368</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.07.022</pub-id><pub-id pub-id-type="pmid">20691898</pub-id><pub-id pub-id-type="pmcid">PMC2950652</pub-id></mixed-citation></ref><ref id="BST-2024-1045C93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Liu</surname><given-names>J.Y.</given-names></string-name><string-name name-style="western"><surname>Zhang</surname><given-names>J.T</given-names></string-name></person-group><year>2023</year><article-title>eIF3d: A driver of noncanonical cap-dependent translation of specific mRNAs and a trigger of biological/pathological processes</article-title><source>J. Biol. Chem.</source><volume>299</volume><elocation-id>104658</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2023.104658</pub-id><pub-id pub-id-type="pmid">36997088</pub-id><pub-id pub-id-type="pmcid">PMC10165153</pub-id></mixed-citation></ref><ref id="BST-2024-1045C94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de la Parra,</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Ernlund</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Alard</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Ruggles</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Ueberheide</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Schneider</surname><given-names>R.J</given-names></string-name></person-group><year>2018</year><article-title>A widespread alternate form of cap-dependent mRNA translation initiation</article-title><source>Nat. Commun.</source><volume>9</volume><elocation-id>3068</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05539-0</pub-id><pub-id pub-id-type="pmid">30076308</pub-id><pub-id pub-id-type="pmcid">PMC6076257</pub-id></mixed-citation></ref><ref id="BST-2024-1045C95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sorrells</surname><given-names>D.L.</given-names></string-name><string-name name-style="western"><surname>Black</surname><given-names>D.R.</given-names></string-name><string-name name-style="western"><surname>Meschonat</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Rhoads</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>De Benedetti</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Gao</surname><given-names>M.</given-names></string-name><etal>et al</etal></person-group><year>1998</year><article-title>Detection of eIF4E gene amplification in breast cancer by competitive PCR</article-title><source>Ann. Surg. Oncol.</source><volume>5</volume><fpage>232</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1007/BF02303778</pub-id><pub-id pub-id-type="pmid">9607624</pub-id></mixed-citation></ref><ref id="BST-2024-1045C96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sorrells</surname><given-names>D.L.</given-names></string-name><string-name name-style="western"><surname>Meschonat</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Black</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Li</surname><given-names>B.D</given-names></string-name></person-group><year>1999</year><article-title>Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor</article-title><source>J. Surg. Res.</source><volume>85</volume><fpage>37</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1006/jsre.1999.5653</pub-id><pub-id pub-id-type="pmid">10383835</pub-id></mixed-citation></ref><ref id="BST-2024-1045C97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Larsson</surname><given-names>O.</given-names></string-name><string-name name-style="western"><surname>Li</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Issaenko</surname><given-names>O.A.</given-names></string-name><string-name name-style="western"><surname>Avdulov</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Peterson</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Smith</surname><given-names>K.</given-names></string-name><etal>et al</etal></person-group><year>2007</year><article-title>Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors</article-title><source>Cancer Res.</source><volume>67</volume><fpage>6814</fpage><lpage>6824</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0752</pub-id><pub-id pub-id-type="pmid">17638893</pub-id></mixed-citation></ref><ref id="BST-2024-1045C98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hariri</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Arguello</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Volpon</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Nielsen</surname><given-names>T.H.</given-names></string-name><string-name name-style="western"><surname>Hiscott</surname><given-names>J.</given-names></string-name><etal>et al</etal></person-group><year>2013</year><article-title>The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-&#954;B and is aberrantly regulated in acute myeloid leukemia</article-title><source>Leukemia</source><volume>27</volume><fpage>2047</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1038/leu.2013.73</pub-id><pub-id pub-id-type="pmid">23467026</pub-id><pub-id pub-id-type="pmcid">PMC4429918</pub-id></mixed-citation></ref><ref id="BST-2024-1045C99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hsieh</surname><given-names>A.C.</given-names></string-name><string-name name-style="western"><surname>Ruggero</surname><given-names>D</given-names></string-name></person-group><year>2010</year><article-title>Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer</article-title><source>Clin. Cancer Res.</source><volume>16</volume><fpage>4914</fpage><lpage>4920</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-0433</pub-id><pub-id pub-id-type="pmid">20702611</pub-id><pub-id pub-id-type="pmcid">PMC7539621</pub-id></mixed-citation></ref><ref id="BST-2024-1045C100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schmidt</surname><given-names>E.V</given-names></string-name></person-group><year>2004</year><article-title>The role of c-myc in regulation of translation initiation</article-title><source>Oncogene</source><volume>23</volume><fpage>3217</fpage><lpage>3221</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207548</pub-id><pub-id pub-id-type="pmid">15094771</pub-id></mixed-citation></ref><ref id="BST-2024-1045C101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amiri</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Mahmood</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Tahmasebi</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Sonenberg</surname><given-names>N</given-names></string-name></person-group><year>2025</year><article-title>eIF4F-mediated dysregulation of mRNA translation in cancer</article-title><source>RNA</source><volume>31</volume><fpage>416</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1261/rna.080340.124</pub-id><pub-id pub-id-type="pmid">39809544</pub-id><pub-id pub-id-type="pmcid">PMC11874970</pub-id></mixed-citation></ref><ref id="BST-2024-1045C102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bartish</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Abraham</surname><given-names>M.J.</given-names></string-name><string-name name-style="western"><surname>Gon&#231;alves</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Larsson</surname><given-names>O.</given-names></string-name><string-name name-style="western"><surname>Rolny</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Del Rinc&#243;n</surname><given-names>S.V</given-names></string-name></person-group><year>2023</year><article-title>The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment</article-title><source>Nat. Rev. Cancer</source><volume>23</volume><fpage>408</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1038/s41568-023-00567-5</pub-id><pub-id pub-id-type="pmid">37142795</pub-id></mixed-citation></ref><ref id="BST-2024-1045C103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pelletier</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Sonenberg</surname><given-names>N</given-names></string-name></person-group><year>2023</year><article-title>Therapeutic targeting of eukaryotic initiation factor (eIF) 4E</article-title><source>Biochem. Soc. Trans.</source><volume>51</volume><fpage>113</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1042/BST20220285</pub-id><pub-id pub-id-type="pmid">36661272</pub-id></mixed-citation></ref><ref id="BST-2024-1045C104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khosravi</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Tam</surname><given-names>K.J.</given-names></string-name><string-name name-style="western"><surname>Ardekani</surname><given-names>G.S.</given-names></string-name><string-name name-style="western"><surname>Martinka</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>McElwee</surname><given-names>K.J.</given-names></string-name><string-name name-style="western"><surname>Ong</surname><given-names>C.J</given-names></string-name></person-group><year>2015</year><article-title>eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion</article-title><source>J. Invest. Dermatol</source><volume>135</volume><fpage>1358</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1038/jid.2014.552</pub-id><pub-id pub-id-type="pmid">25562667</pub-id></mixed-citation></ref><ref id="BST-2024-1045C105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coleman</surname><given-names>L.J.</given-names></string-name><string-name name-style="western"><surname>Peter</surname><given-names>M.B.</given-names></string-name><string-name name-style="western"><surname>Teall</surname><given-names>T.J.</given-names></string-name><string-name name-style="western"><surname>Brannan</surname><given-names>R.A.</given-names></string-name><string-name name-style="western"><surname>Hanby</surname><given-names>A.M.</given-names></string-name><string-name name-style="western"><surname>Honarpisheh</surname><given-names>H.</given-names></string-name><etal>et al</etal></person-group><year>2009</year><article-title>Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity</article-title><source>Br. J. Cancer</source><volume>100</volume><fpage>1393</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605044</pub-id><pub-id pub-id-type="pmid">19367274</pub-id><pub-id pub-id-type="pmcid">PMC2694424</pub-id></mixed-citation></ref><ref id="BST-2024-1045C106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Luo</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Liu</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Zhan</surname><given-names>Y.</given-names></string-name><etal>et al</etal></person-group><year>2022</year><article-title>Overexpression of p-4EBP1 associates with p-eIF4E and predicts poor prognosis for non-small cell lung cancer patients with resection</article-title><source>PLoS ONE</source><volume>17</volume><elocation-id>e0265465</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0265465</pub-id><pub-id pub-id-type="pmid">35737644</pub-id><pub-id pub-id-type="pmcid">PMC9223369</pub-id></mixed-citation></ref><ref id="BST-2024-1045C107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>C.N.</given-names></string-name><string-name name-style="western"><surname>Hsieh</surname><given-names>F.J.</given-names></string-name><string-name name-style="western"><surname>Cheng</surname><given-names>Y.M.</given-names></string-name><string-name name-style="western"><surname>Lee</surname><given-names>P.H.</given-names></string-name><string-name name-style="western"><surname>Chang</surname><given-names>K.J</given-names></string-name></person-group><year>2004</year><article-title>Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome</article-title><source>J. Surg. Oncol.</source><volume>86</volume><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1002/jso.20037</pub-id><pub-id pub-id-type="pmid">15048676</pub-id></mixed-citation></ref><ref id="BST-2024-1045C108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Niu</surname><given-names>Z.</given-names></string-name><string-name name-style="western"><surname>Wang</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Muhammad</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Niu</surname><given-names>W.</given-names></string-name><string-name name-style="western"><surname>Liu</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Peng</surname><given-names>C.</given-names></string-name><etal>et al</etal></person-group><year>2014</year><article-title>Protein expression of eIF4E and integrin &#945;v&#946;6 in colon cancer can predict clinical significance, reveal their correlation and imply possible mechanism of interaction</article-title><source>Cell Biosci.</source><volume>4</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/2045-3701-4-23</pub-id><pub-id pub-id-type="pmid">24839543</pub-id><pub-id pub-id-type="pmcid">PMC4023178</pub-id></mixed-citation></ref><ref id="BST-2024-1045C109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Graff</surname><given-names>J.R.</given-names></string-name><string-name name-style="western"><surname>Konicek</surname><given-names>B.W.</given-names></string-name><string-name name-style="western"><surname>Lynch</surname><given-names>R.L.</given-names></string-name><string-name name-style="western"><surname>Dumstorf</surname><given-names>C.A.</given-names></string-name><string-name name-style="western"><surname>Dowless</surname><given-names>M.S.</given-names></string-name><string-name name-style="western"><surname>McNulty</surname><given-names>A.M.</given-names></string-name><etal>et al</etal></person-group><year>2009</year><article-title>eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival</article-title><source>Cancer Res.</source><volume>69</volume><fpage>3866</fpage><lpage>3873</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3472</pub-id><pub-id pub-id-type="pmid">19383915</pub-id></mixed-citation></ref><ref id="BST-2024-1045C110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mars</surname><given-names>J.C.</given-names></string-name><string-name name-style="western"><surname>Ghram</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2021</year><article-title>The Cap-Binding Complex CBC and the Eukaryotic Translation Factor eIF4E: Co-Conspirators in Cap-Dependent RNA Maturation and Translation</article-title><source>Cancers (Basel)</source><volume>13</volume><elocation-id>6185</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13246185</pub-id><pub-id pub-id-type="pmid">34944805</pub-id><pub-id pub-id-type="pmcid">PMC8699206</pub-id></mixed-citation></ref><ref id="BST-2024-1045C111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ramamurthy</surname><given-names>V.P.</given-names></string-name><string-name name-style="western"><surname>Ramalingam</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Kwegyir-Afful</surname><given-names>A.K.</given-names></string-name><string-name name-style="western"><surname>Hussain</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Njar</surname><given-names>V.C.O</given-names></string-name></person-group><year>2017</year><article-title>Targeting of protein translation as a new treatment paradigm for prostate cancer</article-title><source>Curr. Opin. Oncol.</source><volume>29</volume><fpage>210</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1097/CCO.0000000000000367</pub-id><pub-id pub-id-type="pmid">28282343</pub-id><pub-id pub-id-type="pmcid">PMC5591782</pub-id></mixed-citation></ref><ref id="BST-2024-1045C112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kovalski</surname><given-names>J.R.</given-names></string-name><string-name name-style="western"><surname>Kuzuoglu&#8208;Ozturk</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Ruggero</surname><given-names>D</given-names></string-name></person-group><year>2022</year><article-title>Protein synthesis control in cancer: selectivity and therapeutic targeting</article-title><source>EMBO J.</source><volume>41</volume><elocation-id>e109823</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2021109823</pub-id><pub-id pub-id-type="pmid">35315941</pub-id><pub-id pub-id-type="pmcid">PMC9016353</pub-id></mixed-citation></ref><ref id="BST-2024-1045C113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jones</surname><given-names>R.M.</given-names></string-name><string-name name-style="western"><surname>Branda</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Johnston</surname><given-names>K.A.</given-names></string-name><string-name name-style="western"><surname>Polymenis</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Gadd</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Rustgi</surname><given-names>A.</given-names></string-name><etal>et al</etal></person-group><year>1996</year><article-title>An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc</article-title><source>Mol. Cell. Biol.</source><volume>16</volume><fpage>4754</fpage><lpage>4764</lpage><pub-id pub-id-type="doi">10.1128/MCB.16.9.4754</pub-id><pub-id pub-id-type="pmid">8756633</pub-id><pub-id pub-id-type="pmcid">PMC231476</pub-id></mixed-citation></ref><ref id="BST-2024-1045C114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>C.-J.</given-names></string-name><string-name name-style="western"><surname>Cencic</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Mills</surname><given-names>J.R.</given-names></string-name><string-name name-style="western"><surname>Robert</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Pelletier</surname><given-names>J</given-names></string-name></person-group><year>2008</year><article-title>c-Myc and eIF4F Are components of a feedforward loop that links transcription and translation</article-title><source>Cancer Res.</source><volume>68</volume><fpage>5326</fpage><lpage>5334</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5876</pub-id><pub-id pub-id-type="pmid">18593934</pub-id></mixed-citation></ref><ref id="BST-2024-1045C115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lazaris-Karatzas</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Montine</surname><given-names>K.S.</given-names></string-name><string-name name-style="western"><surname>Sonenberg</surname><given-names>N</given-names></string-name></person-group><year>1990</year><article-title>Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5&#8217; cap</article-title><source>Nature</source><volume>345</volume><fpage>544</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1038/345544a0</pub-id><pub-id pub-id-type="pmid">2348862</pub-id></mixed-citation></ref><ref id="BST-2024-1045C116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Avdulov</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Li</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Michalek</surname><given-names>V.</given-names></string-name><string-name name-style="western"><surname>Burrichter</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Peterson</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Perlman</surname><given-names>D.M.</given-names></string-name><etal>et al</etal></person-group><year>2004</year><article-title>Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells</article-title><source>Cancer Cell</source><volume>5</volume><fpage>553</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2004.05.024</pub-id><pub-id pub-id-type="pmid">15193258</pub-id></mixed-citation></ref><ref id="BST-2024-1045C117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ruggero</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Montanaro</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Ma</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Xu</surname><given-names>W.</given-names></string-name><string-name name-style="western"><surname>Londei</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Cordon-Cardo</surname><given-names>C.</given-names></string-name><etal>et al</etal></person-group><year>2004</year><article-title>The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis</article-title><source>Nat. Med.</source><volume>10</volume><fpage>484</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1038/nm1042</pub-id><pub-id pub-id-type="pmid">15098029</pub-id></mixed-citation></ref><ref id="BST-2024-1045C118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Truitt</surname><given-names>M.L.</given-names></string-name><string-name name-style="western"><surname>Conn</surname><given-names>C.S.</given-names></string-name><string-name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></string-name><string-name name-style="western"><surname>Pang</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Tokuyasu</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Coady</surname><given-names>A.M.</given-names></string-name><etal>et al</etal></person-group><year>2015</year><article-title>Differential Requirements for eIF4E Dose in Normal Development and Cancer</article-title><source>Cell</source><volume>162</volume><fpage>59</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.049</pub-id><pub-id pub-id-type="pmid">26095252</pub-id><pub-id pub-id-type="pmcid">PMC4491046</pub-id></mixed-citation></ref><ref id="BST-2024-1045C119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Makrakis</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Wright</surname><given-names>J.L.</given-names></string-name><string-name name-style="western"><surname>Roudier</surname><given-names>M.P.</given-names></string-name><string-name name-style="western"><surname>Garcia</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Vakar-Lopez</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Porter</surname><given-names>M.P</given-names></string-name>. <etal>et al</etal></person-group><year>2023</year><article-title>A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer</article-title><source>Clin. Genitourin. Cancer</source><volume>21</volume><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.clgc.2022.12.003</pub-id><pub-id pub-id-type="pmid">36710146</pub-id></mixed-citation></ref><ref id="BST-2024-1045C120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beretta</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Gingras</surname><given-names>A.C.</given-names></string-name><string-name name-style="western"><surname>Svitkin</surname><given-names>Y.V.</given-names></string-name><string-name name-style="western"><surname>Hall</surname><given-names>M.N.</given-names></string-name><string-name name-style="western"><surname>Sonenberg</surname><given-names>N</given-names></string-name></person-group><year>1996</year><article-title>Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation</article-title><source>EMBO J.</source><volume>15</volume><fpage>658</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">8599949</pub-id><pub-id pub-id-type="pmcid">PMC449984</pub-id></mixed-citation></ref><ref id="BST-2024-1045C121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Houghton</surname><given-names>P.J</given-names></string-name></person-group><year>2010</year><article-title>Everolimus</article-title><source>Clin. Cancer Res.</source><volume>16</volume><fpage>1368</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-1314</pub-id><pub-id pub-id-type="pmid">20179227</pub-id><pub-id pub-id-type="pmcid">PMC3003868</pub-id></mixed-citation></ref><ref id="BST-2024-1045C122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kwitkowski</surname><given-names>V.E.</given-names></string-name><string-name name-style="western"><surname>Prowell</surname><given-names>T.M.</given-names></string-name><string-name name-style="western"><surname>Ibrahim</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Farrell</surname><given-names>A.T.</given-names></string-name><string-name name-style="western"><surname>Justice</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Mitchell</surname><given-names>S.S.</given-names></string-name><etal>et al</etal></person-group><year>2010</year><article-title>FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma</article-title><source>Oncologist</source><volume>15</volume><fpage>428</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2009-0178</pub-id><pub-id pub-id-type="pmid">20332142</pub-id><pub-id pub-id-type="pmcid">PMC3227966</pub-id></mixed-citation></ref><ref id="BST-2024-1045C123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Qiu</surname><given-names>Q.</given-names></string-name><string-name name-style="western"><surname>Yang</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Cao</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></string-name><etal>et al</etal></person-group><year>2024</year><article-title>Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review</article-title><source>Front. Pharmacol.</source><volume>15</volume><fpage>1173240</fpage><pub-id pub-id-type="doi">10.3389/fphar.2024.1173240</pub-id><pub-id pub-id-type="pmid">38584599</pub-id><pub-id pub-id-type="pmcid">PMC10995224</pub-id></mixed-citation></ref><ref id="BST-2024-1045C124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thoreen</surname><given-names>C.C.</given-names></string-name><string-name name-style="western"><surname>Kang</surname><given-names>S.A.</given-names></string-name><string-name name-style="western"><surname>Chang</surname><given-names>J.W.</given-names></string-name><string-name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></string-name><string-name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></string-name><etal>et al</etal></person-group><year>2009</year><article-title>An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1</article-title><source>J. Biol. Chem.</source><volume>284</volume><fpage>8023</fpage><lpage>8032</lpage><pub-id pub-id-type="doi">10.1074/jbc.M900301200</pub-id><pub-id pub-id-type="pmid">19150980</pub-id><pub-id pub-id-type="pmcid">PMC2658096</pub-id></mixed-citation></ref><ref id="BST-2024-1045C125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></string-name><string-name name-style="western"><surname>Wang</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Kang</surname><given-names>S.A.</given-names></string-name><string-name name-style="western"><surname>Thoreen</surname><given-names>C.C.</given-names></string-name><string-name name-style="western"><surname>Hur</surname><given-names>W.</given-names></string-name><string-name name-style="western"><surname>Ahmed</surname><given-names>T.</given-names></string-name><etal>et al</etal></person-group><year>2011</year><article-title>Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer</article-title><source>J. Med. Chem.</source><volume>54</volume><fpage>1473</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1021/jm101520v</pub-id><pub-id pub-id-type="pmid">21322566</pub-id><pub-id pub-id-type="pmcid">PMC3090687</pub-id></mixed-citation></ref><ref id="BST-2024-1045C126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Apsel</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Blair</surname><given-names>J.A.</given-names></string-name><string-name name-style="western"><surname>Gonzalez</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Nazif</surname><given-names>T.M.</given-names></string-name><string-name name-style="western"><surname>Feldman</surname><given-names>M.E.</given-names></string-name><string-name name-style="western"><surname>Aizenstein</surname><given-names>B.</given-names></string-name><etal>et al</etal></person-group><year>2008</year><article-title>Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</article-title><source>Nat. Chem. Biol.</source><volume>4</volume><fpage>691</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1038/nchembio.117</pub-id><pub-id pub-id-type="pmid">18849971</pub-id><pub-id pub-id-type="pmcid">PMC2880455</pub-id></mixed-citation></ref><ref id="BST-2024-1045C127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feldman</surname><given-names>M.E.</given-names></string-name><string-name name-style="western"><surname>Apsel</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Uotila</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Loewith</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Knight</surname><given-names>Z.A.</given-names></string-name><string-name name-style="western"><surname>Ruggero</surname><given-names>D.</given-names></string-name><etal>et al</etal></person-group><year>2009</year><article-title>Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2</article-title><source>PLoS Biol.</source><volume>7</volume><elocation-id>e1000038</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000038</pub-id><pub-id pub-id-type="pmid">19209957</pub-id><pub-id pub-id-type="pmcid">PMC2637922</pub-id></mixed-citation></ref><ref id="BST-2024-1045C128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Graham</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Banda</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Torres</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Carver</surname><given-names>B.S.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Pisano</surname><given-names>K.</given-names></string-name><etal>et al</etal></person-group><year>2018</year><article-title>A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer</article-title><source>Invest. New Drugs</source><volume>36</volume><fpage>458</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1007/s10637-018-0578-9</pub-id><pub-id pub-id-type="pmid">29508246</pub-id><pub-id pub-id-type="pmcid">PMC6050986</pub-id></mixed-citation></ref><ref id="BST-2024-1045C129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chresta</surname><given-names>C.M.</given-names></string-name><string-name name-style="western"><surname>Davies</surname><given-names>B.R.</given-names></string-name><string-name name-style="western"><surname>Hickson</surname><given-names>I.</given-names></string-name><string-name name-style="western"><surname>Harding</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Cosulich</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Critchlow</surname><given-names>S.E.</given-names></string-name><etal>et al</etal></person-group><year>2010</year><article-title>AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <italic toggle="yes">In vitro</italic> and <italic toggle="yes">In vivo</italic> Antitumor Activity</article-title>. <source>Cancer Res.</source><volume>70</volume><fpage>288</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1751</pub-id><pub-id pub-id-type="pmid">20028854</pub-id></mixed-citation></ref><ref id="BST-2024-1045C130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mateo</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Olmos</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Dumez</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Poondru</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Samberg</surname><given-names>N.L.</given-names></string-name><string-name name-style="western"><surname>Barr</surname><given-names>S.</given-names></string-name><etal>et al</etal></person-group><year>2016</year><article-title>A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies</article-title><source>Br. J. Cancer</source><volume>114</volume><fpage>889</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1038/bjc.2016.59</pub-id><pub-id pub-id-type="pmid">27002938</pub-id><pub-id pub-id-type="pmcid">PMC4984800</pub-id></mixed-citation></ref><ref id="BST-2024-1045C131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rodrik-Outmezguine</surname><given-names>V.S.</given-names></string-name><string-name name-style="western"><surname>Okaniwa</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Yao</surname><given-names>Z.</given-names></string-name><string-name name-style="western"><surname>Novotny</surname><given-names>C.J.</given-names></string-name><string-name name-style="western"><surname>McWhirter</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Banaji</surname><given-names>A.</given-names></string-name><etal>et al</etal></person-group><year>2016</year><article-title>Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor</article-title><source>Nature</source><volume>534</volume><fpage>272</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1038/nature17963</pub-id><pub-id pub-id-type="pmid">27279227</pub-id><pub-id pub-id-type="pmcid">PMC4902179</pub-id></mixed-citation></ref><ref id="BST-2024-1045C132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zou</surname><given-names>Z.Q.</given-names></string-name><string-name name-style="western"><surname>Zhang</surname><given-names>X.H.</given-names></string-name><string-name name-style="western"><surname>Wang</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Shen</surname><given-names>Q.J.</given-names></string-name><string-name name-style="western"><surname>Xu</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Zhang</surname><given-names>L.-N.</given-names></string-name><etal>et al</etal></person-group><year>2009</year><article-title>A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells</article-title><source>Int. J. Mol. Med.</source><volume>24</volume><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.3892/ijmm_00000212</pub-id><pub-id pub-id-type="pmid">19513541</pub-id></mixed-citation></ref><ref id="BST-2024-1045C133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wilhoit</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Patrick</surname><given-names>J.M.</given-names></string-name><string-name name-style="western"><surname>May</surname><given-names>M.B</given-names></string-name></person-group><year>2020</year><article-title>Alpelisib: A Novel Therapy for Patients With <italic toggle="yes">PIK3CA-</italic>Mutated Metastatic Breast Cancer</article-title><source>J. Adv. Pract. Oncol.</source><volume>11</volume><fpage>768</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.6004/jadpro.2020.11.7.9</pub-id><pub-id pub-id-type="pmid">33575071</pub-id><pub-id pub-id-type="pmcid">PMC7646628</pub-id></mixed-citation></ref><ref id="BST-2024-1045C134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xing</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Lin</surname><given-names>N.U.</given-names></string-name><string-name name-style="western"><surname>Maurer</surname><given-names>M.A.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Mahvash</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Sahin</surname><given-names>A.</given-names></string-name><etal>et al</etal></person-group><year>2019</year><article-title>Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation</article-title><source>Breast Cancer Res.</source><volume>21</volume><elocation-id>78</elocation-id><pub-id pub-id-type="doi">10.1186/s13058-019-1154-8</pub-id><pub-id pub-id-type="pmid">31277699</pub-id><pub-id pub-id-type="pmcid">PMC6612080</pub-id></mixed-citation></ref><ref id="BST-2024-1045C135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sweeney</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Bracarda</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Sternberg</surname><given-names>C.N.</given-names></string-name><string-name name-style="western"><surname>Chi</surname><given-names>K.N.</given-names></string-name><string-name name-style="western"><surname>Olmos</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Sandhu</surname><given-names>S</given-names></string-name>. <etal>et al</etal></person-group><year>2021</year><article-title>Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial</article-title><source>Lancet</source><volume>398</volume><fpage>131</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00580-8</pub-id><pub-id pub-id-type="pmid">34246347</pub-id></mixed-citation></ref><ref id="BST-2024-1045C136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Turner</surname><given-names>N.C.</given-names></string-name><string-name name-style="western"><surname>Oliveira</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Howell</surname><given-names>S.J.</given-names></string-name><string-name name-style="western"><surname>Dalenc</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Cortes</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Gomez Moreno</surname><given-names>H.L.</given-names></string-name><etal>et al</etal></person-group><year>2023</year><article-title>Capivasertib in hormone receptor-positive advanced breast cancer</article-title><source>N. Engl. J. Med.</source><volume>388</volume><fpage>2058</fpage><lpage>2070</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2214131</pub-id><pub-id pub-id-type="pmid">37256976</pub-id><pub-id pub-id-type="pmcid">PMC11335038</pub-id></mixed-citation></ref><ref id="BST-2024-1045C137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Toogood</surname><given-names>P.L.</given-names></string-name><string-name name-style="western"><surname>Harvey</surname><given-names>P.J.</given-names></string-name><string-name name-style="western"><surname>Repine</surname><given-names>J.T.</given-names></string-name><string-name name-style="western"><surname>Sheehan</surname><given-names>D.J.</given-names></string-name><string-name name-style="western"><surname>VanderWel</surname><given-names>S.N.</given-names></string-name><string-name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></string-name><etal>et al</etal></person-group><year>2005</year><article-title>Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</article-title><source>J. Med. Chem.</source><volume>48</volume><fpage>2388</fpage><lpage>2406</lpage><pub-id pub-id-type="doi">10.1021/jm049354h</pub-id><pub-id pub-id-type="pmid">15801831</pub-id></mixed-citation></ref><ref id="BST-2024-1045C138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spring</surname><given-names>L.M.</given-names></string-name><string-name name-style="western"><surname>Wander</surname><given-names>S.A.</given-names></string-name><string-name name-style="western"><surname>Andre</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Moy</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Turner</surname><given-names>N.C.</given-names></string-name><string-name name-style="western"><surname>Bardia</surname><given-names>A</given-names></string-name></person-group><year>2020</year><article-title>Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future</article-title><source>Lancet</source><volume>395</volume><fpage>817</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30165-3</pub-id><pub-id pub-id-type="pmid">32145796</pub-id></mixed-citation></ref><ref id="BST-2024-1045C139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kalakonda</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Maerevoet</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Cavallo</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Follows</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>Goy</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Vermaat</surname><given-names>J.S.P</given-names></string-name>. <etal>et al</etal></person-group><year>2020</year><article-title>Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial</article-title><source>Lancet Haematol.</source><volume>7</volume><fpage>e511</fpage><lpage>e522</lpage><pub-id pub-id-type="doi">10.1016/S2352-3026(20)30120-4</pub-id><pub-id pub-id-type="pmid">32589977</pub-id></mixed-citation></ref><ref id="BST-2024-1045C140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gonz&#225;lez-Calle</surname><given-names>V.</given-names></string-name><string-name name-style="western"><surname>Rodr&#237;guez-Otero</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Sureda</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>De Arriba</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Reinoso</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Ribas</surname><given-names>P.</given-names></string-name><etal>et al</etal></person-group><year>2024</year><article-title>Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study</article-title><source>Haematologica</source><volume>109</volume><fpage>2219</fpage><lpage>2228</lpage><pub-id pub-id-type="doi">10.3324/haematol.2023.284089</pub-id><pub-id pub-id-type="pmid">38356463</pub-id><pub-id pub-id-type="pmcid">PMC11215366</pub-id></mixed-citation></ref><ref id="BST-2024-1045C141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reich</surname><given-names>S.H.</given-names></string-name><string-name name-style="western"><surname>Sprengeler</surname><given-names>P.A.</given-names></string-name><string-name name-style="western"><surname>Chiang</surname><given-names>G.G.</given-names></string-name><string-name name-style="western"><surname>Appleman</surname><given-names>J.R.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Clarine</surname><given-names>J.</given-names></string-name><etal>et al</etal></person-group><year>2018</year><article-title>Structure-based Design of Pyridone&#8211;Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition</article-title><source>J. Med. Chem.</source><volume>61</volume><fpage>3516</fpage><lpage>3540</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01795</pub-id><pub-id pub-id-type="pmid">29526098</pub-id></mixed-citation></ref><ref id="BST-2024-1045C142"><label>142</label><mixed-citation publication-type="webpage"><person-group><collab>Clinical Trial <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04622007">NCT04622007</ext-link></collab></person-group><ext-link xlink:href="https://clinicaltrialsgov/study/NCT04622007" ext-link-type="uri">https://clinicaltrialsgov/study/NCT04622007</ext-link>.</mixed-citation></ref><ref id="BST-2024-1045C143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Konicek</surname><given-names>B.W.</given-names></string-name><string-name name-style="western"><surname>Stephens</surname><given-names>J.R.</given-names></string-name><string-name name-style="western"><surname>McNulty</surname><given-names>A.M.</given-names></string-name><string-name name-style="western"><surname>Robichaud</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Peery</surname><given-names>R.B.</given-names></string-name><string-name name-style="western"><surname>Dumstorf</surname><given-names>C.A.</given-names></string-name><etal>et al</etal></person-group><year>2011</year><article-title>Therapeutic Inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases</article-title><source>Cancer Res.</source><volume>71</volume><fpage>1849</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3298</pub-id><pub-id pub-id-type="pmid">21233335</pub-id></mixed-citation></ref><ref id="BST-2024-1045C144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Knauf</surname><given-names>U.</given-names></string-name><string-name name-style="western"><surname>Tschopp</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Gram</surname><given-names>H</given-names></string-name></person-group><year>2001</year><article-title>Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2</article-title><source>Mol. Cell. Biol.</source><volume>21</volume><fpage>5500</fpage><lpage>5511</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.16.5500-5511.2001</pub-id><pub-id pub-id-type="pmid">11463832</pub-id><pub-id pub-id-type="pmcid">PMC87272</pub-id></mixed-citation></ref><ref id="BST-2024-1045C145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Santag</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Siegel</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Wengner</surname><given-names>A.M.</given-names></string-name><string-name name-style="western"><surname>Lange</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>B&#246;mer</surname><given-names>U.</given-names></string-name><string-name name-style="western"><surname>Eis</surname><given-names>K</given-names></string-name>. <etal>et al</etal></person-group><year>2017</year><article-title>BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity</article-title><source>Cancer Lett</source><volume>390</volume><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2016.12.029</pub-id><pub-id pub-id-type="pmid">28043914</pub-id></mixed-citation></ref><ref id="BST-2024-1045C146"><label>146</label><mixed-citation publication-type="webpage"><source>Clinical Trial <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02439346">NCT02439346</ext-link></source>. <ext-link xlink:href="https://clinicaltrialsgov/study/NCT02439346" ext-link-type="uri">https://clinicaltrialsgov/study/NCT02439346</ext-link></mixed-citation></ref><ref id="BST-2024-1045C147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ramalingam</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Ramamurthy</surname><given-names>V.P.</given-names></string-name><string-name name-style="western"><surname>Gediya</surname><given-names>L.K.</given-names></string-name><string-name name-style="western"><surname>Murigi</surname><given-names>F.N.</given-names></string-name><string-name name-style="western"><surname>Purushottamachar</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Huang</surname><given-names>W.</given-names></string-name><etal>et al</etal></person-group><year>2019</year><article-title>The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis</article-title><source>Cancers (Basel)</source><volume>11</volume><elocation-id>299</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11030299</pub-id><pub-id pub-id-type="pmid">30832411</pub-id><pub-id pub-id-type="pmcid">PMC6468747</pub-id></mixed-citation></ref><ref id="BST-2024-1045C148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moerke</surname><given-names>N.J.</given-names></string-name><string-name name-style="western"><surname>Aktas</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Cantel</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Reibarkh</surname><given-names>M.Y.</given-names></string-name><string-name name-style="western"><surname>Fahmy</surname><given-names>A.</given-names></string-name><etal>et al</etal></person-group><year>2007</year><article-title>Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G</article-title><source>Cell</source><volume>128</volume><fpage>257</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.11.046</pub-id><pub-id pub-id-type="pmid">17254965</pub-id></mixed-citation></ref><ref id="BST-2024-1045C149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cencic</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Hall</surname><given-names>D.R.</given-names></string-name><string-name name-style="western"><surname>Robert</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Du</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Min</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Li</surname><given-names>L.</given-names></string-name><etal>et al</etal></person-group><year>2011</year><article-title>Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>108</volume><fpage>1046</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1073/pnas.1011477108</pub-id><pub-id pub-id-type="pmid">21191102</pub-id><pub-id pub-id-type="pmcid">PMC3024666</pub-id></mixed-citation></ref><ref id="BST-2024-1045C150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fischer</surname><given-names>P.D.</given-names></string-name><string-name name-style="western"><surname>Papadopoulos</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Dempersmier</surname><given-names>J.M.</given-names></string-name><string-name name-style="western"><surname>Wang</surname><given-names>Z.-F.</given-names></string-name><string-name name-style="western"><surname>Nowak</surname><given-names>R.P.</given-names></string-name><string-name name-style="western"><surname>Donovan</surname><given-names>K.A.</given-names></string-name><etal>et al</etal></person-group><year>2021</year><article-title>A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders</article-title><source>Eur. J. Med. Chem.</source><volume>219</volume><fpage>113435</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2021.113435</pub-id><pub-id pub-id-type="pmid">33892272</pub-id><pub-id pub-id-type="pmcid">PMC8846605</pub-id></mixed-citation></ref><ref id="BST-2024-1045C151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gallagher</surname><given-names>E.E.</given-names></string-name><string-name name-style="western"><surname>Song</surname><given-names>J.M.</given-names></string-name><string-name name-style="western"><surname>Menon</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Mishra</surname><given-names>L.D.</given-names></string-name><string-name name-style="western"><surname>Chmiel</surname><given-names>A.F.</given-names></string-name><string-name name-style="western"><surname>Garner</surname><given-names>A.L</given-names></string-name></person-group><year>2019</year><article-title>Consideration of binding kinetics in the design of stapled peptide mimics of the disordered proteins eukaryotic translation initiation factor 4E-Binding Protein 1 and Eukaryotic Translation Initiation Factor 4G</article-title><source>J. Med. Chem.</source><volume>62</volume><fpage>4967</fpage><lpage>4978</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00068</pub-id><pub-id pub-id-type="pmid">31033289</pub-id><pub-id pub-id-type="pmcid">PMC6679956</pub-id></mixed-citation></ref><ref id="BST-2024-1045C152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Song</surname><given-names>J.M.</given-names></string-name><string-name name-style="western"><surname>Gallagher</surname><given-names>E.E.</given-names></string-name><string-name name-style="western"><surname>Menon</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Mishra</surname><given-names>L.D.</given-names></string-name><string-name name-style="western"><surname>Garner</surname><given-names>A.L</given-names></string-name></person-group><year>2019</year><article-title>The role of olefin geometry in the activity of hydrocarbon stapled peptides targeting eukaryotic translation initiation factor 4E (eIF4E)</article-title><source>Org. Biomol. Chem.</source><volume>17</volume><fpage>6414</fpage><lpage>6419</lpage><pub-id pub-id-type="doi">10.1039/c9ob01041f</pub-id><pub-id pub-id-type="pmid">31215581</pub-id><pub-id pub-id-type="pmcid">PMC6625666</pub-id></mixed-citation></ref><ref id="BST-2024-1045C153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gallagher</surname><given-names>E.E.</given-names></string-name><string-name name-style="western"><surname>Menon</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Chmiel</surname><given-names>A.F.</given-names></string-name><string-name name-style="western"><surname>Deprey</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Kritzer</surname><given-names>J.A.</given-names></string-name><string-name name-style="western"><surname>Garner</surname><given-names>A.L</given-names></string-name></person-group><year>2020</year><article-title>A cell-penetrant lactam-stapled peptide for targeting eIF4E protein-protein interactions</article-title><source>Eur. J. Med. Chem</source><volume>205</volume><fpage>112655</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112655</pub-id><pub-id pub-id-type="pmid">32739551</pub-id><pub-id pub-id-type="pmcid">PMC7541464</pub-id></mixed-citation></ref><ref id="BST-2024-1045C154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Kopecky</surname><given-names>D.J.</given-names></string-name><string-name name-style="western"><surname>Mihalic</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Jeffries</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Min</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Heath</surname><given-names>J.</given-names></string-name><etal>et al</etal></person-group><year>2012</year><article-title>Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction</article-title><source>J. Med. Chem.</source><volume>55</volume><fpage>3837</fpage><lpage>3851</lpage><pub-id pub-id-type="doi">10.1021/jm300037x</pub-id><pub-id pub-id-type="pmid">22458568</pub-id></mixed-citation></ref><ref id="BST-2024-1045C155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ghosh</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Benyumov</surname><given-names>A.O.</given-names></string-name><string-name name-style="western"><surname>Ghosh</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Avdulov</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Dahlberg</surname><given-names>P.S.</given-names></string-name><etal>et al</etal></person-group><year>2009</year><article-title>Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation</article-title><source>ACS Chem. Biol.</source><volume>4</volume><fpage>367</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1021/cb9000475</pub-id><pub-id pub-id-type="pmid">19351181</pub-id><pub-id pub-id-type="pmcid">PMC2796976</pub-id></mixed-citation></ref><ref id="BST-2024-1045C156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kentsis</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Topisirovic</surname><given-names>I.</given-names></string-name><string-name name-style="western"><surname>Culjkovic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Shao</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B</given-names></string-name></person-group><year>2004</year><article-title>Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>101</volume><fpage>18105</fpage><lpage>18110</lpage><pub-id pub-id-type="doi">10.1073/pnas.0406927102</pub-id><pub-id pub-id-type="pmid">15601771</pub-id><pub-id pub-id-type="pmcid">PMC539790</pub-id></mixed-citation></ref><ref id="BST-2024-1045C157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaur</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Menon</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Garner</surname><given-names>A.L</given-names></string-name></person-group><year>2019</year><article-title>Synthesis of 7-benzylguanosine cap-analogue conjugates for eIF4E targeted degradation</article-title><source>Eur. J. Med. Chem</source><volume>166</volume><fpage>339</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.01.080</pub-id><pub-id pub-id-type="pmid">30735900</pub-id><pub-id pub-id-type="pmcid">PMC6392074</pub-id></mixed-citation></ref><ref id="BST-2024-1045C158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>C&#225;rdenas</surname><given-names>E.L.</given-names></string-name><string-name name-style="western"><surname>O&#8217;Rourke</surname><given-names>R.L.</given-names></string-name><string-name name-style="western"><surname>Menon</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Vega-Hern&#225;ndez</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>Meagher</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Stuckey</surname><given-names>J.</given-names></string-name><etal>et al</etal></person-group><year>2025</year><article-title>Second-generation cap analogue prodrugs for targeting aberrant eukaryotic translation initiation factor 4E activity in cancer</article-title><source>ACS Med. Chem. Lett.</source><volume>16</volume><fpage>96</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.4c00466</pub-id><pub-id pub-id-type="pmid">39811141</pub-id><pub-id pub-id-type="pmcid">PMC11726381</pub-id></mixed-citation></ref><ref id="BST-2024-1045C159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wan</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Yang</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Cuesta</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Pang</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Balius</surname><given-names>T.E.</given-names></string-name><string-name name-style="western"><surname>Irwin</surname><given-names>J.J.</given-names></string-name><etal>et al</etal></person-group><year>2020</year><article-title>Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking</article-title><source>J. Am. Chem. Soc.</source><volume>142</volume><fpage>4960</fpage><lpage>4964</lpage><pub-id pub-id-type="doi">10.1021/jacs.9b10377</pub-id><pub-id pub-id-type="pmid">32105459</pub-id><pub-id pub-id-type="pmcid">PMC7136196</pub-id></mixed-citation></ref><ref id="BST-2024-1045C160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hong</surname><given-names>D.S.</given-names></string-name><string-name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Oh</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Wheler</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Naing</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Brail</surname><given-names>L.</given-names></string-name><etal>et al</etal></person-group><year>2011</year><article-title>A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer</article-title><source>Clin. Cancer Res.</source><volume>17</volume><fpage>6582</fpage><lpage>6591</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-0430</pub-id><pub-id pub-id-type="pmid">21831956</pub-id><pub-id pub-id-type="pmcid">PMC5036398</pub-id></mixed-citation></ref><ref id="BST-2024-1045C161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duffy</surname><given-names>A.G.</given-names></string-name><string-name name-style="western"><surname>Makarova-Rusher</surname><given-names>O.V.</given-names></string-name><string-name name-style="western"><surname>Ulahannan</surname><given-names>S.V.</given-names></string-name><string-name name-style="western"><surname>Rahma</surname><given-names>O.E.</given-names></string-name><string-name name-style="western"><surname>Fioravanti</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Walker</surname><given-names>M.</given-names></string-name><etal>et al</etal></person-group><year>2016</year><article-title>Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer</article-title><source>Int. J. Cancer</source><volume>139</volume><fpage>1648</fpage><lpage>1657</lpage><pub-id pub-id-type="doi">10.1002/ijc.30199</pub-id><pub-id pub-id-type="pmid">27194579</pub-id><pub-id pub-id-type="pmcid">PMC6407898</pub-id></mixed-citation></ref><ref id="BST-2024-1045C162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Graff</surname><given-names>J.R.</given-names></string-name><string-name name-style="western"><surname>Konicek</surname><given-names>B.W.</given-names></string-name><string-name name-style="western"><surname>Vincent</surname><given-names>T.M.</given-names></string-name><string-name name-style="western"><surname>Lynch</surname><given-names>R.L.</given-names></string-name><string-name name-style="western"><surname>Monteith</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Weir</surname><given-names>S.N.</given-names></string-name><etal>et al</etal></person-group><year>2007</year><article-title>Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity</article-title><source>J. Clin. Invest.</source><volume>117</volume><fpage>2638</fpage><lpage>2648</lpage><pub-id pub-id-type="doi">10.1172/JCI32044</pub-id><pub-id pub-id-type="pmid">17786246</pub-id><pub-id pub-id-type="pmcid">PMC1957541</pub-id></mixed-citation></ref><ref id="BST-2024-1045C163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tai</surname><given-names>Y.T.</given-names></string-name><string-name name-style="western"><surname>Landesman</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Acharya</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Calle</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Zhong</surname><given-names>M.Y.</given-names></string-name><string-name name-style="western"><surname>Cea</surname><given-names>M.</given-names></string-name><etal>et al</etal></person-group><year>2014</year><article-title>CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications</article-title><source>Leukemia</source><volume>28</volume><fpage>155</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1038/leu.2013.115</pub-id><pub-id pub-id-type="pmid">23588715</pub-id><pub-id pub-id-type="pmcid">PMC3883926</pub-id></mixed-citation></ref><ref id="BST-2024-1045C164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alzahrani</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Natarajan</surname><given-names>U.</given-names></string-name><string-name name-style="western"><surname>Rathinavelu</surname><given-names>A</given-names></string-name></person-group><year>2022</year><article-title>Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells</article-title><source>Cancer Genet.</source><volume>266&#8211;267</volume><fpage>57</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.cancergen.2022.06.003</pub-id><pub-id pub-id-type="pmid">35785714</pub-id></mixed-citation></ref><ref id="BST-2024-1045C165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pinto-D&#237;ez</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Ferreras-Mart&#237;n</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Carri&#243;n-Marchante</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>V.M.</given-names></string-name><string-name name-style="western"><surname>Mart&#237;n</surname><given-names>M.E</given-names></string-name></person-group><year>2020</year><article-title>Deeping in the Role of the MAP-Kinases Interacting Kinases (MNKs) in Cancer</article-title><source>Int. J. Mol. Sci.</source><volume>21</volume><elocation-id>2967</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21082967</pub-id><pub-id pub-id-type="pmid">32340135</pub-id><pub-id pub-id-type="pmcid">PMC7215568</pub-id></mixed-citation></ref><ref id="BST-2024-1045C166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ferrario</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Mackey</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Gelmon</surname><given-names>K.A.</given-names></string-name><string-name name-style="western"><surname>Levasseur</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Sorensen</surname><given-names>P.H.</given-names></string-name><string-name name-style="western"><surname>Oo</surname><given-names>H.Z.</given-names></string-name><etal>et al</etal></person-group><year>2025</year><article-title>Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer</article-title><source>Clin. Cancer Res.</source><volume>31</volume><fpage>491</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-24-0841</pub-id><pub-id pub-id-type="pmid">39576211</pub-id></mixed-citation></ref><ref id="BST-2024-1045C167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Knight</surname><given-names>J.R.P.</given-names></string-name><string-name name-style="western"><surname>Alexandrou</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Skalka</surname><given-names>G.L.</given-names></string-name><string-name name-style="western"><surname>Vlahov</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Pennel</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Officer</surname><given-names>L.</given-names></string-name><etal>et al</etal></person-group><year>2021</year><article-title>MNK Inhibition Sensitizes <italic toggle="yes">KRAS</italic> -Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression</article-title>. <source>Cancer Discov.</source><volume>11</volume><fpage>1228</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0652</pub-id><pub-id pub-id-type="pmid">33328217</pub-id><pub-id pub-id-type="pmcid">PMC7611341</pub-id></mixed-citation></ref><ref id="BST-2024-1045C168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Zingaro</surname><given-names>V.A.</given-names></string-name><string-name name-style="western"><surname>Lincoff</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Tom</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Oikawa</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Oses-Prieto</surname><given-names>J.A.</given-names></string-name><etal>et al</etal></person-group><year>2024</year><article-title>Remodelling of the translatome controls diet and its impact on tumorigenesis</article-title><source>Nature</source><volume>633</volume><fpage>189</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07781-7</pub-id><pub-id pub-id-type="pmid">39143206</pub-id><pub-id pub-id-type="pmcid">PMC12147720</pub-id></mixed-citation></ref><ref id="BST-2024-1045C169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Casaos</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Gorelick</surname><given-names>N.L.</given-names></string-name><string-name name-style="western"><surname>Huq</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Choi</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Serra</surname><given-names>R.</given-names></string-name><etal>et al</etal></person-group><year>2019</year><article-title>The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?</article-title><source>Mol. Cancer Ther.</source><volume>18</volume><fpage>1185</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-18-0666</pub-id><pub-id pub-id-type="pmid">31263027</pub-id></mixed-citation></ref><ref id="BST-2024-1045C170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Assouline</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Culjkovic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Cocolakis</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Rousseau</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Beslu</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Amri</surname><given-names>A.</given-names></string-name><etal>et al</etal></person-group><year>2009</year><article-title>Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin</article-title><source>Blood</source><volume>114</volume><fpage>257</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-02-205153</pub-id><pub-id pub-id-type="pmid">19433856</pub-id></mixed-citation></ref><ref id="BST-2024-1045C171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Assouline</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Bergeron</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Caplan</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Cocolakis</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Lambert</surname><given-names>C.</given-names></string-name><etal>et al</etal></person-group><year>2015</year><article-title>A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E</article-title><source>Haematologica</source><volume>100</volume><fpage>e7</fpage><lpage>e9</lpage><pub-id pub-id-type="doi">10.3324/haematol.2014.111245</pub-id><pub-id pub-id-type="pmid">25425688</pub-id><pub-id pub-id-type="pmcid">PMC4281321</pub-id></mixed-citation></ref><ref id="BST-2024-1045C172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Borden</surname><given-names>K.L.B.</given-names></string-name><string-name name-style="western"><surname>Culjkovic-Kraljacic</surname><given-names>B</given-names></string-name></person-group><year>2010</year><article-title>Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?</article-title><source>Leuk. Lymphoma</source><volume>51</volume><fpage>1805</fpage><lpage>1815</lpage><pub-id pub-id-type="doi">10.3109/10428194.2010.496506</pub-id><pub-id pub-id-type="pmid">20629523</pub-id><pub-id pub-id-type="pmcid">PMC2950216</pub-id></mixed-citation></ref><ref id="BST-2024-1045C173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Svitkin</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Lee</surname><given-names>J.M.</given-names></string-name><string-name name-style="western"><surname>Bisaillon</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Pelletier</surname><given-names>J</given-names></string-name></person-group><year>2005</year><article-title>Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap</article-title><source>RNA</source><volume>11</volume><fpage>1238</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1261/rna.2930805</pub-id><pub-id pub-id-type="pmid">16043507</pub-id><pub-id pub-id-type="pmcid">PMC1370807</pub-id></mixed-citation></ref><ref id="BST-2024-1045C174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jones</surname><given-names>N.H.</given-names></string-name><string-name name-style="western"><surname>Kapoor</surname><given-names>T.M</given-names></string-name></person-group><year>2023</year><article-title>Achieving the promise and avoiding the peril of chemical probes using genetics</article-title><source>Curr. Opin. Struct. Biol.</source><volume>81</volume><fpage>102628</fpage><pub-id pub-id-type="doi">10.1016/j.sbi.2023.102628</pub-id><pub-id pub-id-type="pmid">37364429</pub-id><pub-id pub-id-type="pmcid">PMC10561518</pub-id></mixed-citation></ref><ref id="BST-2024-1045C175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>C&#225;rdenas</surname><given-names>E.L.</given-names></string-name><string-name name-style="western"><surname>O&#8217;Rourke</surname><given-names>R.L.</given-names></string-name><string-name name-style="western"><surname>Menon</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Meagher</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Stuckey</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Garner</surname><given-names>A.L</given-names></string-name></person-group><year>2023</year><article-title>Design of cell-permeable inhibitors of eukaryotic translation initiation factor 4E (eIF4E) for Inhibiting aberrant cap-dependent translation in cancer</article-title><source>J. Med. Chem.</source><volume>66</volume><fpage>10734</fpage><lpage>10745</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c00917</pub-id><pub-id pub-id-type="pmid">37471629</pub-id><pub-id pub-id-type="pmcid">PMC11469893</pub-id></mixed-citation></ref><ref id="BST-2024-1045C176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cai</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Jankowska-Anyszka</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Centers</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Chlebicka</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Stepinski</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Stolarski</surname><given-names>R.</given-names></string-name><etal>et al</etal></person-group><year>1999</year><article-title>Quantitative assessment of mRNA cap analogues as inhibitors of in vitro translation</article-title><source>Biochemistry</source><volume>38</volume><fpage>8538</fpage><lpage>8547</lpage><pub-id pub-id-type="doi">10.1021/bi9830213</pub-id><pub-id pub-id-type="pmid">10387101</pub-id></mixed-citation></ref><ref id="BST-2024-1045C177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grudzien</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Stepinski</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Jankowska-Anyszka</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Stolarski</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Darzynkiewicz</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Rhoads</surname><given-names>R.E</given-names></string-name></person-group><year>2004</year><article-title>Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency</article-title><source>RNA</source><volume>10</volume><fpage>1479</fpage><lpage>1487</lpage><pub-id pub-id-type="doi">10.1261/rna.7380904</pub-id><pub-id pub-id-type="pmid">15317978</pub-id><pub-id pub-id-type="pmcid">PMC1370634</pub-id></mixed-citation></ref><ref id="BST-2024-1045C178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arrowsmith</surname><given-names>C.H.</given-names></string-name><string-name name-style="western"><surname>Audia</surname><given-names>J.E.</given-names></string-name><string-name name-style="western"><surname>Austin</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Baell</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Bennett</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Blagg</surname><given-names>J.</given-names></string-name><etal>et al</etal></person-group><year>2015</year><article-title>The promise and peril of chemical probes</article-title><source>Nat. Chem. Biol.</source><volume>11</volume><fpage>536</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1867</pub-id><pub-id pub-id-type="pmid">26196764</pub-id><pub-id pub-id-type="pmcid">PMC4706458</pub-id></mixed-citation></ref><ref id="BST-2024-1045C179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sekiyama</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Arthanari</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Papadopoulos</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Rodriguez-Mias</surname><given-names>R.A.</given-names></string-name><string-name name-style="western"><surname>Wagner</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>L&#233;ger-Abraham</surname><given-names>M</given-names></string-name></person-group><year>2015</year><article-title>Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>112</volume><fpage>E4036</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1073/pnas.1512118112</pub-id><pub-id pub-id-type="pmid">26170285</pub-id><pub-id pub-id-type="pmcid">PMC4522750</pub-id></mixed-citation></ref><ref id="BST-2024-1045C180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Santini</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Huynh</surname><given-names>T.N.</given-names></string-name><string-name name-style="western"><surname>Longo</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Koo</surname><given-names>S.Y.</given-names></string-name><string-name name-style="western"><surname>Mojica</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>D&#8217;Andrea</surname><given-names>L.</given-names></string-name><etal>et al</etal></person-group><year>2017</year><article-title>Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice</article-title><source>Sci. Signal.</source><volume>10</volume><elocation-id>eaan0665</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aan0665</pub-id><pub-id pub-id-type="pmid">29114037</pub-id><pub-id pub-id-type="pmcid">PMC5858943</pub-id></mixed-citation></ref><ref id="BST-2024-1045C181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gkogkas</surname><given-names>C.G.</given-names></string-name><string-name name-style="western"><surname>Khoutorsky</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Ran</surname><given-names>I.</given-names></string-name><string-name name-style="western"><surname>Rampakakis</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Nevarko</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Weatherill</surname><given-names>D.B.</given-names></string-name><etal>et al</etal></person-group><year>2013</year><article-title>Autism-related deficits via dysregulated eIF4E-dependent translational control</article-title><source>Nature</source><volume>493</volume><fpage>371</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1038/nature11628</pub-id><pub-id pub-id-type="pmid">23172145</pub-id><pub-id pub-id-type="pmcid">PMC4133997</pub-id></mixed-citation></ref><ref id="BST-2024-1045C182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Santini</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Huynh</surname><given-names>T.N.</given-names></string-name><string-name name-style="western"><surname>MacAskill</surname><given-names>A.F.</given-names></string-name><string-name name-style="western"><surname>Carter</surname><given-names>A.G.</given-names></string-name><string-name name-style="western"><surname>Pierre</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Ruggero</surname><given-names>D.</given-names></string-name><etal>et al</etal></person-group><year>2013</year><article-title>Exaggerated translation causes synaptic and behavioural aberrations associated with autism</article-title><source>Nature</source><volume>493</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1038/nature11782</pub-id><pub-id pub-id-type="pmid">23263185</pub-id><pub-id pub-id-type="pmcid">PMC3548017</pub-id></mixed-citation></ref><ref id="BST-2024-1045C183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ghosh</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Mizuno</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Tiwari</surname><given-names>S.S.</given-names></string-name><string-name name-style="western"><surname>Proitsi</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Gomez Perez-Nievas</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Glennon</surname><given-names>E.</given-names></string-name><etal>et al</etal></person-group><year>2020</year><article-title>Alzheimer&#8217;s disease-related dysregulation of mRNA translation causes key pathological features with ageing</article-title><source>Transl. Psychiatry</source><volume>10</volume><fpage>192</fpage><pub-id pub-id-type="doi">10.1038/s41398-020-00882-7</pub-id><pub-id pub-id-type="pmid">32546772</pub-id><pub-id pub-id-type="pmcid">PMC7297996</pub-id></mixed-citation></ref><ref id="BST-2024-1045C184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Soliman</surname><given-names>G.A.</given-names></string-name><string-name name-style="western"><surname>Schooling</surname><given-names>C.M</given-names></string-name></person-group><year>2020</year><article-title>Causal association between mTOR-dependent EIF-4E and EIF-4A circulating protein levels and type 2 diabetes: a Mendelian randomization study</article-title><source>Sci. Rep.</source><volume>10</volume><elocation-id>15737</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-71987-8</pub-id><pub-id pub-id-type="pmid">32978410</pub-id><pub-id pub-id-type="pmcid">PMC7519073</pub-id></mixed-citation></ref><ref id="BST-2024-1045C185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Le Bacquer</surname><given-names>O.</given-names></string-name><string-name name-style="western"><surname>Petroulakis</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Paglialunga</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Poulin</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Richard</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Cianflone</surname><given-names>K.</given-names></string-name><etal>et al</etal></person-group><year>2007</year><article-title>Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2</article-title><source>J. Clin. Invest.</source><volume>117</volume><fpage>387</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1172/JCI29528</pub-id><pub-id pub-id-type="pmid">17273556</pub-id><pub-id pub-id-type="pmcid">PMC1783830</pub-id></mixed-citation></ref><ref id="BST-2024-1045C186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Conn</surname><given-names>C.S.</given-names></string-name><string-name name-style="western"><surname>Yang</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Tom</surname><given-names>H.J.</given-names></string-name><string-name name-style="western"><surname>Ikeda</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Oses-Prieto</surname><given-names>J.A.</given-names></string-name><string-name name-style="western"><surname>Vu</surname><given-names>H.</given-names></string-name><etal>et al</etal></person-group><year>2021</year><article-title>The major cap-binding protein eIF4E regulates lipid homeostasis and diet-induced obesity</article-title><source>Nat. Metab.</source><volume>3</volume><fpage>244</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1038/s42255-021-00349-z</pub-id><pub-id pub-id-type="pmid">33619378</pub-id><pub-id pub-id-type="pmcid">PMC10350339</pub-id></mixed-citation></ref><ref id="BST-2024-1045C187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zeitz</surname><given-names>M.J.</given-names></string-name><string-name name-style="western"><surname>Smyth</surname><given-names>J.W</given-names></string-name></person-group><year>2020</year><article-title>Translating Translation to Mechanisms of Cardiac Hypertrophy</article-title><source>J. Cardiovasc. Dev. Dis.</source><volume>7</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.3390/jcdd7010009</pub-id><pub-id pub-id-type="pmid">32164190</pub-id><pub-id pub-id-type="pmcid">PMC7151157</pub-id></mixed-citation></ref><ref id="BST-2024-1045C188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duncan</surname><given-names>R.F.</given-names></string-name><string-name name-style="western"><surname>Peterson</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Hagedorn</surname><given-names>C.H.</given-names></string-name><string-name name-style="western"><surname>Sevanian</surname><given-names>A</given-names></string-name></person-group><year>2003</year><article-title>Oxidative stress increases eukaryotic initiation factor 4E phosphorylation in vascular cells</article-title><source>Biochem. J.</source><volume>369</volume><fpage>213</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1042/BJ20020435</pub-id><pub-id pub-id-type="pmid">12215171</pub-id><pub-id pub-id-type="pmcid">PMC1223074</pub-id></mixed-citation></ref><ref id="BST-2024-1045C189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Montero</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Garc&#237;a-Rom&#225;n</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Mora</surname><given-names>S.I</given-names></string-name></person-group><year>2015</year><article-title>eIF4E as a control target for viruses</article-title><source>Viruses</source><volume>7</volume><fpage>739</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.3390/v7020739</pub-id><pub-id pub-id-type="pmid">25690796</pub-id><pub-id pub-id-type="pmcid">PMC4353914</pub-id></mixed-citation></ref><ref id="BST-2024-1045C190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Istomine</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Al-Aubodah</surname><given-names>T.A.</given-names></string-name><string-name name-style="western"><surname>Alvarez</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Smith</surname><given-names>J.A.</given-names></string-name><string-name name-style="western"><surname>Wagner</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Piccirillo</surname><given-names>C.A</given-names></string-name></person-group><year>2023</year><article-title>The eIF4EBP-eIF4E axis regulates CD4<sup>+</sup> T cell differentiation through modulation of T cell activation and metabolism</article-title><source>iScience</source><volume>26</volume><elocation-id>106683</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2023.106683</pub-id><pub-id pub-id-type="pmid">37187701</pub-id><pub-id pub-id-type="pmcid">PMC10176268</pub-id></mixed-citation></ref><ref id="BST-2024-1045C191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wong</surname><given-names>Y.L.</given-names></string-name><string-name name-style="western"><surname>LeBon</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Basso</surname><given-names>A.M.</given-names></string-name><string-name name-style="western"><surname>Kohlhaas</surname><given-names>K.L.</given-names></string-name><string-name name-style="western"><surname>Nikkel</surname><given-names>A.L.</given-names></string-name><string-name name-style="western"><surname>Robb</surname><given-names>H.M.</given-names></string-name><etal>et al</etal></person-group><year>2019</year><article-title>eIF2B activator prevents neurological defects caused by a chronic integrated stress response</article-title><source>Elife</source><volume>8</volume><elocation-id>e42940</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.42940</pub-id><pub-id pub-id-type="pmid">30624206</pub-id><pub-id pub-id-type="pmcid">PMC6326728</pub-id></mixed-citation></ref><ref id="BST-2024-1045C192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Joshi</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Platanias</surname><given-names>L.C</given-names></string-name></person-group><year>2012</year><article-title>Mnk kinases in cytokine signaling and regulation of cytokine responses</article-title><source>Biomol. Concepts</source><volume>3</volume><fpage>127</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1515/bmc-2011-0057</pub-id><pub-id pub-id-type="pmid">23710261</pub-id><pub-id pub-id-type="pmcid">PMC3662029</pub-id></mixed-citation></ref><ref id="BST-2024-1045C193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amorim</surname><given-names>I.S.</given-names></string-name><string-name name-style="western"><surname>Lach</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>Gkogkas</surname><given-names>C.G</given-names></string-name></person-group><year>2018</year><article-title>The Role of the Eukaryotic Translation Initiation Factor 4E (eIF4E) in Neuropsychiatric Disorders</article-title><source>Front. Genet.</source><volume>9</volume><elocation-id>561</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2018.00561</pub-id><pub-id pub-id-type="pmid">30532767</pub-id><pub-id pub-id-type="pmcid">PMC6265315</pub-id></mixed-citation></ref><ref id="BST-2024-1045C194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Hoeffer</surname><given-names>C.A.</given-names></string-name><string-name name-style="western"><surname>Takayasu</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Miyawaki</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>McBride</surname><given-names>S.M.</given-names></string-name><string-name name-style="western"><surname>Klann</surname><given-names>E.</given-names></string-name><etal>et al</etal></person-group><year>2010</year><article-title>Dysregulation of mTOR signaling in fragile X syndrome</article-title><source>J. Neurosci.</source><volume>30</volume><fpage>694</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3696-09.2010</pub-id><pub-id pub-id-type="pmid">20071534</pub-id><pub-id pub-id-type="pmcid">PMC3665010</pub-id></mixed-citation></ref><ref id="BST-2024-1045C195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shukla</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Perish</surname><given-names>J.M.</given-names></string-name><string-name name-style="western"><surname>Ploski</surname><given-names>J.E.</given-names></string-name><string-name name-style="western"><surname>Stumpf</surname><given-names>C.R.</given-names></string-name><string-name name-style="western"><surname>Webster</surname><given-names>K.R</given-names></string-name>. <etal>et al</etal></person-group><year>2021</year><article-title>A Highly Selective MNK Inhibitor Rescues Deficits Associated with Fragile X Syndrome in Mice</article-title><source>Neurotherapeutics</source><volume>18</volume><fpage>624</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1007/s13311-020-00932-4</pub-id><pub-id pub-id-type="pmid">33006091</pub-id><pub-id pub-id-type="pmcid">PMC8116363</pub-id></mixed-citation></ref><ref id="BST-2024-1045C196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gkogkas</surname><given-names>C.G.</given-names></string-name><string-name name-style="western"><surname>Khoutorsky</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Cao</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Jafarnejad</surname><given-names>S.M.</given-names></string-name><string-name name-style="western"><surname>Prager-Khoutorsky</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Giannakas</surname><given-names>N</given-names></string-name>. <etal>et al</etal></person-group><year>2014</year><article-title>Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes</article-title><source>Cell Rep</source><volume>9</volume><fpage>1742</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.10.064</pub-id><pub-id pub-id-type="pmid">25466251</pub-id><pub-id pub-id-type="pmcid">PMC4294557</pub-id></mixed-citation></ref><ref id="BST-2024-1045C197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gantois</surname><given-names>I.</given-names></string-name><string-name name-style="western"><surname>Popic</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Khoutorsky</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Sonenberg</surname><given-names>N</given-names></string-name></person-group><year>2019</year><article-title>Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders</article-title><source>Annu. Rev. Med.</source><volume>70</volume><fpage>167</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-081117-041238</pub-id><pub-id pub-id-type="pmid">30365357</pub-id></mixed-citation></ref><ref id="BST-2024-1045C198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Proteau-Lemieux</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Lacroix</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Galarneau</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Corbin</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Lepage</surname><given-names>J.F.</given-names></string-name><string-name name-style="western"><surname>&#199;aku</surname><given-names>A</given-names></string-name></person-group><year>2021</year><article-title>The safety and efficacy of metformin in fragile X syndrome: An open-label study</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><volume>110</volume><fpage>110307</fpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2021.110307</pub-id><pub-id pub-id-type="pmid">33757860</pub-id></mixed-citation></ref><ref id="BST-2024-1045C199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Du</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Zhao</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name></person-group><year>2018</year><article-title>A preclinical overview of metformin for the treatment of type 2 diabetes</article-title><source>Biomedicine &amp; Pharmacotherapy</source><volume>106</volume><fpage>1227</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.07.085</pub-id><pub-id pub-id-type="pmid">30119191</pub-id></mixed-citation></ref><ref id="BST-2024-1045C200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reifsnyder</surname><given-names>P.C.</given-names></string-name><string-name name-style="western"><surname>Flurkey</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Te</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Harrison</surname><given-names>D.E</given-names></string-name></person-group><year>2016</year><article-title>Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes</article-title><source>Aging (Milano)</source><volume>8</volume><fpage>3120</fpage><lpage>3130</lpage><pub-id pub-id-type="doi">10.18632/aging.101117</pub-id><pub-id pub-id-type="pmcid">PMC5191889</pub-id><pub-id pub-id-type="pmid">27922820</pub-id></mixed-citation></ref><ref id="BST-2024-1045C201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blagosklonny</surname><given-names>M.V</given-names></string-name></person-group><year>2019</year><article-title>Fasting and rapamycin: diabetes versus benevolent glucose intolerance</article-title><source>Cell Death Dis.</source><volume>10</volume><fpage>607</fpage><pub-id pub-id-type="doi">10.1038/s41419-019-1822-8</pub-id><pub-id pub-id-type="pmid">31406105</pub-id><pub-id pub-id-type="pmcid">PMC6690951</pub-id></mixed-citation></ref><ref id="BST-2024-1045C202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blonde</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Dailey</surname><given-names>G.E.</given-names></string-name><string-name name-style="western"><surname>Jabbour</surname><given-names>S.A.</given-names></string-name><string-name name-style="western"><surname>Reasner</surname><given-names>C.A.</given-names></string-name><string-name name-style="western"><surname>Mills</surname><given-names>D.J</given-names></string-name></person-group><year>2004</year><article-title>Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study</article-title><source>Curr. Med. Res. Opin.</source><volume>20</volume><fpage>565</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1185/030079904125003278</pub-id><pub-id pub-id-type="pmid">15119994</pub-id></mixed-citation></ref><ref id="BST-2024-1045C203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>DeFronzo</surname><given-names>R.A.</given-names></string-name><string-name name-style="western"><surname>Goodman</surname><given-names>A.M</given-names></string-name></person-group><year>1995</year><article-title>Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter metformin study group</article-title><source>N. Engl. J. Med.</source><volume>333</volume><fpage>541</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1056/NEJM199508313330902</pub-id><pub-id pub-id-type="pmid">7623902</pub-id></mixed-citation></ref><ref id="BST-2024-1045C204"><label>204</label><mixed-citation publication-type="journal"> (<year>1998</year><article-title>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)</article-title><source>The Lancet</source><volume>352</volume><fpage>854</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(98)07037-8</pub-id><pub-id pub-id-type="pmid">9742977</pub-id></mixed-citation></ref><ref id="BST-2024-1045C205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Figarola</surname><given-names>J.L.</given-names></string-name><string-name name-style="western"><surname>Rahbar</surname><given-names>S</given-names></string-name></person-group><year>2013</year><article-title>Small&#8209;molecule COH-SR4 inhibits adipocyte differentiation via AMPK activation</article-title><source>Int. J. Mol. Med.</source><volume>31</volume><fpage>1166</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2013.1313</pub-id><pub-id pub-id-type="pmid">23525347</pub-id></mixed-citation></ref><ref id="BST-2024-1045C206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ziqubu</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Mazibuko-Mbeje</surname><given-names>S.E.</given-names></string-name><string-name name-style="western"><surname>Mthembu</surname><given-names>S.X.H.</given-names></string-name><string-name name-style="western"><surname>Mabhida</surname><given-names>S.E.</given-names></string-name><string-name name-style="western"><surname>Jack</surname><given-names>B.U.</given-names></string-name><string-name name-style="western"><surname>Nyambuya</surname><given-names>T.M.</given-names></string-name><etal>et al</etal></person-group><year>2023</year><article-title>Anti-obesity effects of metformin: A scoping review evaluating the feasibility of brown adipose tissue as a therapeutic target</article-title><source>Int. J. Mol. Sci.</source><volume>24</volume><elocation-id>2227</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24032227</pub-id><pub-id pub-id-type="pmid">36768561</pub-id><pub-id pub-id-type="pmcid">PMC9917329</pub-id></mixed-citation></ref><ref id="BST-2024-1045C207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seifarth</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Schehler</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Schneider</surname><given-names>H.J</given-names></string-name></person-group><year>2013</year><article-title>Effectiveness of metformin on weight loss in non-diabetic individuals with obesity</article-title><source>Exp. Clin. Endocrinol. Diabetes</source><volume>121</volume><fpage>27</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1055/s-0032-1327734</pub-id><pub-id pub-id-type="pmid">23147210</pub-id></mixed-citation></ref><ref id="BST-2024-1045C208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>T.M.</given-names></string-name><string-name name-style="western"><surname>Lin</surname><given-names>S.Z.</given-names></string-name><string-name name-style="western"><surname>Chang</surname><given-names>N.C</given-names></string-name></person-group><year>2017</year><article-title>Effect of lithium on ventricular remodelling in infarcted rats via the Akt/mTOR signalling pathways</article-title><source>Biosci. Rep.</source><volume>37</volume><elocation-id>BSR20160257</elocation-id><pub-id pub-id-type="doi">10.1042/BSR20160257</pub-id><pub-id pub-id-type="pmid">28115595</pub-id><pub-id pub-id-type="pmcid">PMC5469250</pub-id></mixed-citation></ref><ref id="BST-2024-1045C209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Brink</surname><given-names>M</given-names></string-name></person-group><year>2016</year><article-title>mTOR, cardiomyocytes and inflammation in cardiac hypertrophy</article-title><source>Biochim. Biophys. Acta</source><volume>1863</volume><fpage>1894</fpage><lpage>1903</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.01.003</pub-id><pub-id pub-id-type="pmid">26775585</pub-id></mixed-citation></ref><ref id="BST-2024-1045C210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McMullen</surname><given-names>J.R.</given-names></string-name><string-name name-style="western"><surname>Sherwood</surname><given-names>M.C.</given-names></string-name><string-name name-style="western"><surname>Tarnavski</surname><given-names>O.</given-names></string-name><string-name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Dorfman</surname><given-names>A.L.</given-names></string-name><string-name name-style="western"><surname>Shioi</surname><given-names>T.</given-names></string-name><etal>et al</etal></person-group><year>2004</year><article-title>Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload</article-title><source>Circulation</source><volume>109</volume><fpage>3050</fpage><lpage>3055</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000130641.08705.45</pub-id><pub-id pub-id-type="pmid">15184287</pub-id></mixed-citation></ref><ref id="BST-2024-1045C211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaplan</surname><given-names>J.L.</given-names></string-name><string-name name-style="western"><surname>Rivas</surname><given-names>V.N.</given-names></string-name><string-name name-style="western"><surname>Walker</surname><given-names>A.L.</given-names></string-name><string-name name-style="western"><surname>Grubb</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Farrell</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Fitzgerald</surname><given-names>S.</given-names></string-name><etal>et al</etal></person-group><year>2023</year><article-title>Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial</article-title><source>J. Am. Vet. Med. Assoc.</source><volume>261</volume><fpage>1628</fpage><lpage>1637</lpage><pub-id pub-id-type="doi">10.2460/javma.23.04.0187</pub-id><pub-id pub-id-type="pmid">37495229</pub-id><pub-id pub-id-type="pmcid">PMC10979416</pub-id></mixed-citation></ref><ref id="BST-2024-1045C212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De Mol</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>De Korte</surname><given-names>D.H.</given-names></string-name><string-name name-style="western"><surname>Smit</surname><given-names>V.</given-names></string-name><string-name name-style="western"><surname>Kuiper</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Foks</surname><given-names>A.C</given-names></string-name></person-group><year>2024</year><article-title>Rapamycin reduces atherosclerotic plaque inflammation in aged mice</article-title><source>Cardiovasc. Res.</source><volume>120</volume><pub-id pub-id-type="doi">10.1093/cvr/cvae088.204</pub-id></mixed-citation></ref><ref id="BST-2024-1045C213"><label>213</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beaucourt</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Vignuzzi</surname><given-names>M</given-names></string-name></person-group><year>2014</year><article-title>Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance</article-title><source>Curr. Opin. Virol</source><volume>8</volume><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2014.04.011</pub-id><pub-id pub-id-type="pmid">24846716</pub-id><pub-id pub-id-type="pmcid">PMC7102760</pub-id></mixed-citation></ref><ref id="BST-2024-1045C214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ram&#237;rez-Olivencia</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>Est&#233;banez</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Membrillo</surname><given-names>F.J.</given-names></string-name><string-name name-style="western"><surname>Ybarra</surname><given-names>M.D.C</given-names></string-name></person-group><year>2019</year><article-title>Use of ribavirin in viruses other than hepatitis C. A review of the evidence</article-title><source>Enferm. Infecc. Microbiol. Clin. (Engl Ed)</source><volume>37</volume><fpage>602</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1016/j.eimc.2018.05.008</pub-id><pub-id pub-id-type="pmid">38620198</pub-id><pub-id pub-id-type="pmcid">PMC7103312</pub-id></mixed-citation></ref><ref id="BST-2024-1045C215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Loustaud-Ratti</surname><given-names>V.</given-names></string-name><string-name name-style="western"><surname>Debette-Gratien</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Jacques</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Alain</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Marquet</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Sautereau</surname><given-names>D.</given-names></string-name><etal>et al</etal></person-group><year>2016</year><article-title>Ribavirin: Past, present and future</article-title><source>World J. Hepatol.</source><volume>8</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.4254/wjh.v8.i2.123</pub-id><pub-id pub-id-type="pmid">26807208</pub-id><pub-id pub-id-type="pmcid">PMC4716528</pub-id></mixed-citation></ref><ref id="BST-2024-1045C216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tam</surname><given-names>R.C.</given-names></string-name><string-name name-style="western"><surname>Pai</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Bard</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Lim</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Averett</surname><given-names>D.R.</given-names></string-name><string-name name-style="western"><surname>Phan</surname><given-names>U.T.</given-names></string-name><etal>et al</etal></person-group><year>1999</year><article-title>Ribavirin polarizes human T cell responses towards a type 1 cytokine profile</article-title><source>J. Hepatol.</source><volume>30</volume><fpage>376</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/s0168-8278(99)80093-2</pub-id><pub-id pub-id-type="pmid">10190717</pub-id></mixed-citation></ref><ref id="BST-2024-1045C217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hultgren</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Milich</surname><given-names>D.R.</given-names></string-name><string-name name-style="western"><surname>Weiland</surname><given-names>O.</given-names></string-name><string-name name-style="western"><surname>S&#228;llberg</surname><given-names>M</given-names></string-name></person-group><year>1998</year><article-title>The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses</article-title><source>J. Gen. Virol.</source><volume>79 ( Pt 10)</volume><fpage>2381</fpage><lpage>2391</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-79-10-2381</pub-id><pub-id pub-id-type="pmid">9780043</pub-id></mixed-citation></ref><ref id="BST-2024-1045C218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ge</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Ma</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Cui</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Dong</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Sun</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Li</surname><given-names>Y.</given-names></string-name><etal>et al</etal></person-group><year>2023</year><article-title>Rapamycin suppresses inflammation and increases the interaction between p65 and I&#954;B&#945; in rapamycin-induced fatty livers</article-title><source>PLoS ONE</source><volume>18</volume><elocation-id>e0281888</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0281888</pub-id><pub-id pub-id-type="pmid">36867603</pub-id><pub-id pub-id-type="pmcid">PMC9983852</pub-id></mixed-citation></ref><ref id="BST-2024-1045C219"><label>219</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Allan</surname><given-names>S</given-names></string-name></person-group><year>2008</year><article-title>Seeing mTOR in a new light</article-title><source>Nat. Rev. Immunol.</source><volume>8</volume><fpage>904</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1038/nri2457</pub-id></mixed-citation></ref><ref id="BST-2024-1045C220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mannick</surname><given-names>J.B.</given-names></string-name><string-name name-style="western"><surname>Del Giudice</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>Lattanzi</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Valiante</surname><given-names>N.M.</given-names></string-name><string-name name-style="western"><surname>Praestgaard</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Huang</surname><given-names>B.</given-names></string-name><etal>et al</etal></person-group><year>2014</year><article-title>mTOR inhibition improves immune function in the elderly</article-title><source>Sci. Transl. Med.</source><volume>6</volume><pub-id pub-id-type="doi">10.1126/scitranslmed.3009892</pub-id><pub-id pub-id-type="pmid">25540326</pub-id></mixed-citation></ref><ref id="BST-2024-1045C221"><label>221</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kraig</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Linehan</surname><given-names>L.A.</given-names></string-name><string-name name-style="western"><surname>Liang</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Romo</surname><given-names>T.Q.</given-names></string-name><string-name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></string-name><string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>. <etal>et al</etal></person-group><year>2018</year><article-title>A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects</article-title><source>Exp. Gerontol.</source><volume>105</volume><fpage>53</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2017.12.026</pub-id><pub-id pub-id-type="pmid">29408453</pub-id><pub-id pub-id-type="pmcid">PMC5869166</pub-id></mixed-citation></ref><ref id="BST-2024-1045C222"><label>222</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Ou</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Li</surname><given-names>A.</given-names></string-name><etal>et al</etal></person-group><year>2024</year><article-title>Rapamycin promotes the intestinal barrier repair in ulcerative colitis via the mTOR/PBLD/AMOT signaling pathway</article-title><source>Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease</source><volume>1870</volume><fpage>167287</fpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2024.167287</pub-id><pub-id pub-id-type="pmid">38862095</pub-id></mixed-citation></ref><ref id="BST-2024-1045C223"><label>223</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Zhang</surname><given-names>S.-X</given-names></string-name></person-group><year>2023</year><article-title>Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis</article-title><source>Arthritis Res. Ther.</source><volume>25</volume><fpage>187</fpage><pub-id pub-id-type="doi">10.1186/s13075-023-03181-w</pub-id><pub-id pub-id-type="pmid">37784141</pub-id><pub-id pub-id-type="pmcid">PMC10544394</pub-id></mixed-citation></ref><ref id="BST-2024-1045C224"><label>224</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Long</surname><given-names>S.A.</given-names></string-name><string-name name-style="western"><surname>Rieck</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Sanda</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Bollyky</surname><given-names>J.B.</given-names></string-name><string-name name-style="western"><surname>Samuels</surname><given-names>P.L.</given-names></string-name><string-name name-style="western"><surname>Goland</surname><given-names>R.</given-names></string-name><etal>et al</etal></person-group><year>2012</year><article-title>Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs &#946;-cell function</article-title><source>Diabetes</source><volume>61</volume><fpage>2340</fpage><lpage>2348</lpage><pub-id pub-id-type="doi">10.2337/db12-0049</pub-id><pub-id pub-id-type="pmid">22721971</pub-id><pub-id pub-id-type="pmcid">PMC3425404</pub-id></mixed-citation></ref><ref id="BST-2024-1045C225"><label>225</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Shi</surname><given-names>O.</given-names></string-name><string-name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Henrich-Noack</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Qiao</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Cai</surname><given-names>C.</given-names></string-name><etal>et al</etal></person-group><year>2014</year><article-title>Functional protection of learning and memory abilities in rats with vascular dementia</article-title><source>Restor. Neurol. Neurosci.</source><volume>32</volume><fpage>689</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.3233/RNN-140409</pub-id><pub-id pub-id-type="pmid">25015703</pub-id></mixed-citation></ref><ref id="BST-2024-1045C226"><label>226</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mah&#233;</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Rios-Fuller</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Katsara</surname><given-names>O.</given-names></string-name><string-name name-style="western"><surname>Schneider</surname><given-names>R.J</given-names></string-name></person-group><year>2024</year><article-title>Non-canonical mRNA translation initiation in cell stress and cancer</article-title><source>NAR Cancer</source><volume>6</volume><elocation-id>zcae026</elocation-id><pub-id pub-id-type="doi">10.1093/narcan/zcae026</pub-id><pub-id pub-id-type="pmid">38828390</pub-id><pub-id pub-id-type="pmcid">PMC11140632</pub-id></mixed-citation></ref><ref id="BST-2024-1045C227"><label>227</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Joyce</surname><given-names>C.E.</given-names></string-name><string-name name-style="western"><surname>Yanez</surname><given-names>A.G.</given-names></string-name><string-name name-style="western"><surname>Mori</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Yoda</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Carroll</surname><given-names>J.S.</given-names></string-name><string-name name-style="western"><surname>Novina</surname><given-names>C.D</given-names></string-name></person-group><year>2017</year><article-title>differential regulation of the melanoma proteome by eIF4A1 and eIF4E</article-title><source>Cancer Res.</source><volume>77</volume><fpage>613</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-1298</pub-id><pub-id pub-id-type="pmid">27879264</pub-id><pub-id pub-id-type="pmcid">PMC5362820</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>